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Preterm birth (PTB) is one of the most pressing challenges to maternal and child health in the 
United States (US). There remains an urgent need to identify important and modifiable risk 
factors for PTB among those most at risk- such as urban low income, Non-Hispanic blacks. This 
dissertation aimed to: i) evaluate the relationship between maternal folate status and risk of PTB 
and ii) investigate the biologic plausibility of the folate-PTB association by evaluating the role of 
folate on major pathogenic pathways leading to PTB –namely preeclampsia and intrauterine 
infection/inflammation (IUI). The analyses included 7565 mother-newborn dyads and a 
subsample (n=2313) with plasma folate assay at delivery in Boston Birth Cohort.  
There was an inverse relationship between the frequency of multivitamin supplement intake and 
PTB. Compared to less frequent use, multivitamin supplement intake 3-5 times/week (adjusted 
odds ratio (aOR)= 0.78, 95% confidence interval (CI): 0.64, 0.96) or >5 times/week (aOR= 0.77, 
95% CI: 0.64, 0.93) throughout pregnancy was associated with reduced risk of PTB. 
Multivitamin supplement intake of three or more times a week in the 3rd trimester was 
associated with reduced odds of preeclampsia (aOR=0.77, 95% CI: 0.65, 0.93). Each 
interquartile increase in plasma folate reduced the odds of preeclampsia by 20% (aOR=0.80, 
95% CI: 0.68,0.95). Preeclampsia mediated 62% of the relationship between multivitamin 
supplement intake and medically indicated PTB. Multivitamin supplement intake of three or 
more times a week in the 3rd trimester (aOR=0.74, 95% CI: 0.63, 0.87) was associated with 
reduced odds of IUI. Each interquartile increase in plasma folate reduced the odds of IUI by 15% 
(aOR=0.85, 95% CI: 0.73, 0.98). Joint analysis of IUI and multivitamin supplement intake 
showed that multivitamin intake attenuated the relationship between IUI and PTB.  
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Findings from this study are relevant to policies and interventions, specifically among vulnerable 
populations. The results of this dissertation have a potential impact on ongoing research, clinical 
and programmatic efforts to improve prenatal nutrition and birth outcomes. Findings may inform 
the design and implementation of nutrition-based screening and interventions to prevent PTB and 
associated short-term and long-term consequences.   
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Preterm birth (PTB) has been recognized as one of the most pressing challenges to maternal 
and child health in the US (1). It is associated with high neonatal, infant and childhood morbidity 
and mortality as well as cardiovascular and metabolic diseases in adulthood (2). National PTB 
rates have declined only slightly from 2007 to 2016 (10.4% and 9.8% respectively) (3), with the 
PTB rate in Non-Hispanic blacks (13.8%) highest compared to Hispanics (9.4%) and Non-
Hispanic Whites (9.04%) (3, 4). One major hurdle in reducing the intractable national PTB rate 
is the multi-factorial etiology involved in both spontaneous and medically indicated PTBs (5-7). 
Major biomedical risk factors for PTB include preeclampsia disorders and intrauterine infection 
inflammation (IUI) which are major causes of medically indicated and spontaneous PTB 
respectively (8, 9). There remains an urgent need to identify important and modifiable risk 
factors for PTB among those most at risk- such as urban low income, Non-Hispanic blacks (10, 
11). 
Low maternal folate status has been linked with adverse pregnancy outcomes such as neural 
tube defects, congenital abnormalities, low birth weight, anemia and preeclampsia (12-14). 
National recommendations regarding folate intake and supplementation were instituted in 1992 
while mandatory folic acid fortification programs were implemented in 1998 to improve 
pregnancy outcomes (15, 16). The 2012 National Health and Nutrition Examination Survey 
(NHANES), however, suggests that 25% of women of reproductive age have insufficient folate 
levels (17). Non-Hispanic Black and Hispanic women are more likely to have lower folate levels 
than non-Hispanic white women (18). To date, attention has been paid to the role of folate intake 
during preconception and early pregnancy on neural tube defects (occurring during first 
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trimester). Considerable knowledge gaps remain on the role of folate in PTB (a third trimester 
event). 
Maternal folate status has been linked to PTB in many studies (19-25), however some studies 
have found no relation (26-30). These mixed results are likely due to  variations across studies in 
terms of sociodemographic characteristics of the study population (31-33), presence of folic acid 
fortification programs (31, 32), population folate status (34), folate measurement (self-reported 
intake versus biomarkers) (30-32) or timing of folic acid supplementation (preconception versus 
specific trimesters of pregnancy) (34). 
It is biologically plausible that folate may affect PTB (35). Folate is essential for DNA 
synthesis and repair, gene expression, fetal organ/system formation, normal metabolism and 
immune function (36) and possesses anti-oxidative and anti-inflammatory properties (37, 38). 
Folate is needed for normal endothelial function (39, 40) and its deficiency is associated with 
hypertension and cardiovascular diseases in adults (41). Thus, folate deficiency may be linked to 
preeclampsia- defined as pregnancy induced hypertension with proteinuria- and a major cause of 
medically indicated PTB. A few studies suggest that the relationship between preeclampsia and 
PTB is moderated by folate status (42, 43). In addition, folate deficient individuals are 
susceptible to infections and have increased circulating biomarkers of inflammation (44). IUI has 
been associated with folate deficiency and is hypothesized to lead to 25-40% of PTB cases (9, 
35). These plausible pathways through which folate may influence PTB are described later in 
detail.   
This dissertation examined the association between maternal folate status and PTB (as well 
as two major pathogenic pathways (preeclampsia and intrauterine infection/inflammation (IUI)) 
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using data from the Boston Birth Cohort (BBC)- a US urban low-income minority (about 50% 
African American) population. The BBC is a well-established cohort study, specifically designed 
to study PTB, with sufficient sample size of PTB subtypes (spontaneous or medically indicated) 
allowing for the exploration of the association between folate and PTB subtypes. In addition, the 
presence of data on pregnancy complications (such as preeclampsia and IUI) in the BBC allows 
for a research of plausible biological pathways underlying the folate-PTB relationship- 
specifically: the inflammation and vascular pathological pathways leading to PTB. Maternal 
folate status was assessed using both self-reported multivitamin supplement intake from 
preconception to each trimester of pregnancy via standard questionnaire interview, as well as 
folate biomarkers in archived maternal plasma samples obtained at delivery (a proxy of 3rd 
trimester folate status). These data allowed for the investigation of the temporal association of 
folate status in relation to PTB, and further delineating dose-response relationships using 
objective biomarkers.   
Study Aims 
The dissertation is organized along the following aims and hypotheses: 
Aim 1. Evaluate the relationship between maternal folate status and risk of PTB 
(overall and subtypes of PTB).  
Maternal folate status was assessed using complimentary measures of self-reported 
multivitamin supplement intake from preconception to third trimester and plasma folate 
concentrations at delivery.  
Null hypotheses include: 
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1a Self-reported frequency of multivitamin supplement intake during the 
preconception (6-month prior to preconception) period is not associated with PTB (including 
PTB subtypes- spontaneous and medically indicated PTB) 
1b Self-reported frequency of multivitamin supplement intake during pregnancy 
(first, second and third trimester) is not associated with PTB (including PTB subtypes- 
spontaneous and medically indicated PTB) 
1c Maternal plasma folate levels at delivery (a proxy of 3rd trimester folate status) is 
not associated with PTB (including PTB subtypes- spontaneous and medically indicated 
PTB) 
 
Aim 2. Investigate the biologic plausibility of the folate-PTB association by evaluating 
the role of folate on major pathogenic pathways leading to PTB. 
Null hypotheses include: 
2a Maternal folate status (assessed by self-report and biomarker) does not moderate 
the relationship between preeclampsia in pregnancy and PTB (including overall and 
medically indicated PTB). 
2b Preeclampsia does not mediate the relationship between maternal folate status and 
PTB (including overall and medically indicated PTB). 
2c Maternal folate status (assessed by self-report and biomarker) does not moderate 
the relationship between IUI and PTB (including overall and spontaneous PTB). 
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2d IUI does not mediate the relationship between maternal folate status and PTB 
(including overall and spontaneous PTB). 
Findings from this study are directly relevant to vulnerable US- urban low-income 
minority populations. The results of this dissertation have a potential impact on ongoing 
research, clinical and programmatic efforts to improve prepregnancy and prenatal nutrition 
and birth outcomes and may help inform the design and implementation of nutrition-based 
screening and interventions to prevent PTB and its consequences.  Globally, mandatory folic 
acid fortification of grain products has been implemented in some countries including the 
US, Canada, and Australia, while many other countries have not.  Our findings may also 
have implications for populations in the developing countries with low folate intake, but 
caution is needed in extrapolating our findings to populations with different demographic 
and clinical characteristics and contexts.  
Conceptual Framework 
A schematic representation of the conceptual framework highlighting the analytical approach 
for testing the study hypotheses is shown in the figure below. The framework reflects the study 
aims to elucidate the direct and indirect relationships between maternal folate status and PTB as 
well as to explore the potential moderating and mediating effects of two major causes of PTB 
(preeclampsia as well as IUI) on the folate-PTB relationship. These interrelationships were 
explored using complementary measures of maternal folate status across multiple time points 
from preconception to delivery, leveraging extensive clinical and epidemiological data relevant 
to this study.  
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Figure 1-1: Conceptual Framework 
 
The exploration of maternal folate status across multiple time points is based on the life course 
approach to health. The life course theory achieved prominence in health with research 
conducted by Barker which demonstrated that PTB has a causal relationship to the origins of 
hypertension, coronary heart disease, and non-insulin-dependent diabetes later in life (45-47). In 
the life course health development model developed by Halfon et al, health is defined as an 
emergent capacity of human beings that dynamically develops over time, in response to multiple 
nested, and ever changing genetic, biological, behavioral, social and economic contexts (48). 
With this model, the goal of health practice is reiterated as the promotion of positive health at all 
stages of life and not just the avoidance of disease (49). This life course health development 
model feeds directly into the conceptual framework of this study as it spans from the 
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preconception to the peripartum period incorporating distal and proximal factors influencing 
PTB.  
Dissertation Overview 
The dissertation is presented in seven chapters. This chapter introduces the study aims and 
presented relevant background information. The second chapter presents a literature review and a 
study rationale, followed by the conceptual framework that guided the research. The third 
chapter presents the study design, data collection procedures, sample size and power 
calculations, definition of key variables and statistical analysis methods. Chapter four presents 
the first manuscript on maternal folate status and PTB in the BBC. Chapter five presents the 
second manuscript on interrelationships between maternal folate status, preeclampsia and PTB 
while Chapter six presents the third manuscript on interrelationships between maternal folate 
status, IUI and PTB. Chapter seven summarizes this dissertation, with a discussion of the 
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This chapter provides an in-depth review of the literature on PTB and folate status in the 
US. Systematic literature reviews conducted on the relationship folate and PTB are summarized. 
Then, prospective and retrospective studies specific to the US population are presented, given the 
unique context conferred by the presence of mandatory folic acid fortification programs, the 
racial/ethnic composition and low national prevalence of folate deficiency (1). This chapter also 
discusses potential mechanisms for the relationship between folate and PTB. 
Preterm Birth Review 
A review of the literature on PTB in the US is highlighted below. This includes the definition, 
distribution, etiology and measurement of PTB as well as a description of PTB subtypes in the 
US. 
Definition and Distribution  











Figure 2-1: Trends in Preterm Birth rates in the United States.  
Data source- final 2007, 2014, and 2015 and provisional 2016 natality data 
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After decades of rising annual PTB rates, rates have slowly declined from 10.4% in 2007 to 
9.6% in 2014, but has increased since then to 9.8% in 2016 (4), presumably due to reduced birth 
rates in teenagers (5). Natality data from the Division of Vital Statistics (6), show considerable 
racial/ethnic variation in PTBs in the US. The rate of PTB among non-Hispanic black women 
(13.8%) was about 50% higher than the rate of PTB among non-Hispanic white women (8.9%) 
(4) (2). PTB also varies by maternal age (7-9), and socioeconomic status (10-12). 
Subtypes 
Based on gestational age, natality data shows that about 70% of all PTBs are “late” 
(occurring between 34-36 weeks of gestation) with the remaining classified as “early” (before 34 
weeks of gestation) - a trend which has persisted since 2007 (6). On the basis of the clinical 
presentation, PTB may be classified as (i) spontaneous PTB when preterm labor starts 
spontaneously, (ii) preterm prelabor rupture of membranes (pPROM), or (iii) medically indicated 
PTB when delivery is indicated for pregnancy complications (induction of labor or elective 
caesarean birth before 37 completed weeks of gestation for maternal or fetal indications (both 
"urgent" or "discretionary"), or other non-medical reasons) (3). PTBs are sometimes referred to 
as either spontaneous (first 2 clinical conditions are often combined) or medically indicated (13). 
Data on the national prevalence of spontaneous or medically indicated sub groups of PTB are not 
reported though it appears that spontaneous PTB are more prevalent than medically indicated 
PTB (14). Between 1987 and 2012, medically indicated PTB demonstrated an increasing trend 
with a concomitant decrease in the incidence of spontaneous PTB (15).  
Measurement 
Until 2014, natality data calculated gestational age based on the date of the last normal 
menstrual period (LMP). Alternative measures of gestational age, termed the “clinical estimate” 
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(1989 revision) and the “obstetric estimate” (2003 revision) based on the birth attendant's final 
estimate of gestational age, have also been collected (16, 17). A comparison of these estimates of 
gestational age suggests that LMP-based data may overestimate the PTB rate. Early ultrasound 
dating (<20 weeks of gestation) is considered to be a more accurate method of determining 
gestational age (18, 19). The obstetric estimate, which incorporates all perinatal factors including 
ultrasound data, may have higher validity than LMP data, which may be less accurate due to 
poor maternal recall and individual variation in menstrual cycle length (20). Based on the 
obstetric estimate, the national PTB rate was only 9.6% in 2013 compared to 11.4% based on 
maternal LMP.  
Etiology 
PTB has been described as a complex condition resulting from multiple etiologic pathways 
(16). A precise mechanism cannot be established in most cases; therefore, factors associated with 
PTB, but not necessarily in the causal pathway, have been sought to explain preterm delivery 
(21).  
Etiology of spontaneous preterm birth  
Spontaneous PTB may be considered a clinical syndrome, arising from different pathological 
processes that activate prematurely one or more mechanisms leading to parturition (13). These 
processes include infection or inflammation, uteroplacental ischemia or hemorrhage, uterine 
over-distension, stress, and other immunologically mediated processes (22).  
Infection and its related activation of inflammatory responses have been suggested as leading 
risk factors of spontaneous PTB with infection/inflammation detected in at least 25% of all PTBs 
according to a recent study (23). Increased production of proinflammatory cytokines has been 
18 
 
linked with uterine activation of contraction and PTB, whereas production of anti-inflammatory 
cytokines has been associated with uterine quiescence during gestation (24, 25). Other identified 
risk factors for spontaneous PTB include young or advanced maternal age, short inter-pregnancy 
intervals and low maternal body mass index (21, 26). Obstetric factors include prior PTB and 
uterine over distension with multiple pregnancy (27). Medical risk factors include infections 
such as urinary tract infections (28), malaria (29), bacterial vaginosis (28), HIV (29) and syphilis 
(30). Some lifestyle factors include stress and excessive physical work or long times spent 
standing (26), smoking, excessive alcohol consumption and periodontal disease (31). 
Spontaneous PTB have been found to vary by maternal age and socio-environmental context 
(29) but the cause for spontaneous PTB remains idiopathic in up to 50% of all cases (32).  The 
role of maternal nutrition remains a promising area of investigation. 
Etiology of medically indicated preterm birth 
A US study published in 2011 showed that more than half of all medically indicated “late” 
PTB did not have a definitive medical indication (33). Unintended medically indicated PTB also 
can occur with the elective delivery of a baby thought to be term due to errors in assessment of 
gestational age (34). However, such unintended PTB have reduced with the advent of routine 
ultrasounds during prenatal care. Clinical conditions that may lead to medically-indicated PTB 
include placental abruption, uterine rupture, fetal distress and fetal growth restriction (35) and 
preeclampsia (5, 36, 37). Preeclampsia, has been shown to account for as much as 15% of PTB 
cases, due to medically indicated PTB (38).  Studies have shown that the association between 
preeclampsia and medically indicated PTB is more than two times stronger than the 
preeclampsia- spontaneous PTB association (39). Medically indicated preterm deliveries of 
women with preeclampsia are justified because of the concerns about maternal and fetal safety 
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with continued gestation. The American College of Obstetricians and Gynecologists (ACOG) 
recommends that in the presence of severe preeclampsia, delivery be induced after 34 weeks of 
gestation (40).  
Medically indicated PTB in the US have been linked with a variety of behavioral risk factors 
such as prenatal care (41), substance abuse (42) as well as stress, depression and anxiety (43-48).  
Again, the role of vitamin/micronutrient levels (49-51) merits further investigation. 
Folate Status Review 
A detailed introduction to folate status in the US is highlighted below. This includes the 
definition and function of folate as well as the measurement of folate status at a population level. 
In addition, normal and pathological folate status in the US is discussed. 
Definition 
Folate, also known as vitamin B9, is a naturally occurring water-soluble B vitamin involved 
in many cellular pathways and biological reactions needed for fetal and placental growth. 
Sources of folate include: vegetables, fruits, nuts, beans, peas, grains, brewer’s yeast and liver. 
Folate is a generic term for a group of compounds including folic acid and its derivatives. Folic 
acid is a synthetic form of folate which does not exist in nature, although oxidation of folates to 
folic acid is seen in stored or cooked foods. 5-Methyl Tetrahydrofolate (5-MeTHF) is a 
biologically active form of folate and is the most abundant form found in plasma, representing 
over 90% of folate and is the predominant active metabolite of ingested folic acid (52). The 
bioavailability of naturally occurring folate is less than that of folic acid. A schematic of folate 
derivatives and folate metabolism is presented below. 
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Figure 2-2: Folate Metabolism 
 
Function 
Folate plays an essential role in one-carbon metabolism, facilitating the transfer of one-
carbon units in reactions required for metabolism of nucleic acids, amino acids and methylating 
agents required for normal metabolism and gene regulation. Its role in prevention of neural tube 
defect is via its function as an essential cofactor in folate-mediated one-carbon metabolism and 
in the epigenetic regulation of the transcription of genes that control neural closure (53). Folate 
also plays a role in the prevention of oxidative stress and inflammation (54, 55). Recently, the 
epigenetic effect of folate in its role in methylation has been identified as a crucial link between 
nutrition and health manifesting at both the individual and trans-generational level (56-58). 
Among adults, folate has been associated with hypertension (59, 60) and subsequent 




Folate status can be assessed using biomarkers in urine, serum, plasma or the red blood cells 
using a variety of techniques including microbiological methods, radioisotope competitive 
binding, and enzyme linked or chemiluminescence assays. Red blood cell (rbc) folate 
concentrations measure long-term folate status as they respond very slowly to changes in folate 
intake. This slow response is because erythrocytes, which have a 120-day lifespan, accumulate 
folate only during erythropoiesis.  
Plasma or serum folate reflects recent folate intake and low levels are an early indicator of 
inadequate folate status. A single plasma folate measurement cannot be used to differentiate 
between a transitory decrease in dietary folate intake and chronic deficiency states. Repeated low 
values of plasma folate within an individual over the course of a month, however, are indicative 
of low folate status or folate depletion (62, 63). Measurement of plasma folate may be preferred 
over rbc-folate because it can be reliably measured using immunological or chromatography 
methods, shows faster response after supplementation, and reflects the amount available for 
transfer via the placenta (64). Alternative approach for assessing folate status using biomarkers 
involves surrogate measurement of metabolites known to increase in folate deficiencies (65). 
One of these, total homocysteine (tHcy) is used as a surrogate functional marker for folate status 
(66).  
Folate status can also be estimated based on folate intake. This approach includes the use of 
food frequency questionnaires (FFQ), 24-hour dietary recall and intake of supplements (66). 
These methods are non- invasive, cheaper and easier to implement compared with biomarker 
assessments. As they are self-reported assessments, they are sometimes flawed with multiple 
errors such as interviewer bias or recall bias. Though they have been validated as correlated with 
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biomarker measurements (67, 68), they often require an exhaustive list of various sources of 
dietary intake and may involve complex computation to determine dietary folate equivalents 
(DFE)- the measure of daily intake which takes into account the higher bioavailability of 
synthetic folic acid compared to naturally occurring folate in food (69).  
A US based study found the correlation coefficients between total folate intake and 
biological markers to be r=0.41 for serum and 0.25 for red blood cell folate (P < .05 for both). 
Serum folate correlated with rbc folate, r = 0.50 (P < .05). Their results suggest that the estimate 
of folate from the food frequency questionnaire, and the pregnancy supplement use questions 
reflect short-term as opposed to long-term folate status in the population (70). 
Abnormal folate level 
In the US, early NHANES results defined low red cell folate as less than 140 ng/mL and low 
plasma folate levels as less than 3 ng/mL (63). More recently, the World Health Organization 
(WHO) established guidelines for utilising serum and red blood cell folate concentrations to 
assess folate status in populations. Their guidelines discuss two major measurement methods in 
defining folate status. The first involves the use of macrocytic anemia as a hematological 
indicator and defines folate deficiency as serum/plasma folate levels less than 6.8 nmol/L; 
possible folate deficiency as 6.8-13.4nmol/L; normal folate values as 13.5-45.3nmol/L and 
elevated levels as higher than 45.3nmol/L (62). Red cell folate levels less than <226.5nmol/L are 
also indicative of folate deficiency. 
The second assessment defines folate deficiency based on the folate concentration below 
which homocysteine concentrations start to rise. With this guideline, folate deficiency 




Folate deficiency may occur due to low dietary intake, poor gastrointestinal absorption of 
ingested folate and increased need (such as in physical activity, pregnancy); it can also be caused 
by pathological liver conditions, and a dysfunction in folate metabolism which may be due to 
genetics or drug interactions (71, 72). Excessive folate is linked with vitamin B12 deficiency, 
interaction with drugs that inhibit folate metabolism, decreased zinc absorption, hypersensitivity 
reactions, association with cancer, neurotoxicity and epileptogenic effects and increased 
susceptibility to malaria (73). 
Folate status in the US Female Population 
Higher doses of folate are recommended for pregnant (600 mcg DFE) and lactating (500 mcg 
DFE) mothers to prevent neural tube defects (74). However, NHANES data from 2000 to 2010 
suggests that 25% of women of reproductive age in the US have insufficient folate levels to 
prevent neural tube defects (75). Other findings from the NHANES show that minority women 
are more likely to have lower folate levels than non-Hispanic white women(76). Also, women 
who were non-white, aged 18-24 years, had less than a high school education, or had a 
household income of <$25,000 were the least likely to report daily consumption of a supplement 
containing folic acid (77). In addition, minority populations are less likely to have heard about 
folic acid, to know it can prevent birth defects or pregnancy complications, consume foods 
fortified with folic acid, or take vitamins containing folic acid before pregnancy (78-81).  
Review of the Relationship between folate status and PTB 
Systematic literature reviews  
A systematic review of recent observational studies identified a link between reduced 
maternal folate levels and PTB while three reviews of randomized control trials (RCTs) did not 
corroborate this relationship.  
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The review by Mantovani et al. (82), examined the results from recent observational studies 
(2009 onwards) on the effect of periconceptional (started before conception and continued until 
12 weeks of gestational age) folic acid supplementation on PTB. Their search was restricted to 
Medline and involved a manual search of observational studies from 2009 onwards that analyzed 
the rate of PTB in patients who received supplementation with folic acid before and/or 
throughout pregnancy. Their findings from 7 selected studies (two of which were conducted in 
the US) suggest a slight reduction of PTBs.  
Fekete et al. (83) conducted a systematic review of the MEDLINE, EMBASE and Cochrane 
Library CENTRAL databases from inception to February 2010 for RCTs in which folate intake 
and health outcomes in pregnancy were investigated. Their analysis of six studies from five 
publications involving only 380 participants showed no relation between maternal folate intake 
(folic acid plus dietary folate) and PTB. Of the six studies included in their analysis, three were 
published over 25 years ago and none was based in US.  
Lassi et al. (84) broadened the scope of their systematic review to all randomised, cluster-
randomised and cross-over controlled trials evaluating supplementation of folic acid alone or 
with other micronutrients versus no folic acid (placebo or same micronutrients but no folic acid) 
in pregnancy. They included all pregnant women regardless of age and parity but excluded 
studies in which women were supplemented during the periconception period. Three trials 
involving 2959 women are included in their meta-analysis of folate on PTB risk. They found no 
impact of folic acid on PTB (risk ratio (RR) 1.01, 95% confidence interval (CI) 0.73 to 1.38). 
However, they acknowledged that only one of the studies defined PTB correctly- two of these 
studies defined PTB as births before 38 weeks of gestation. Furthermore, none of the studies 
were conducted in the US. 
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Saccone and Berghella’s review (85) in 2016 evaluated the efficacy of folic acid 
supplementation during pregnancy to prevent PTB. Five randomized trials including 5,332 
asymptomatic singleton gestations without prior PTB who were randomized to prophylactic 
treatment with either folic acid supplementation or control were included in the analysis. Women 
who received folic acid supplementation had a similar rate of PTB (22.6% vs 22.9%; RR 0.99, 
95% CI 0.82-1.18), PTB<34 weeks (7.1% vs 8.7%; RR 0.77, 95% CI 0.55-1.09). However, three 
of the included studies were conducted during the 1970s and the authors found poor compliance 
with random allocation in these studies. Moreover, only one RCT had PTB as primary outcome, 
none of the studies randomized folic acid preconceptionally and none was conducted in the US.  
In summary, differences in the systematic review findings might relate to quality of the 
studies reviewed- majority of the RCTs included in the meta-analysis were conducted four 
decades ago and PTB was poorly defined. In addition, the systematic reviews did not provide 
information on the folate status of participants and the folic acid fortification context in the 
included studies. Also, it is possible that the timing of folate administration may play a role as 
only the review by Mantovani limited the timing to the preconception period. There is also the 
possibility that folic acid supplementation is only beneficial in women with folic acid deficiency. 
Finally, it could also be that folic acid supplementation is truly not effective in preventing PTB. 
Review of US studies on the relationship between folate status and PTB 
A major gap in the study of the folate-PTB association is the paucity of US based studies. 
Studies have been conducted across varying populations such as China (86), Greece (87), 
Venezuela (88), Hungary (89), Netherlands (90) and Norway (91). These populations are not 
comparable with the US due to differences in racial composition, implementation of national 
folic acid fortification programs and folate deficiency levels in women (1). While no RCT has 
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been conducted in the US, prospective studies conducted in the US demonstrated that a low 
dietary intake or plasma level of folate were associated with increased risk of PTB, controlling 
for other known risks whereas retrospective studies showed conflicting results. A review of 
seven US studies demonstrated a reduction in PTB with increased folate or national folic acid 
fortification programs in five studies, while one study did not find an association and another 
found mixed results. These studies were conducted among vulnerable as well as nationally 
representative populations and included different methods of folate assessment as well as timing 
of folate administration as seen in the table 1 below. 
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Prospective studies  
A study in New Jersey was conducted in 1995 prior to the national mandatory folic acid 
fortification program among an urban poor, predominantly African American population 
(N=827) (92). Compared with women who had a folate intake >400μg/day, those with 
intermediate folate intake (241–400μg/day) and low folate intake (≤240μg/day) had a 
progressively increased risk of PTB (RR 3.4, 95% CI 1.9–6.1 and RR 1.9, 95% CI 1.0–3.6, 
respectively). In addition, each 1 nmol/L increase in serum folate concentrations at 28 weeks of 
gestation was also associated with reduced risk of PTB (aOR: 0.984; 95% CI: 0.969, 0.998). 
Their analyses controlled for gestation at entry, age, parity, ethnicity, cigarettes smoking, 
gestational weight gain, plasma vitamin B-12 and dietary intake of energy, zinc, fiber.  
Between 1995 and 2000- around the timing of the folic acid fortification program- 2648 
middle to low income women from 4 prenatal centers were recruited between 24 and 29 weeks' 
gestation in a North Carolina study (70). Women completed a questionnaire that provided data 
on sociodemographic characteristics and health behaviors both before and during the pregnancy, 
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as well as provided blood at the time of the interview (2314 women had dietary data, 2026 
specimens were available for the serum folate analysis, and 1034 specimens for the red blood 
cell analysis). Those with low serum folate levels in the second trimester had a nearly twofold 
increased risk of PTB (RR 1.8, 95% CI 1.3–2.5) controlling for prenatal supplement use and time 
of storage of folate sample. However, only covariates that changed the coefficient of the 
maternal folate exposure variables by greater than 10% were retained in the final model. Thus, 
other sociodemographic and dietary covariates were not included in the final model.  
In the years following the folic acid fortification program- 1999-2002, Bukowski, Radek, et 
al. (93) conducted secondary data analysis from a multicenter cohort aneuploidy risk study in the 
US and explored the link between preconceptional folic acid supplementation and PTB. They 
studied data from 34,480 women from 15 US centers who delivered singleton pregnancies at 20 
to 42 weeks. The association between preconceptional folic acid supplementation and the risk of 
spontaneous PTB was evaluated using survival analysis. Adjusting for maternal age, race, body 
mass index, education, marital status, smoking, parity, and history of prior preterm, folic acid 
supplementation for 1 y or longer was associated with spontaneous PTB between 20 and 28, and 
28 to 32 weeks (adjusted HR 0.31, 95% CI 0.11-0.90, p = 0.031 and 0.53, 0.28-0.99, p = 0.046, 
respectively). However, preconceptional folic acid supplementation was not significantly 
associated with the risk of spontaneous PTB beyond 32 wk. These hazard rates were comparable 
to those seen in the unadjusted analysis. The authors concluded that, folic acid supplementation 
for 1 y or longer prior to conception decreased the risk of spontaneous PTB, and that this 
association was strong, specific, dose-dependent, consistent with other studies, biologically 




Between 2003-2007, years after the implementation of the fortification program, a 
prospective cohort study in Pittsburg, Pennsylvania attempted to identify specific folate subtypes 
related to PTB (94). They analyzed nonfasting blood samples from 313 pregnant women enrolled 
before 16 weeks of gestation. Study participants were from antepartum clinics serving a 
predominantly publicly insured, low-income population that was 55% black and 44% white. 
Eligible women had singleton pregnancies, were non-Hispanic whites or non-Hispanic blacks 
based on self-reports, and had no known preexisting conditions, vaginal bleeding, fetal 
anomalies, or current or planned cervical cerclage. At enrollment, women completed an 
interviewer-administered questionnaire to collect data on sociodemographic characteristics, 
medical, reproductive, and sexual history, and maternal behaviors. Women also provided a 
nonfasting blood sample that was banked for later analysis. After adjustment for race-ethnicity, 
education, smoking, and obesity, 1-SD increases in serum total folate and serum 5-
methyltetrahydrofolate (5MeTHF) concentrations were associated with significant reductions in 
the risk of spontaneous PTB (P < 0.05). Study findings also demonstrated that the relationship 
between serum total folate concentrations and spontaneous PTB were driven by serum 5MeTHF 
concentrations. 
A population based study was conducted by Shaw et al. (95) to explore the frequencies of 
low birthweight and preterm delivery among approximately 6 million California infants before 
and after compulsory food fortification with folic acid. They designated the period “before 
fortification” as January 1, 1990, through December 31, 1997, and the period of “fortification” as 
October 1, 1998, through December 31, 2000. The unadjusted prevalence of preterm delivery did 
not substantially vary across birth years. However, Poisson regression analyses adjusting for 
maternal age, parity, race/ethnicity, education, year of birth, and fortification period revealed a 
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reduced risk for PTB (relative risk ratios (RR) = 0.96; 95% CI 0.94, 0.97) for preterm delivery. 
There was no individual level information on dietary intake, supplement use, folate status or 
timing of consumption of folate fortified foods.  
Retrospective studies 
US based retrospective studies, have shown mixed results. Shaw, Gary M., et al. (96) 
investigated periconceptional intake of multiple sources of folate and folic acid (dietary folate, 
folic acid intake and folate containing supplement use respectively) to determine their 
association with preterm delivery. They conducted telephone interviews with 5952 women 
enrolled in the multi-state National Birth Defects Prevention Study who delivered in the post 
folic acid fortification period from 1998 to 2005. These interviews took place between 6 weeks 
to 24 months postpartum. In their analysis of folic acid supplement use, their reference group 
was women with preconception supplement use. Folate use in the first as well as second/third 
trimester was associated with reduced odds of PTB (first trimester-aOR:0.69; 95% CI: 0.52, 0.99 
and second/third trimester-aOR: 0.54; 95% CI: 0.31, 0.93). However, sporadic or non-use was 
not associated with significantly different odds of PTB. There was also no association between 
dietary folate and dietary folic acid intake and PTB. 
In Nashville, Dunlop and colleagues explored maternal micronutrient status and PTB for 
Black and White US Women (97). Biospecimens and medical record data for this study were 
derived from a subsample of women enrolled into the Nashville Birth Cohort during 2003-2006. 
The study randomly selected 160 women (stratified by race- non-Hispanic black and non-
Hispanic white- as well as PTB status) out of 1547 eligible women as this was a pilot 
investigation. There was no significant difference in the mean concentration of folate collected at 
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delivery for women with PTB versus term birth. Their adjusted logistic regressions might have 
been hampered by insufficient power as seen with the very wide confidence intervals. 
In summary, although many studies on the folate- PTB relationship have been done in 
various settings, the results have been inconclusive. Systematic reviews revealed important 
limitations of previous studies, including dated studies, inaccurate definition of PTB and small 
sample sizes. US based studies suggest a significant reduction in PTB risk with folic acid 
supplementation or increased plasma folate, particularly among low income minority women. 
However, some gaps highlighted include the small sample size of studies of plasma folate assays. 
This present study is one of the few studies that explore the relation between folate and PTB 
using a relatively large number of plasma folate samples along with self-reported multivitamin 
supplementation. 
Review of potential mechanistic pathways in the folate-PTB- relationship 
Specific pathways that may explain the folate – PTB relationship include preeclampsia and 
intrauterine infection/inflammation (IUI) summarized in Table 2-2 below. 
Table 2-1: Summary of studies on intrauterine inflammation or preeclampsia in the folate-
PTB relationship 




cohort study in 
Pittsburgh, PA.  
Pregnant women (n = 417) 
at <16 weeks' gestation had 
serum samples that were 
analyzed for folate species and 
cervical fluid that was assayed 
for cytokine concentrations. 
Analyses include spearman 
correlation and locally weighted 
regressions. 
After confounder 
adjustment, maternal serum 
folate level had a strong negative 
association with elevated anti-
inflammatory scores; (P< .05). 
Maternal serum folate was 
associated with cervical cytokine 
concentrations, which suggests a 
possible mechanistic link 






Birth outcomes of newborns 
were evaluated in 1,017 (2.7%) 
pregnant women with medically 
recorded pre-eclampsia and 
There was a lower risk of 
PTB (6.8%) of newborn infants 
born to pregnant women with 
early onset pre-eclampsia after 
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37,134 pregnant women without 
pre-eclampsia 
folic acid supplementation from 
early pregnancy. There was no 
significant reduction in the rate 
of PTB and low birthweight in 
pregnant women with late onset 







The levels of folate, vitamin 
B12 and homocysteine were 
measured in mothers delivering 
preterm (PT; gestation <37 
weeks; n = 67), those delivering 
preterm due to preeclampsia 
(PT-PE; n = 49) and women 
delivering at term (control 
group; n = 76). 
Plasma folate levels were 
significantly reduced in the PT 
group (8.01 ± 5.1 ng/ml, p = 
0.014), while there was no 
difference in the PT-PE group 
(9.2 ± 5.8 ng/ml) as compared to 




The link between folate and PTB may also be possibly explained by preeclampsia-which 
complicates about 4-5% of pregnancies and occurs when physiologic expansion of the maternal 
circulation and hormonal changes leading to vasodilation and reduced blood pressure fail to 
occur (98-100).  
Few studies have explored the role of hypertension in the relation between folate and PTB. In 
Hungary, researchers evaluated the rate of PTB in the newborns of pregnant women with early 
and late onset pre-eclampsia according to folic acid supplementation (89). The study was 
conducted prior to folic acid fortification programs in 1998 and study participants include 1,017 
(2.7%) preeclamptic women and 37,134 pregnant women without pre-eclampsia enrolled in a 
National surveillance system between 1980 and 1996.  The study groups were differentiated per 
supplementation of high dose of folic acid alone from early pregnancy. Pregnant women with 
pre-eclampsia had a higher rate of PTB compared to those without preeclampsia (10.2% versus 
9.1%). There was a lower risk of PTB (6.8%) of newborn infants born to pregnant women with 
early onset pre-eclampsia after folic acid supplementation from early pregnancy. Folic acid 
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significantly reduced the rate of PTB (OR with 95% CI: 0.41, 0.18–0.94) in pregnant women 
with early onset PE.  
A cross sectional study in India assessed the relation between folate, preeclampsia and PTB 
(101). The levels of folate, vitamin B12 and homocysteine were measured in mothers enrolled in 
2007-2010, delivering preterm (PT; gestation <37 weeks; n = 67), delivering preterm due to 
preeclampsia (PT-PE; n = 49) and delivering at term (control group; n = 76). Women were given 
tablets of iron (100 mg per tablet) and folic acid (1 mg per tablet) during the 1st trimester of 
pregnancy. A food frequency questionnaire was used to estimate the frequency of intake of foods 
rich in folic acid and all women had limited access to folate fortified foods. Blood samples were 
collected just before delivery. Reduced folate levels were observed only in PT and not in PT-PE 
women as compared to the controls. Plasma folate levels were significantly reduced in the PT 
group (8.01 ± 5.1 ng/ml, p = 0.014), while there was no difference in the PT-PE group (9.2 ± 5.8 
ng/ml) as compared to the control group (9.2 ± 4.8 ng/ml). 
Although recent systemic reviews (102, 103) did not demonstrate a direct relation between 
folate and preeclampsia, other studies have shown that folate may prevent preeclampsia among 
high risk women. Similar patterns of associations were observed in analysis by RBC and serum 
folate levels and in dose-response analysis. A 2016 prospective cohort study in Canada (104) 
demonstrated that folate is associated with preeclampsia in high risk women. Specifically, the 
rate of PE was lower in the supplementation group (either supplementation with multiple 
vitamins containing folic acid or folic acid alone) than in the no supplementation group, but this 
difference was only statistically significant in high risk women- obese, with prior preeclampsia, 
chronic hypertension, diabetes or multiple pregnancy- (aOR: 0.42; 95% CI: 0.18, 0.98) for 
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supplementation with folate containing multivitamins and aOR: 0.17; 95% CI: 0.03, 0.95 for 
folic acid supplementation alone).  
In a 2016 retrospective study (105) a cohort of women who received daily oral 5-MeTHF 
15 mg supplementation as prophylactic treatment since the first trimester for recurrent 
preeclampsia were compared with women who did not. All asymptomatic singleton gestations 
with prior preeclampsia (in the previous pregnancy) were included and women with chronic 
hypertension were excluded. The study showed that women with prior preeclampsia who 
received daily oral 5-MeTHF 15 mg supplementation had a significantly lower incidence of 
overall preeclampsia, severe preeclampsia and early-onset preeclampsia.  
Intrauterine infection/inflammation  
There is evidence from the literature that IUI is a primary cause of 25%-40% of PTB cases 
(23). Specifically: (i) amniotic fluid of women with preterm labor have higher rates of microbial 
colonization and levels of inflammatory cytokines than women with preterm deliveries not 
associated with PPROM or term patients in labor (106); (b) intrauterine or systemic 
administration of microbes or microbial products to pregnant animals can result in preterm labor 
and delivery (107, 108); (c) subclinical intrauterine infections are associated with preterm labor 
and delivery (109); (d) patients with intra-amniotic infection (110) or intrauterine inflammation 
(i.e. elevation of amniotic fluid cytokines (111) and matrix-degrading enzymes (112) identified 
as early as the mid-trimester are at risk for subsequent preterm delivery. 
Studies suggest that PTB is associated with abnormal inflammatory responses, which may be 
triggered by intrauterine infection or hemorrhage (113). Folate is needed for normal immune 
function and folate-deficient individuals demonstrate immune dysfunction at both the cell-
mediated and humoral levels (114). In addition, the phagocytic and bactericidal role of 
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polymorphonuclear leukocytes have been shown to be decreased in individuals with folate 
deficiency, thereby increasing their susceptibility to infections such as asymptomatic bacteriuria 
and PTB (114-116). Inadequate maternal folate levels in pregnancy increases serum-C reactive 
proteins and inflammatory cytokine concentration which in turn is associated with shortened 
gestational age at delivery(117).  
Only one study has specifically explored the possibility of infection/inflammation as a 
mechanistic pathway in the folate-PTB relationship. Simhan, Bodnar and colleagues (118) 
conducted a follow up study in Pittsburgh in 2011 using the same population presented in 
Bodnar et al. The authors sought to explore the role of lower genital tract infection as a 
mechanistic link between folate and PTB. Their analysis included 417 women with plasma folate 
samples. In addition, their cervical fluid was analyzed for cytokine concentrations. Like Bodnar 
et al., study participants were patients of resident antepartum clinics in Pittsburgh, PA. The 
antepartum clinics served a predominantly publicly insured, low-income population that is 
approximately 55% black and 44% white. Eligible women were <16 weeks' gestation, non-
Hispanic white or non-Hispanic black (based on self-report), and had singleton pregnancies with 
no known preexisting conditions, vaginal bleeding, fetal anomalies, or current or planned 
cervical cerclage. At enrollment, a mean of 9.5 weeks of gestation, women underwent a standard 
pelvic examination and provided a nonfasting blood sample and completed a questionnaire on 
sociodemographic characteristics; medical, reproductive, and sexual history; and maternal 
behaviors. Results demonstrated that anti-inflammatory cytokine scores were negatively 
associated with serum 5MeTHF concentrations (r = –0.11; P < .05) and were positively 
associated with serum 5FoTHF (r = 0.19; P < .001). 
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The authors’ conclusions drew from their previous research (94) which showed that women 
with low 5MeTHF and high 5FoTHF had the highest risk of PTB. They identified this same 
subgroup of women as having a unique environment in their lower genital tract. The authors 
however alluded to some of the limitations of their study such as the sample size and study 
design limited their ability to study the relation between folate status and infection/inflammation 
in the upper genital tract. 
This dissertation aims to contribute significantly to the scant literature on the mechanistic 
pathways of the folate-PTB relationships. By using a relatively large sample of PTB, 
preeclampsia, as well as folate and placental pathology samples, this research is better poised to 
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This chapter presents research methodology of this dissertation, including the study design, data 
collection procedures, sample size and power calculations, definition of key variables, statistical 
analysis methods and ethical considerations. 
Study Population 
The data analyzed was from the ongoing Boston Birth Cohort (BBC) study on PTB, which 
commenced in 1998. To date, about 8500 mother-infant dyads have been enrolled at birth at the 
Boston Medical Center (BMC), a large urban hospital serving a predominantly low-income, 
minority, inner-city patient population. The overall rates of PTB were approximately 17% in this 
population compared with the national average of 9.6% (1).  Eligibility for the BBC study 
included delivery of a live singleton birth at BMC.  Exclusion criteria included pregnancies that 
are a result of in vitro fertilization or that involve multiple gestations, fetuses with chromosomal 
abnormalities or major birth defects, preterm deliveries due to maternal trauma, and women with 
congenital or acquired uterine lesions or incompetent cervix.  The BBC oversampled PTB and/or 
low birthweight, using an approximately 1:2 case-control ratio:  Cases were defined as women 
who delivered singleton, live, LBW (<2500 grams) or preterm infants (<37 weeks of gestation) 
regardless of birth weight. Controls were matched for maternal age and ethnicity and were 
defined as women who delivered singleton, live, term infants with birth weight 2500 g or more.  
Data Collection 
All eligible mothers were approached within 72 hours postpartum by research staff, who were 
fluent in Spanish, English or Haitian creole; and who were trained in research ethics as well as 
the study protocol to ensure data collection quality. Among eligible cases and controls who were 
approached by the research staff, about 90% agreed to participate in the study. After informed 
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consent was obtained, the study staff collected the following: epidemiologic data, clinical data 
and maternal venous blood and placental samples.  
Epidemiologic data was collected via maternal questionnaire interview with a standard 
questionnaire including the following modules: demographic characteristics, cigarette smoking, 
alcohol consumption, diet, medical and reproductive history. The interviews were typically 
conducted in the post-delivery ward and lasted on average 40 minutes.  
A standardized abstraction form was used to record data from medical records review, including 
prenatal and intrapartum clinical care, pre-pregnancy conditions, pregnancy complications, birth 
outcomes, ultrasonographic findings and laboratory test results.  
Placenta samples for histopathology, as well as maternal venous blood samples, were obtained 
according to standard protocol (2). A perinatal pathologist, not blinded to clinical information, 
examined all placentas (in accordance with College of American Pathologists guidelines (3)  
when clinically indicated, per BBC protocol. Pathologic placental lesions were diagnosed 
according to standard criteria (4). To verify reliability of diagnoses, a second perinatal 
pathologist independently reviewed a subset of placentas. Placental pathology diagnoses were 
recoded by a third perinatal pathologist into eight predominantly inflammatory and vascular 
categories, based upon the classification proposed by Redline (5). To establish reliability, the 
second perinatal pathologist confirmed the placental coding. Categories of the placental 
pathology include chorioamnionitis, chronic villitis, Maternal Vascular Malperfusion, marginal 
(venous) abruption, umbilical cord obstruction, fetal vascular malperfusion, villous stromal-
vascular abnormalities, and a miscellaneous group. A detailed description of the placental 




This dissertation employed data from 8,494 mother-infant dyads enrolled in the BBC. The final 
sample for analysis was 7,576 women with information on folic acid intake as well as a subset of 
the BBC (N=2,560) with measured folate biomarkers of folate at delivery. This subset of mothers 
was selected purposefully because their children were enrolled in the postnatal follow-up at the 
BMC. Of the 7,576, a total of 7,050 had data on IUI and thus for the hypotheses 2 c-d analyses, 
the sample size was 7,050 women and a subsample of 2,241 with folate biomarkers. 
Figure 3-1: Study Participants Flowchart 
 
As the study consists of a high-risk urban minority population and employs a case-control study 
design, the table below summarizes differences in the racial composition, socioeconomic status 
and key outcomes of interest between the BBC and national estimates.  
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Table 3-1: Comparison of the BBC study population with national estimates (N=7576) 
 
Key Variables 
The key outcome, PTB was defined as delivery before 37 completed weeks of gestation. 
Gestational age was determined using an algorithm based on last menstrual period and the result 
of early ultrasound dating (<20 weeks' gestation) as previously published (1). The last menstrual 
period estimate was used only if confirmed by an ultrasound within 7 days or if no ultrasound 
estimate was obtained; otherwise, the ultrasound estimate was used.  
Subtypes of Preterm birth: Spontaneous PTB was defined as PTB when preterm labor starts 
spontaneously or because of preterm premature rupture of membranes (pPROM). Medically 
indicated PTB was defined as delivery due to induction of labor or caesarean birth before 37 
completed weeks of gestation (8). 
The main predictor, maternal folate status is based on two complementary assessments: self-
reported multivitamin supplement intake and plasma biomarkers of folate status. 
Self-reported supplement intake: The data source is the postpartum questionnaire which 
includes the following questions: “Did you take prenatal vitamins prescribed by your doctor?” 
and “Did you take any over the counter vitamins?”.  

















Government assistance 84 21 (7) 
Preterm birth 27 9.6 
Preeclampsia 13 3-5 
Intrauterine infection/Inflammation 15 N/A 
Abbreviations: N/A: not applicable 
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Folic acid intake was determined during the maternal interview based on responses to the 
following questions: “Did you take prenatal vitamins prescribed by your doctor?” and “Did you 
take any over-the-counter multivitamins?” during pre-pregnancy (6 months prior to conception), 
1st trimester (day 1 to day 90 of pregnancy), 2nd trimester (day 91 to day 180 of pregnancy), 3rd 
trimester (day 181 of pregnancy to birth)? Response options for both questions is yes or no. 
Follow up questions assess frequency of use in the prepregnancy (6 months prior to conception), 
1st-, 2nd-and 3rd- trimester among those who responded yes. Response options include: less than 
once a week, one to two times a week, three to five times a week, almost daily.  
Based on responses to these two questions, preconception multivitamin intake was 
dichotomized (none vs. any). Intake for each trimester as well as across all trimesters was 
divided into the following categories: none, 1-2 times per week, 3-5 times, almost daily. In the 
US, prenatal or over-the-counter multivitamins typically contain 400 or 800 micrograms of folic 
acid and are instructed to be taken daily (9). A continuous measure of overall multivitamin 
supplement intake across all trimesters (referred to as “multivitamin supplement intake index”) 
was developed using principal component analysis to derive a composite index of multivitamin 
supplement intake across the three trimesters. For each trimester, frequency of intake was coded 
as none=0, 1-2 times per week=1, 3-5 times per week=3, almost daily=4. Thus, the composite 
index ranged from 0 to 12.  
Plasma folate assay is a more objective measurement of folate status in maternal blood (10). 
Plasma folate levels were measured using chemiluminescent immunoassay with diagnostic kits 
(Shenzhen New Industries Biomedical Engineering Co., Ltd. China) (11) using a Beckman 
Coulter ACCESS Immunoassay System (Beckman-Coulter Canada, Mississauga, Canada) (11). 
Plasma folate levels were assessed as i) a continuous variable in nmol/L; ii) a transformed 
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continuous variable for each interquartile unit in nmol/L; iii) quartiles of plasma folate levels; 
and iv) categorizations per the World Health Organization (WHO) guidelines (folate 
deficiency/insufficiency (<13.5nmol/l); normal (13.5-45.3nmol/l) and elevated (> 
45.3nmol/l)).(12). 
Preeclampsia was defined as hypertension of new-onset during pregnancy and proteinuria ≥300 
mg protein in 24 h. Gestational hypertension was defined as new onset hypertension during 
pregnancy without proteinuria.  Eclampsia was the occurrence of seizures in a woman with 
preeclampsia that could not be attributed to other causes. The constellation of hemolysis, 
elevated liver enzymes and low platelets developing during pregnancy defined HELLP syndrome 
[32]. Data sources include abstracted medical records for all study participants. In the data 
analyses, the term preeclampsia includes all four conditions: preeclampsia, gestational 
hypertension, eclampsia, and HELLP syndrome. 
Intrauterine infection/inflammation (IUI) is defined as presence of maternal intrapartum fever 
as documented in medical records and/or placental pathology evidence of IUI: specifically, the 
presence of villitis, deciduitis, chorioamnionitis, chorionitis, subchorionitis, funisitis, and free 
membranitis from placental histology (13).  
Other covariates included sociodemographic factors such as: maternal age at delivery (<20, 20-
34, 35+ years), maternal education (≤elementary, high school or ≥college), race/ethnicity (non-
Hispanic Black, non-Hispanic White, Hispanic and Other), marital status (unmarried versus 
married), parity (nulliparous versus multiparous),  receipt of public assistance including: WIC 
(Women Infants and Children), food stamps, AFDC (Aid to families with dependent children), 
housing assistance or fuel assistance (yes versus no) and maternal nativity (US born versus non-
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US born). Behavioral risk factors included alcohol use (never versus any), smoking status (never 
used, ever used, used in pregnancy) and stress (mother’s report of life or pregnancy as being 
‘very’ stressful). The above variables were based on maternal questionnaire interview.  
Other maternal factors from medical records include maternal diabetes (presence of either 
gestational or pre-gestational diabetes) and prepregnancy BMI grouped into 4 categories: normal 
weight (18.5-24.9kg/m2), underweight (<18.5kg/m2), overweight (25-29.9kg/m2), and obesity 
(>30kg/m2).  
The table below highlights the variables included in the analytical models. 
Table 3-2: Description of Variables Included in Analysis 
Variables of interest Data source Definition  Value labels 
Key variables 
Preterm birth Medical Records Gestational age derived 
from LMP and early 
ultrasound <20 weeks 
Binary: <37 weeks yes 
or no (reference).  
Plasma folate levels Plasma folate 
assay  






quartiles, per WHO 
categorization ( 
Folate insufficiency, 
normal (reference) and 
excess levels) 




Intake of supplement in 
pre-pregnancy, 1st, 2nd 
and 3rd trimester 
Categorical: by time 
periods and by 































Other covariates of interest 
Other medical conditions  











weight in kg/height in 





Demographic factors  




Maternal age in years Categorical: <20, 20-








Hispanic and Other 
Marital status Postpartum 
questionnaire 
Marital status at 
delivery 
Binary: Unmarried or 
married (reference) 
Education  Postpartum 
questionnaire 




school or ≥college 
Public assistance Postpartum 
questionnaire 
Receipt of any of the 
following: WIC 
(Women Infants and 
Children), Food 
Stamps, AFDC (Aid to 
families with 
dependent children), 
Housing assistance or 
Fuel assistance 
Binary: Yes, versus no  
Parity Postpartum 
questionnaire 




(≥1) or primiparous  
Behavioral risk factors 




Use of cigarettes, 
cigars, tobacco or snuff 
6 months pre-
pregnancy and by 
trimester 
Categorical: never 




Variables of interest Data source Definition  Value labels 




Alcohol consumption 6 
months pre-pregnancy 
and by trimester 
Categorical: never 
used, ever used, used in 
pregnancy 
Stress  Postpartum 
questionnaire 
Self-reported 
categorization of the 
amount of stress in life 
or pregnancy as being 
‘very’, ‘average’ or 
‘not’ stressful. 
Categorical: no stress 




Data Preparation: All analyses were conducted using STATA version 14. Preliminary data 
analysis was performed in the total sample and plasma folate subsample. Exploratory data 
analysis included descriptive statistics of all variables included in the analytic model - 
frequencies, means, standard deviations as well as histograms, box- and scatter- plots were used 
to identify invalid responses, outliers, and missing values. Chi-squared tests for categorical 
variables and t-tests for continuous variables were used to compare maternal characteristics by 
PTB status. 
Aim 1: Evaluate the relationship between maternal folate status (using complementary 
measures and assessed from preconception to delivery) and risk of PTB. 
Hypothesis:  
 Self-reported frequency of multivitamin supplement intake during the preconception 
(6-month prior to preconception) period is not associated with PTB (including PTB 
subtypes- spontaneous and medically indicated PTB) 
 Self-reported frequency of multivitamin supplement intake during pregnancy (first, 
second and third trimester) is not associated with PTB (including PTB subtypes- 
spontaneous and medically indicated PTB) 
 Maternal plasma folate levels at delivery (a proxy of 3rd trimester folate status) is not 





Principal component analysis was used to create a “multivitamin supplement intake index” 
during pregnancy. For each trimester, frequency of intake was coded as none=0, 1-2 times per 
week=1, 3-5 times per week=3, almost daily=4. Thus, the composite index ranged from 0 to 12 
(Cronbach’s alpha=0.87). Unadjusted and adjusted logit regressions were used to graph the 
probability of PTB by plasma folate level. Crude and adjusted logistic regressions were used to 
explore the relationship between PTB and self-reported multivitamin supplement intake and 
plasma folate level. Additional analyses were conducted for the PTB subgroups of spontaneous 
and medically indicated PTB. All P-values in the analyses were two-sided and the Type I error 
rate was set at 0.05.  
An example of the multivariate logistic regression model (full model) used to explore the 
relationship between PTB and multivitamin supplement intake is presented as 
log𝑒 (
Pr( 𝑝𝑟𝑒𝑡𝑒𝑟𝑚 𝑏𝑖𝑟𝑡ℎ = 𝑦𝑒𝑠)
Pr( 𝑝𝑟𝑒𝑡𝑒𝑟𝑚 𝑏𝑖𝑟𝑡ℎ = 𝑛𝑜)
) =  𝛽0 +  𝛽1 . 𝑋𝑝𝑟𝑒𝑐𝑜𝑛𝑐𝑒𝑝𝑡𝑖𝑜𝑛 𝑓𝑜𝑙𝑎𝑡𝑒 𝑖𝑛𝑡𝑎𝑘𝑒 +  𝛽2 . 𝑋2 + ⋯ + 𝛽15 . 𝑋15  
In the equation above, other covariates include maternal race, age, nativity, education, marital 
status, receipt of public assistance, parity, cigarette use, alcohol use, stress, body mass index 
(BMI), preeclampsia, IUI and diabetes mellitus. 
Similar logistic regressions were conducted using maternal plasma folate levels as i) a 
continuous variable in nmol/L; ii) a transformed continuous variable for each interquartile unit in 
nmol/L; iii) quartiles of plasma folate levels; and iv) categorizations per the World Health 
Organization (WHO) guidelines (folate deficiency/insufficiency (<13.5nmol/l); normal (13.5-
45.3nmol/l) and elevated (> 45.3nmol/l)). An example of the multivariate logistic regression 
model used to explore the relationship between PTB and plasma folate concentration at delivery 




Pr( 𝑝𝑟𝑒𝑡𝑒𝑟𝑚 𝑏𝑖𝑟𝑡ℎ = 𝑦𝑒𝑠)
Pr( 𝑝𝑟𝑒𝑡𝑒𝑟𝑚 𝑏𝑖𝑟𝑡ℎ = 𝑛𝑜)
) =  𝛽0 +  𝛽1 . 𝑋𝑝𝑙𝑎𝑠𝑚𝑎 𝑓𝑜𝑙𝑎𝑡𝑒 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 +  𝛽2 . 𝑋2 + ⋯ + 𝛽15 . 𝑋15  
 
Aim 2: Investigate biologic plausibility of the folate-PTB association by evaluating the role 
of folate on major pathogenic pathways leading to PTB (including PTB subtypes- 
spontaneous and medically indicated PTB). 
 
Hypotheses 2a and 2c:  
 Maternal folate status (assessed by self-report and biomarker) does not moderate 
the relationship between preeclampsia in pregnancy and PTB (including overall 
and medically indicated PTB). 
 Maternal folate status (assessed by self-report and biomarker) does not moderate 
the relationship between IUI and PTB (including overall and spontaneous PTB). 
 
Potential interaction of preeclampsia or IUI on the relationship between folate status and PTB 
can include either additive or multiplicative effects. Additive effects can be described as the 
extent to which the effect of two factors on an outcome together exceeds the effect of each 
considered individually. On the other hand, the multiplicative effects measure the extent to 
which the effect of both exposures together exceeds the product of the effects of the two 
exposures considered separately.  Thus, in a logistic model, additive effects would be equal to 
OR11 - OR10 - OR01 +1 while the multiplicative effects would be OR11/ OR10 x OR01 where OR11 
would be interpreted as the effect of both factors together and the expressions OR10 and OR01 
would be the effects of the first factor and the second factor, respectively. In a hypothetical 
model: 
𝑙𝑜𝑔𝑖𝑡 1{𝑃(𝐷 = 1| 𝐺 = 𝑔, 𝐸 = 𝑒, 𝐶 = 𝑐)} = 𝛾0 +  𝛾1𝑔 + 𝛾2𝑒 +  𝛾3𝑒𝑔 +  𝛾4𝑐 
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The main effects, γ1 and γ2, when exponentiated, simply give the odds ratios for each of the two 
exposures. The coefficient γ3, when exponentiated, gives the measure of multiplicative 
interaction for odds ratios while the additive effects would be equal to:  
 𝑒𝛾1+ 𝛾2+ 𝛾3 − 𝑒𝛾1 − 𝑒𝛾2 + 1.   
Thus, the use of logistic regressions in data analysis will help to explore both additive and 
multiplicative effects of preeclampsia and IUI on the relationship between folate status and PTB.  
 
Hypotheses 2b and 2d:  
 Preeclampsia does not mediate the relationship between maternal folate status and 
PTB (including overall and medically indicated PTB). 
 IUI does not mediate the relationship between maternal folate status and PTB 
(including overall and spontaneous PTB). 
 
To explore the potential mediating influence of preeclampsia or IUI on the relationship between 
plasma folate levels and PTB, mediation analysis was done using the Baron and Kenny approach 
(14) with a series of logistic regressions. According to Baron and Kenny (15), mediation is 
demonstrated when the following conditions are met: (a) the main independent variable is 
significantly associated with the main dependent variable; (b) the independent variable is 
significantly related to the mediator variable; and [3] the mediator variable is significantly 
associated with the dependent variable when the independent variable is controlled for. Thus, the 
total effect is the sum of the direct effect between the independent and dependent variable and 
indirect effect that occurs via the mediator variable. This can be represented as:  
c = c' + ab 
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Where c is the total effect, c’ is the direct effect and ab is the indirect effect which is the product 
of the two path coefficients from the independent to the mediator and from the mediator to the 
dependent variable. Following the Baron and Kenny analysis strategy to explore preeclampsia 
mediating the relationship between folate status and PTB, the mediation analysis first identified 
the relationship between folate status (causal variable) and PTB (dependent variable). Next, the 
relationship between folate status and preeclampsia (mediating variable), and the relationship of 
preeclampsia with PTB were explored. Finally, the association between folate status and PTB 
controlling for preeclampsia was conducted. 
In Stata, the binary_mediation command was used to perform the mediation analysis because the 
mediating variable- preeclampsia disorder- was dichotomous. In addition, the bootstrap 
command was used to obtain standard errors and confidence intervals of direct and indirect 
effects while the medeff command was used to provide standard errors and confidence intervals 
for the mediation effect.(15). All analyses were conducted using software STATA version 14. 
All P-values in the analyses were two-sided and Type I errors were set at 0.05.  
 
Sample size/power calculation 
The sample size and power calculation for the proposed research was influenced by the 
recommendations of Hsieh (16, 17) who suggested the following: 1) The use of a simplified 
sample size formulae for comparing proportions in order to calculate the required sample size for 
a simple logistic regression model and 2) Subsequently, one can then adjust the required sample 
size for a multiple logistic regression model by a variance inflation factor that takes into account 
the multiple correlation coefficient of covariates included in the model. This method requires no 
assumption of low response probability in the logistic model. 
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The sample size and power calculation for this dissertation was calculated for interactions 
between folate status and preeclampsia (Aim 2c) presented below. As this aim uses a sub-group 
of the sample with plasma folate assays (N=2313), it is chosen as an example to demonstrate 
power and sample sizes. 
First, the sample size was calculated for univariate logistic regressions (17) having an 
overall PTB proportion (P=0.31, from the plasma folate data) and an odds ratio of PTB due to 
folate insufficiency ranging from 1.1-1.3 with an alpha of 0.05 (one tailed) and power ranging 
from 0.7-0.9. The resulting sample size was then adjusted for multivariate logistic regressions by 
dividing the sample size by a variance inflation factor of 1-ρ2 where ρ is the multiple correlation 
coefficient relating folate to the other confounding variables included in the analysis (1-ρ2 is 
estimated at 0.9811 from the data).  














0.05 0.31 0.9 1.1 0.9811 5139 
0.8 1.1 3711 
0.9 1.2 1413 
0.8 1.2 1022 
0.9 1.3 689 
0.8 1.3 499 
Abbreviations: OR: odds ratio; PTB: preterm birth; ρ: multiple correlation coefficient Note: 




This dissertation conducted secondary data analysis using BBC study data. The BBC study 
protocol was approved by the institutional review boards of Boston University Medical Center, 
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the Ann & Robert H. Lurie Children’s Hospital of Chicago (formerly Children’s Memorial 
Hospital of Chicago), and the Johns Hopkins Bloomberg School of Public Health (JHSPH). All 
research conformed to data procurement, management and analysis procedures set forth by the 
JHSPH IRB. Furthermore, I completed all the necessary training of ethics of health research and 
have been approved as a student investigator to use the BBC data for my dissertation research by 
JHSPH IRB. 
The main potential risk involved in this study is the breach of confidentiality of Health 
Information Portability and Accountability Act (HIPAA) protected patient information for study 
participants. All data used in this study did not contain personal identifiers and was stored on 
encrypted secure network servers.  
Table 3-4: Study Timeline 
 ACTIVITY 2017 2018 
  04 05 06 07 08 09 10 12 01 02 03 














      
Dataset merging             
Aim 1 analyses            
Aim 2 a-b analyses            
Aim 2 c-d analyses             
  
Dissertation preparation  
and manuscript development 
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Chapter Four: Manuscript I 
Maternal folate status and preterm birth in a high-risk US population 





Background: While maternal folate deficiency has been linked to poor pregnancy outcomes such 
as neural tube defects, anemia and low birth weight, the relationship between folate and preterm 
birth (PTB) in the context of US post folic acid fortification era is inconclusive. 
Objective: To explore the relationship between maternal folate status and PTB and its subtypes– 
spontaneous and medically indicated PTB.   
Design: This analysis included 7,675 mother-infant dyads enrolled in the Boston Birth Cohort, 
an observational study of a predominantly urban, low income, race-ethnic minority population at 
a high-risk for PTB. We examined complementary measures of folate status: the frequency of 
multivitamin supplement intake prior to and during pregnancy and maternal plasma folate 
concentration at delivery. A subsample (n=2,313) of these dyads had maternal plasma folate 
assays.  
Results: Unadjusted and adjusted logistic regressions revealed an inverse relationship between 
the frequency of multivitamin supplement intake and PTB. Compared to less frequent use, 
multivitamin supplement intake 3-5 times/week (adjusted odds ratio (aOR)= 0.78, 95% 
confidence interval (CI): 0.64, 0.96) or >5 times/week (aOR= 0.77, 95% CI: 0.64, 0.93) 
throughout pregnancy was associated with reduced risk of PTB. Consistently, higher plasma 
folate levels (highest versus lowest quartile) were associated with lower risk of PTB (aOR= 0.74, 
95% CI: 0.56, 0.97). The above associations were similar among spontaneous and medically 
indicated PTBs.  
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Conclusions: Our findings raise the possibility that optimizing maternal folate levels across 
pregnancy may help to reduce the risk of PTB among the most vulnerable US population in post 





Preterm birth (PTB, birth before 37 completed weeks of gestation) has been recognized as 
one of the most pressing challenges to maternal and child health in the United States and the 
world (1). The role of maternal nutrition remains a promising but understudied area of 
investigation in the identification of important and modifiable risk factors for PTB. 
Folates are a group of naturally occurring water-soluble B vitamins involved in biological 
reactions needed for fetal and placental growth such as DNA synthesis, repair and methylation 
(2). Maternal folate deficiency is a modifiable nutritional status that has been linked with adverse 
pregnancy outcomes such as neural tube defects, congenital anomalies, low birthweight, 
maternal megaloblastic anemia and preeclampsia (3-5). Folic acid is a synthetic form of folate 
that is used in multivitamin supplements and grain product fortification. Despite the 
establishment of national folate intake recommendations and mandatory folic acid fortification 
programs in the US since 1998 (6, 7), folate consumption is still of public health significance as 
data suggests that 25% of women of reproductive age have insufficient folate levels (8).  
To date, much attention has been paid to the role of periconception folate intake to prevent 
neural tube defects (NTDs) in offspring (a first trimester event) (9-12). However, considerable 
knowledge gaps remain regarding the role of folate in PTB (a third trimester event). Some US 
studies have found an association between lower folate status and PTB, (13-17) while other 
studies found no association. (18, 19). These mixed results may be due to variations across 
studies in terms of sociodemographic characteristics of the study population, whether the studies 
were conducted prior to or after the mandatory folic acid fortification program, differences in 
definitions and measurement of folate status (self-reported intake versus biomarkers), and/or 
timing of folic acid administration (preconception versus specific trimesters). The optimal timing 
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of folic acid intake in relation to PTB remains unclear i.e., whether there is a critical window of 
folic acid intake such as the periconception period as has been demonstrated in the folate-NTDs 
relationship versus during specific trimester of gestation, given PTB is a later event. To date, 
most relevant studies were based on self-report of folic acid supplementation, which is known to 
be imprecise and associated with large variation in plasma folate levels, a biomarker of folate 
nutritional status (20). There is a need for contemporary post folic-acid-fortification studies that 
examine the associations between folic acid intake as well as folate biomarkers and PTB and 
how the association between folate status and PTB varies by PTB sub types- spontaneous vs. 
medically indicated (induced) PTB in high-risk US populations. 
Our study sought to address the aforementioned gaps in understanding of the association 
between maternal folate status and PTB in a large, predominantly urban low-income minority 
birth cohort in the US. Specifically, we examined the relationship between PTB and self-reported 
preconception (six months prior to pregnancy) and pregnancy multivitamin supplementation 
(during each trimester), as well as biomarker measures of maternal plasma folate at delivery. We 
also explored whether the associations differed for spontaneous vs. medically indicated PTB. 
Subjects and methods 
Study population 
We analyzed data from the ongoing Boston Birth Cohort (BBC) study which commenced in 
1998 (21, 22). The BBC is registered at https://clinicaltrials.gov/ct2/show/NCT03228875.  
To date, over 8,500 mother-infant dyads have been enrolled in the study. Mothers who 
delivered at the Boston Medical Center (BMC), which serves a predominantly low-income, 
minority, inner-city patient population, were recruited 24-72 hours after delivery while still 
hospitalized. Cases were defined as mother-infant dyads with singleton, live, low birthweight 
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(LBW; <2,500 grams) or preterm infants (<37 weeks of gestation) regardless of birthweight. 
Controls were defined as mother-infant dyads with singleton, live, term infants with birthweight 
2,500 g or more. Of note, this paper specifically examines PTB versus. term birth, regardless of 
birthweight. 
Data collection 
After informed consent was obtained, the study staff collected the epidemiological data, 
clinical data and maternal venous blood and placental samples. Epidemiological data were 
collected via an in person maternal questionnaire interview. Clinical data were abstracted from 
medical records using a standardized form. Plasma folate levels were measured in a subsample 
of the maternal blood samples obtained within 24-72 hours postpartum from mothers who 
continued to receive care at BMC.   
Definition of key variables 
PTB was defined as delivery before 37 completed weeks of gestation. Gestational age was 
determined using an algorithm based on the first day of the last menstrual period and the results 
of early ultrasound (<20 weeks' gestation), as previously published (22).  
Multivitamin supplement intake was determined during the maternal interview based on 
responses to the following questions: “Did you take prenatal vitamins prescribed by your 
doctor?” and “Did you take any over-the-counter multivitamins?” during pre-pregnancy (6 
months prior to conception), 1st trimester (day 1 to day 90 of pregnancy), 2nd trimester (day 91 to 
day 180 of pregnancy), 3rd trimester (day 181 of pregnancy to birth)? Response categories 
included: none, 1 time per week, 2 times per week, 3-5 times per week, and almost daily. Based 
on responses to these two questions, preconception multivitamin intake was dichotomized (none 
vs. any). Intake for each trimester as well as across all trimesters was divided into the following 
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categories: none, 1-2 times per week, 3-5 times, almost daily. In the US, prenatal or over-the-
counter multivitamins typically contain 400 or 800 micrograms of folic acid and are to be taken 
daily (23). A continuous measure of overall multivitamin supplement intake across all trimesters 
(henceforth referred to as the “multivitamin supplement intake index”) was developed by adding 
multivitamin intake across the three trimesters to create a composite index of multivitamin 
supplement intake across pregnancy. For each trimester, frequency of intake was coded as 
none=0, 1-2 times per week=1, 3-5 times per week=3, almost daily=4. Thus, the composite index 
ranged from 0 to 12.  
Plasma folate concentrations were measured using chemiluminescent immunoassay with 
diagnostic kits (Shenzhen New Industries Biomedical Engineering Co., Ltd. China) using a 
Beckman Coulter ACCESS Immunoassay System (Beckman-Coulter Canada, Mississauga, 
Canada) (24). Plasma folate levels were assessed as i) a continuous variable in nmol/L; ii) 
quartiles of plasma folate levels; and iii) categorizations per the World Health Organization 
(WHO) guidelines (folate deficiency/insufficiency (<13.5nmol/l); normal (13.5-45.3nmol/l) and 
elevated (> 45.3nmol/l)) (25). 
Other covariates included sociodemographic factors such as: maternal age at delivery (<20, 
20-34, 35+ years), maternal education (≤elementary, high school or ≥college), race/ethnicity 
(non-Hispanic Black, non-Hispanic White, Hispanic and Other), marital status (unmarried versus 
married), parity (nulliparous versus multiparous),  receipt of public assistance including: WIC 
(Women Infants and Children), food stamps, AFDC (Aid to Families with Dependent Children 
now known as Temporary Aid to Needy Families), housing assistance or fuel assistance (yes 
versus no) and maternal nativity (US born versus foreign born). Behavioral risk factors included 
alcohol use (never versus any), smoking status (never used, ever used, used in pregnancy) and 
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stress (an indicator for mother’s report of life or pregnancy as being ‘very’ stressful). Biomedical 
factors from abstracted records included preeclampsia (preeclampsia, eclampsia, gestational 
hypertension, hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome), 
maternal diabetes (presence of either gestational or pre-gestational diabetes), intrauterine 
infection/inflammation (IUI, defined as presence of maternal fever or placenta pathology 
findings of villitis, deciduitis, chorioamnionitis, chorionitis, subchorionitis, funisitis, free 
membranitis) and prepregnancy BMI grouped into 4 categories: underweight (<18.5kg/m2), 
normal weight (18.5-24.9kg/m2), overweight (25-29.9kg/m2), and obesity (>30kg/m2).  
Ethics 
The study protocol was approved by the Institutional Review Boards of Boston University 
Medical Center and the Johns Hopkins Bloomberg School of Public Health. 
Statistical analysis 
All analyses were conducted using STATA version 14 (College Station, TX: StataCorp LP). 
Preliminary data analysis was performed in the full sample (N= 7,576) of all enrolled women 
with multivitamin supplement intake data and plasma folate subsample (n=2313) of these women 
that received follow- up pediatric care at BMC. Chi-squared tests for categorical variables and t-
tests for continuous variables were used to compare maternal characteristics by PTB status. 
Cronbach’s alpha was used to ensure the reliability of the scale “multivitamin supplement intake 
index” (Cronbach’s alpha=0.87). Unadjusted and adjusted logit regressions were used to graph 
the probability of PTB by plasma folate level. Crude and adjusted logistic regressions were used 
to explore the relationship between PTB and self-reported multivitamin supplement intake and 
plasma folate level. Supplemental analyses were conducted for the PTB subgroups of 
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spontaneous and medically indicated PTB. All P-values in the analyses were two-sided and the 
Type I error rate was set at 0.05.  
Results 
This study was based on a full sample of 7,576 women with complete multivitamin 
supplement intake information from six months before conception to the third trimester of 
pregnancy and a sub-sample (n=2,313) with plasma folate samples collected at delivery. Those 
included in the full sample and those who had plasma folate data had similar baseline 
characteristics, except for a higher proportion of non-Hispanic Black mothers and PTBs in the 
subsample.    
Table 1 displays the maternal characteristics for the total study population and plasma folate 
subsample (maternal characteristics by PTB subtype are presented in Supplemental Table 1). In 
the full sample, 27% of women had a preterm delivery. Compared to women with term births, 
women with PTB were more likely to be Non-Hispanic Black, older, US-born, unmarried, 
cigarette smokers, alcohol consumers and report a very stressful life or pregnancy. These women 
were also likely to have had preeclampsia, IUI, diabetes mellitus and be obese/overweight.  
Within the plasma folate subsample, 31% of women experienced PTB. The mean plasma 
folate concentration at delivery was 32.3 nmol/L for PTB, significantly lower than 36.3 nmol/L 
for term births. Significant associations between maternal characteristics and PTB that were seen 
in the total supplement intake sample persisted in the plasma folate subsample. Plasma folate 




Table 2 displays the association between self-reported multivitamin supplement intake and 
PTB (analysis by PTB subtypes is presented in Supplemental Table 2). The overall 
multivitamin supplement intake across pregnancy was significantly associated with PTB. 
Specifically, each unit increase in the multivitamin supplement intake index reduced the odds of 
PTB (aOR= 0.98, 95% CI:0.97, 0.99). As a categorical variable, consistent multivitamin 
supplement intake (3-5 times/week or >5 times/week) reduced the odds of PTB compared to no 
intake across pregnancy (aOR= 0.78, 95% CI: 0.64, 0.96; aOR= 0.77, 95% CI: 0.64, 0.93, 
respectively). The relationship between multivitamin supplement intake across different time 
points and PTB showed that intake during the preconception period did not reduce PTB odds. 
Intake during the first trimester (>5 times/week) was associated with a reduction in PTB odds 
(aOR= 0.85, 95% CI: 0.73, 0.98). During the third trimester, intake of 3-5 times/week and >5 
times/week was associated with lower odds of PTB (aOR= 0.75, 95% CI: 0.63, 0.85; aOR= 0.74, 
95% CI: 0.64, 0.87, respectively). There was no significant difference in the odds of PTB among 
women with consistent multivitamin supplement intake of one to two times/week throughout 
pregnancy compared to no intake throughout pregnancy. Sensitivity analysis presented in 
Supplemental Table 2 showed a consistent pattern of multivitamin supplement intake at all time 
points with PTB among non-Hispanic Blacks only. 
Table 3 displays the unadjusted and adjusted odds of PTB by plasma folate concentration 
(analysis by PTB subtypes is presented in Supplemental Table 3). Each unit and interquartile 
increase in plasma folate concentration reduced the odds of PTB (aOR= 0.99, 95% CI: 0.99, 
1.00; aOR= 0.88, 95% CI:0.79, 0.97, respectively). This association persisted when plasma 
folate concentration was categorized. Compared to the lowest quartile (<19.4 nmol/L), the 
highest quartile of plasma folate concentration (>43.8 nmol/L) was associated with an over 25% 
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reduction in PTB odds (aOR= 0.72, 95% CI: 0.54, 0.94). Similarly, excess plasma folate 
concentration (>45.3 nmol/L) was associated with reduced odds of PTB (aOR= 0.74, 95% CI: 
0.56, 0.97) compared with normal plasma concentration (13.5-45.3 nmol/L).  
Figure 1 displays the association between plasma folate concentration at delivery and 
probability of PTB, stratified by subtypes. Plasma folate concentration demonstrated a mild 
curvilinear relationship with overall PTB, a linear relationship with spontaneous PTB, and a 
curvilinear relationship with medically indicated PTB where higher concentrations of plasma 
folate were associated with a reduced probability of PTB or its subtypes.  
In Table 4, the relationship between plasma folate concentration and spontaneous versus 
medically indicted PTB is presented. The final regression model for medically indicated PTB did 
not include biomedical risk factors to avoid the introduction of factors potentially in the causal 
pathway. Each unit increase in plasma folate concentration was associated with reduced odds of 
spontaneous (aOR= 0.99, 95% CI: 0.99, 1.00) as well as medically indicated (aOR= 0.98, 95 % 
CI: 0. 0.98, 0.99) PTB. Among medically indicated PTB, plasma folate concentration in the 
highest quartile was associated with a reduction in the odds of PTB; this relationship did not 
reach statistical significance for spontaneous PTB. Plasma folate concentrations greater than 45.3 
nmol/L were associated with a 30% reduction in the odds of spontaneous (aOR: 0.72; 95% CI: 
0.55, 0.95) and medically indicated PTB (aOR: 0.58; 95% CI: 0.40, 0.82).  
Discussion 
In our full sample, multivitamin supplement intake and plasma folate concentrations were 
generally adequate or high, as expected in this era of mandatory folic acid fortification of the 
food supply.  Still, about a quarter of women had a relatively low plasma folate concentration 
(<19.4nmol/L), which was associated with an increased risk of PTB. 
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After controlling for confounding factors, our analysis shows that multivitamin supplement 
intake of at least 3 times/week throughout pregnancy was significantly associated with a 
reduction in the odds of PTB, consistent with other US based prospective studies that have 
assessed dietary folate intake (13, 15). A study in a low-income minority population showed that 
low (≤240μg/day) and intermediate (241–400μg/day) dietary folate intake were associated with 
an increased risk of PTB, respectively, as compared with women who had a folate intake 
>400μg/day (13). In another study, dietary folate intake ≤500μg was associated with an almost 
two times greater risk of preterm delivery (15). 
We note that there was no significant association between preconceptional supplement intake 
and PTB, contrary to the findings of Bukowski et al., which demonstrated a 50%-70% related 
reduction in the incidence of early spontaneous PTB. However, in our study, preconception 
supplement intake was very low (7.1%) and may have resulted in reduced statistical power to 
detect significant associations. Multivitamin supplementation in the first and third trimester were 
both significantly associated with reduced PTB odds, with use during the third trimester 
associated with a greater reduction in PTB odds compared to use during the first trimester. While 
it is unclear why second trimester multivitamin supplement intake is not associated with PTB, 
these findings suggest that the third trimester may be a critical time window in the folate-PTB 
relationship. While folate is needed for maternal tissue and fetal and placental growth throughout 
pregnancy, the rapid fetal development occurring during the third trimester is associated with 
maximum folate catabolism and thus increased requirements during this critical period (26, 27). 
Studies show that women who stopped multivitamin or folic acid supplementation after the first 
trimester had lower concentrations of maternal serum and red blood cell folate concentrations 
(26-28). The association between multivitamin supplement intake and PTB was corroborated 
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using plasma folate concentration at delivery. Increasing plasma folate concentrations 
significantly reduced the odds of PTB. Our findings are consistent with other US-based studies 
wherein each 1 nmol/L increase in serum folate concentration at 28 weeks of gestation was also 
associated with reduced risk of PTB (13) and serum folate concentration less than 36.9 nmol/L in 
the second trimester led to a nearly twofold increased risk of PTB (15). These findings 
demonstrating the relationship between maternal folate status and PTB are particularly important 
given that the national PTB rates have remained high, 10.4% in 2007, and 9.8% in 2016 despite 
research and intervention efforts (29). Our research on a predominantly minority population is 
also appropriate given that PTB rates was lowest among non-Hispanic Asian births (8.6%) and 
highest among non-Hispanic black births (13.8%) (29).  
Maternal factors well demonstrated in the literature to be associated with, but not necessarily 
in the causal pathway of PTB, include demographic, obstetric, medical, and psychosocial risk 
factors (30). However, the underlying mechanisms for the link between folate and PTB are not 
well-understood, but appear to be biologically plausible. For example, variations in key genes 
involved in folate metabolism such as dihydro folate reductase (DHFR) and serine hydroxy-
methyl transferase (SHMT1) appear to increase the risk for spontaneous PTB (31). Other 
mechanistic pathways that may explain the folate – PTB relationship include 
hyperhomocysteinemia, placental implantation and IUI (32, 33). Low folate status is associated 
with hyperhomocysteinemia, which has been linked with increased arterial stiffness, insulin 
resistance and endothelial dysfunction. Folate may also affect placental implantation and 
vascular remodeling through its role as a superoxide scavenger in antioxidant defenses (32). 
Folate deficiency is also associated with abnormal inflammatory responses, which could 
conceivably trigger premature parturition in the context of IUI (34, 35).  
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Strengths of our study include the use of complementary measures of folate status- from 
maternal self-report (capturing pattern of long-term use) and more objective biomarkers, 
providing multi-measure consistent evidence to support the folate-PTB relationship. The study is 
the largest investigation with recent birth cohort data on plasma folate and PTB published to 
date, and is the first one that performed PTB subtype analyses. While maternal folate status has 
been linked with spontaneous PTB (17), its relationship with medically indicated PTB has only 
been demonstrated in animal studies (36). Again, such research is particularly relevant among 
high risk populations such as Non-Hispanic Blacks which have lower folate levels compared to 
other race/ethnic groups (8) and higher proportion of medically indicated PTB (37).  
Our study contributes new knowledge to the field by exploring specific patterns of 
multivitamin supplementation during the preconception period and across trimesters. This 
facilitates identifying the critical period over the course of pregnancy to reinforce adequate folate 
intake to reduce PTB. Finally, our study focuses on the high-risk non-Hispanic black US 
populations in need for interventions to address both PTB and lower folate status.   
We, however, acknowledge some limitations. Plasma folate concentration at delivery can 
only be used as a proxy for third trimester folate concentration as it reflects short term folate 
status within the past few days (38).  In addition, multivitamin supplement intake was based on 
self-report, which is subject to recall bias. Also, the determination of folate status based on the 
frequency of supplement intake may be incomplete since folate status may also be influenced by 
dietary intake of folate rich/fortified foods and other factors affecting folate metabolism. Due to 
the high correlations between multivitamin supplement intake across all trimesters (rho: 0.58- 
0.85, p<0.001), further adjustments for intake during other trimesters were not conducted when 
we explored the associations in each trimester. This was an observational study enriched by PTB, 
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and by its nature cannot enable causal inference (39) as unobserved or uncontrolled confounding 
remains a threat to validity. While no randomized controlled trial has been conducted in the US 
and is unlikely given the advantageous role of folate on pregnancy outcomes, study findings 
need to be confirmed in other prospective longitudinal studies.  
There are important implications to be gleaned from this study. The association between 
folate and PTB among this predominantly minority, urban low-income population is important as 
studies have shown that women who were non-white (Non-Hispanic Black and Hispanic 
women), aged 18-24 years, and had less than a high school education or had a household income 
of <$25,000 are the least likely to report daily consumption of a supplement containing folic acid 
(40). In addition, minority populations are less likely to have heard about folic acid, to know it 
can prevent birth defects, and to consume foods fortified with folic acid or take vitamins 
containing folic acid (41, 42).  
Lastly, our study reaffirms the importance of consistent folate intake throughout pregnancy 
to mitigate PTB risk  (9, 26, 43). This study demonstrated minimal difference in PTB mitigation 
related to multivitamin supplement intake of 3-5 times/week versus >5 times/week, suggesting a 
possible threshold dosing schedule of 3 times/week. If corroborated by other studies, this finding 
may impact the recommendations for frequency of multivitamin supplement intake before and 
during pregnancy. Specifically, this finding suggests that the same protective benefit can be 
derived from a 3 times weekly dose compared to a daily dose. Finally, folate has a broad 
biological function, and there is increasing recognition that folic acid supplementation during 
pregnancy may affect both short-term and long-term health of the offspring. For example, in the 
same cohort, we demonstrated beneficial effects of adequate maternal plasma folate levels on 
offspring obesity (44, 45). Furthermore, our recent study (20) along with that of others (46) 
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raised concern about the potential risk of extremely high levels of folate on autism. Therefore, 
more work remains to be done to determine optimal range of maternal folate levels throughout 
pregnancy for major organs and systems in the offspring. Ultimately, we need to define an 
optimal range of folate levels (neither too low nor too high) preconception and during pregnancy, 
which can maximize its health benefits and minimize its risk. This may require careful 
consideration of a woman’s health conditions, dietary intake and folic acid supplementation, and 
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Plasma folate subsample 
Term PTB Term PTB 
N % N % N % N % 
5,507 73 2,069 27 1,593 69 720  31 
Race/ethnicity         
Non-Hispanic Black1  2,764  50.2 1,083  52.3 1,133  71.1 555  77.1 
Non-Hispanic White 645 11.7 275  13.3 65  4.1 27  3.8 
Hispanic 1,614  29.3 536  25.9 323  20.3 115  16.0 
Other 451  8.2 163  7.9 72  4.5 23  3.2 
Missing 33  0.6 12  0.6 0  0.0 0  0.0 
Age in years          
<20 608  11.0 195  9.4 159  10.0 67  9.3 
20-34 4,053  73.6 1,446  69.9 1,171  73.5 494  68.6 
35+ 813  14.8 416  20.1 263  16.5 159  22.1 
Missing 33 0.6 12  0.6 0  0.0 0  0.0 
Nativity (US born)         
Foreign born  3,403  61.8 1,118  54.0 970 60.9 377 52.4 
US born 2,029  36.8 935  45.2 596 37.4 338 46.9 
Missing 75  1.4 16  0.8 27 1.7 5 0.7 
Education         
Less than high school 1,680 30.5 623 30.1 434 27.2 204 28.3 
High School/GED 1,800  32.7 741 35.8 575 36.1 279 38.8 
Some/beyond College 1,970  35.8 684 33.1 578 36.3 234 32.5 
Missing 57  1.0 21 1.0 6 0.4 3 0.4 
Marital Status         
Married 2,038  37.0 698  33.7 564  35.4 225 31.3 
Unmarried 3,339  60.6 1,339  64.7 1,019  64.0 488 67.8 
Missing 130  2.4 32  1.5 10  0.6 7 1.0 
Receipt of public 
assistance 2  
        
No 856  15.5 354 17.1 208  13.1 112 15.6 
Yes 4,651  84.5 1,715  82.9 1,385  86.9 608 84.4 
Parity         
Multiparous 3,119  56.6 1,180  57.0 933  58.6 425 59.0 
Nulliparous 2,374  43.1 885  42.8 657  41.2 294 40.8 
Missing 14  0.3 4  0.2 3  0.2 1 0.1 
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Cigarette smoking         
Never 4,449 80.8 1,534  74.1 1,321  82.9 545 75.7 
Ever 376  6.8 175  8.5 114  7.2 73 10.1 
Continued in 
pregnancy 
611  11.1 336  16.2 145  9.1 99 13.8 
Missing 17  1.3 24  1.2 13 0.8 3 0.4 
Alcohol consumption          
No 4,858 88.2 1,782 86.1 1,431 89.8 644 89.4 
Yes 474 8.6 218 10.5 124 7.8 67 9.3 
Missing 175 3.2 69 3.3 38 2.4 9 1.3 
Stress3         
No 4,404 80 1,544 74.6 1,270 79.7 535 74.3 
Yes 1,078 19.6 516 24.9 317 19.9 183 25.4 
Missing 25 0.5 9 0.4 6 0.4 2 0.3 
Body Mass Index 
categories  
        
Underweight 227 4.1 97 4.7 62 3.9 27 3.8 
Normal 2,494 45.3 859 41.5 701 44.0 269 37.4 
Overweight/obese  2,367 43 973 47 745 46.8 386 53.6 
Missing 419 7.6 140 6.8 85 5.3 38 5.3 
Preeclampsia 4         
No 5,047 91.6 1,582 76.5 1,483 93.1 534 74.2 
Yes 460 8.4 487 23.5 110 6.9 186 25.8 
Intrauterine 
infection/inflammation 
        
No 4,371 79.4 1,557 75.3 1,361 85.4 560 77.8 
Yes 690 12.5 432 20.9 169 10.6 151 21.0 
Missing 446 8.1 80 3.9 63 4.0 9 1.3 
Diabetes Mellitus         
None 5,162 93.7 1,850 89.4 1,498 94.0 632 87.8 
Gestational  220 4.0 124 6 53 3.3 49 6.8 
Pre-gestational  75 1.4 79 3.8 31 1.9 34 4.7 
Missing 50 0.9 16 0.8 11 0.7 5 0.7 
Multivitamin 
supplement intake 
        
Preconception   93.3 
 
       
None 5,137 93.3 1,940 93.8 1,504 94.4 671 93.2 
Any  370 6.7 129 6.2 89 5.6 49 6.8 
First trimester         
None  914 16.6 402 19.4 248 15.6 137 19.0 
1-2x a week  204 3.7 97 4.7 60 3.8 28 3.9 
3-5x a week 1,482 26.9 539 26.1 514 32.3 232 32.2 
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>5x a week 2,907 52.8 1,031 49.8 771 48.4 323 44.9 
Second trimester         
None  642 11.7 290 14 183 11.5 96 13.3 
1-2x a week  220 4.0 108 5.2 67 4.2 33 4.6 
3-5x a week 1,558 28.3 570 27.5 518 32.5 242 33.6 
>5x a week 3,087 56.1 1,101 53.2 825 51.8 349 48.5 
Third trimester         
None 655 11.9 345 16.7 193 12.1 126 17.5 
1-2x a week  255 4.6 99 4.8 75 4.7 32 4.4 
3-5x a week 1,558 28.3 543 26.2 512 32.1 227 31.5 
>5x a week 3,039 55.2 1,082 52.3 813 51.0 335 46.5 
Pregnancy (1st to 3rd 
trimester) 
        
None  436 7.9 219 10.6 122 7.7 78 10.8 
1-2x a week  933 16.9 406 19.6 267 16.8 134 18.6 
3-5x a week 1,373 24.9 476 23 471 29.6 200 27.8 
>5x a week 2,765 50.2 968 46.8 733 46.0 308 42.8 
Plasma folate 
concentration(nmol/L) 
        
Mean (SD) n/a  n/a  36.3  24.7 32.3  20.0 
WHO classification         
Insufficiency/deficien
cy: <13.5 nmol/L 
n/a  n/a  155 9.7 82 11.4 
Normal: 13.5-45.3  n/a  n/a  1,030 64.7 508 70.6 
Excess: ≥45.3 n/a  n/a  408 25.6 130 18.1 
1 Non-Hispanic Black includes Black, African American, Haitian, Cape Verdian. 
2 Public assistance is defined as receipt of any of the following: WIC (Women Infants and 
Children), food stamps, AFDC (Aid to families with dependent children), housing assistance or 
fuel assistance.  
3 Mother’s self-report of life or pregnancy being very stressful. 
4 Preeclampsia is defined as the presence of preeclampsia, gestational hypertension and 
hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome 
Abbreviation: GED-General Equivalency Diploma; N-number; PTB-preterm birth; SD-standard 
deviation; US-United States; WHO-World Health Organization.  
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Unadjusted Adjusted OR1 
N of 
cases  
(%) OR  95% CI OR  95% CI 
Multivitamin supplement intake in pregnancy (1st to 3rd trimester) 
Continuous (index) 2 n/a n/a 0.97  0.96, 0.98 0.98  0.97, 0.99 
Categorical       





1-2x a week  406  30.3 0.87  0.71, 1.06 0.91  0.74, 1.12 
3-5x a week 476  25.7 0.69  0.57, 0.84 0.78  0.64, 0.96 
>5x a week 968  25.9 0.70  0.58, 0.83 0.77 0.64, 0.93 
Multivitamin supplement intake in specific time periods 
Preconception        





Any  129  25.9 0.92  0.75, 1.14 0.90 0.72, 1.12 
First trimester       





1-2x a week  97  32.3 1.08  0.83, 1.41 1.08  0.82, 1.43 
3-5x a week 539  26.7 0.83  0.71, 0.96 0.90 0.76, 1.06 
>5x a week 1,031  26.2 0.81  0.70, 0.92 0.85 0.73, 0.98 
Second trimester       





1-2x a week  108  32.9 1.09  0.83, 1.42 1.19  0.90, 1.57 
3-5x a week 570  26.8 0.81  0.68, 0.96 0.92  0.77, 1.10 
>5x a week 1,101  26.3 0.79  0.68, 0.92 0.86  0.73, 1.02 
Third trimester       





1-2x a week  99  28.0 0.74  0.56, 0.96 0.80  0.61, 1.06 
3-5x a week 543  25.8 0.66  0.56, 0.78 0.75 0.63, 0.90 
>5x a week 1,082  26.3 0.68  0.58, 0.78 0.75 0.64, 0.87 
1 Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, 
parity, cigarette use, alcohol use, stress, body mass index (BMI), preeclampsia, intrauterine 
infection/inflammation and diabetes mellitus. 
2 Composite measure of supplement intake from 1st to 3rd trimester 
Abbreviations: CI-confidence interval; N-number, OR-odds ratio  
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Table 4-3: Relationship between maternal plasma folate levels and preterm birth (n=2313) 
Plasma folate sample  Preterm 
(n=720) 
Unadjusted Adjusted OR1 
 N of 
cases 
% OR  95% CI OR  95% CI 
Continuous plasma folate concentration(nmol/L) 
Each unit increase  n/a  0.991  0.986, 
0.995 
0.994  0.990, 
0.999 
Each interquartile 
increase in folate level 
n/a  0.81  0.73, 
0.90 
0.88  0.79, 0.97 
Quartiles of plasma folate concentration(nmol/L) 
Lowest quartile: 6.6 to 
19.4 (reference) 





Second quartile: 19.4- 
30.0  
192  33.2 0.94  0.73, 
1.19 
1.02  0.79, 1.33 
Third quartile:30.0-43.8 185  32.0 0.89  0.69, 
1.13 
1.09  0.83, 1.42 
Highest quartile: 43.8-
185.5 
142  24.5 0.61  0.47, 
0.79 
0.74 0.56, 0.97 
WHO classification (nmol/L) 
Insufficiency/deficiency: 
<13.5  
82  34.6 1.07  0.80,1.43 0.86  0.63, 1.18 
Normal: 13.5-45.3 
(reference) 






Excess: ≥45.3 130  24.2 0.65 0.52, 
0.81 
0.70  0.55, 0.89 
1 Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, 
parity, tobacco use, alcohol use, stress, BMI, preeclampsia, intrauterine infection/inflammation, 
and diabetes.  





Table 4-4: Plasma folate levels and unadjusted and adjusted odds of PTB subtypes 
Plasma folate 
levels  
Spontaneous PTB Medically indicated PTB 
N of 
cases  





Continuous plasma folate concentration(nmol/L) 
Each unit 
increase  
n/a n/a 0.995  0.990, 
1.000 
n/a n/a 0.99 0.98, 0.99 
Each 
interquartile 
increase in folate 
level 
n/a n/a 0.90  0.80,1.01 n/a n/a 0.73 0.62, 0.87 

























0.86 0.62, 1.18 46  9.5 0.46 0.31, 0.69 
WHO classification (nmol/L) 
Insufficiency/def
iciency: <13.5  
45  22.
5 







n/a 187  15.4 1.00 
(ref) 
n/a 
Excess: ≥45.3 87  17.
6 
0.72 0.55, 0.95 43  9.5 0.58 0.40, 0.82 
1 Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, 
parity, tobacco use, alcohol use, stress, BMI, preeclampsia, intrauterine infection/inflammation, 
diabetes. 
2 Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, 
parity, tobacco use, alcohol use, stress 
Abbreviation: aOR-adjusted odds ratio; n/a-not applicable; N-number; ref-reference; PTB: 




Figure 4-1: Probability of Overall (A), Spontaneous (B) and Medically Indicated (C) 






Supplemental Table 4-1: Maternal characteristics by overall PTB and PTB subtypes 











 % % % % 
Maternal race/ethnicity     
 Non-Hispanic Black1 71.8 28.2 17.6 10.6 
 Non-Hispanic White 70.1 29.9 21.3 8.6 
 Hispanic 75.1 24.9 16.9 8.0 
 Other 73.5 26.5 18.2 8.3 
 Missing 73.3 26.7 13.3 13.3 
Age in years      
 <20 75.7 24.3 18.3 6.0 
 20-34 73.7 26.3 17.7 8.6 
 35+ 66.2 33.8 18.6 15.2 
 Missing 73.3 26.7 13.3 13.3 
Nativity (US born)     
 Not born in US  75.3 24.7 15.6 9.1 
 Born in US 68.5 31.5 21.5 10.1 
 Missing 82.4 17.6 13.2 4.4 
Education     
 Less than high school 72.9 27.1 18.5 8.6 
 High School/GED 70.8 29.2 18.8 10.4 
 College or more 74.2 25.8 16.4 9.3 
 Missing 73.1 26.9 17.9 9.0 
Marital Status     
 Married 74.5 25.5 15.8 9.8 
 Unmarried 71.4 28.6 19.3 9.3 
 Missing 80.2 19.8 11.1 8.6 
Receipt of public assistance 2      
 No 70.7 29.3 17.8 11.5 
 Yes 73.1 26.9 17.9 9.1 
Parity     
 Multiparous 69.1 30.9 20.5 10.3 
 Nulliparous 74.0 26.0 16.9 9.1 
 Missing 77.8 22.2 16.7 5.6 
Cigarette smoking     
 Never 74.4 25.6 16.2 9.4 
 Ever 68.2 31.8 21.1 10.7 
 Continuous in pregnancy 64.5 35.5 26.7 8.8 
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 Missing 74.7 25.3 12.6 12.6 
Alcohol consumption     
 No 73.2 26.8 17.6 9.2 
 Yes 68.5 31.5 20.8 10.7 
 Missing 71.7 28.3 16.0 12.3 
Stress 3      
 No 74.0 26.0 17.3 8.6 
 Yes 67.6 32.4 19.8 12.5 
 Missing 73.5 26.5 17.6 8.8 
BMI     
 Underweight 70.1 29.9 23.5 6.5 
 Overweight 74.4 25.6 17.9 7.8 
 Obese  70.9 29.1 17.8 11.3 
 Missing 75.0 25.0 15.0 10 
Preeclampsia 4     
 No 76.1 23.9 19.3 4.6 
 Yes 48.6 51.4 7.7 43.7 
Intrauterine infection/inflammation     
 No 73.7 26.3 15.9 10.3 
 Yes 61.5 38.5 31.0 7.5 
 Missing 84.8 15.2 11.6 3.6 
Diabetes Mellitus     
 No 73.6 26.4 17.6 8.8 
 Gestational Diabetes Mellitus 64.0 36.0 22.1 14.0 
 Diabetes Mellitus 48.7 51.3 22.7 28.6 
 Missing 75.8 24.2 16.7 7.6 
Folate intake in preconception     
 None 72.6 27.4 17.9 9.5 
 Any  74.1 25.9 16.6 9.2 
First trimester      
 None (ref) 69.5 30.5 21.6 9.0 
 1-2x a week  67.8 32.2 21.3 11.0 
 3-5x a week 73.3 26.7 17.2 9.5 
 >5x a week 73.8 26.2 16.7 9.5 
Second trimester     
 None (ref) 68.9 31.1 21.7 9.4 
 1-2x a week  67.1 32.9 23.2 9.8 
 3-5x a week 73.2 26.8 17.4 9.4 
 >5x a week 73.7 26.3 16.8 9.5 
Third trimester     
 None (ref) 65.5 34.5 23.4 11.1 
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 1-2x a week  72.0 28.0 19.8 8.2 
 3-5x a week 74.2 25.8 16.9 8.9 
 >5x a week 73.7 26.3 16.8 9.4 
Folate intake in pregnancy     
 None (ref) 66.6 33.4 22.7 10.7 
 1-2x a week  69.7 30.3 21.5 8.8 
 3-5x a week 74.3 25.7 16.5 9.2 
 >5x a week 74.1 25.9 16.4 9.6 
     
1 Non-Hispanic Black includes Black, African American, Haitian, Cape Verdian;  
2 Public assistance is defined as receipt of any of the following: food stamps, WIC, AFDC, fuel 
or housing assistance.  
3 Mother’s report of index pregnancy or life being very stressful.  
4 Preeclampsia is defined as the presence of preeclampsia, gestational hypertension and 
hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome. 





Supplemental Table 4-2: Relationship Between Multivitamin Supplement Intake and 
Preterm Birth among Non-Hispanic Blacks only (N=3,847) 
Period Preterm 
(N=1,803) 
Unadjusted Adjusted OR1 
 N of 
cases  
(%) OR  95% CI OR  95% CI 
Multivitamin supplement intake in pregnancy (1st to 3rd trimester) 
Continuous (index) 2 n/a n/a 0.97  0.95, 0.99 0.97  0.97, 0.99 
Categorical       
None (reference) 125  34.8 1.00 n/a 1.00 n/a 
1-2x a week  229  30.9 0.81  0.62, 1.05 0.86 0.65, 1.15 
3-5x a week 242  27.5 0.71  0.55, 0.92 0.79 0.58, 1.04 
>5x a week 487  26.4 0.67  0.53, 0.85 0.75  0.58, 0.97 
Multivitamin supplement intake in specific time periods 
Preconception        
None (reference) 1,014  28.2 1.00 n/a 1.00 n/a 
Any  69  27.9 0.99  0.74, 1.32 0.99  0.73, 1.34 
First trimester       
None (reference) 224  30.4 1.00 n/a 1.00 n/a 
1-2x a week  59  32.4 1.10  0.77, 1.55 1.12  0.77, 1.62 
3-5x a week 279  28.4 0.91  0.74, 1.12 0.95 0.76, 1.19 
>5x a week 521  26.8 0.84  0.69, 1.01 0.87  0.71, 1.06 
Second trimester       
None (reference) 164  32.9 1.00 n/a 1.00 n/a 
1-2x a week  66  32.4 0.97  0.69, 1.38 1.09  0.75, 1.57 
3-5x a week 301  26.7 0.82  0.65, 1.03 0.91 0.71, 1.16 
>5x a week 552  26.3 0.73  0.59, 0.90 0.80 0.64, 1.00 
Third trimester       
None (reference) 202  36.9 1.00 n/a 1.00 n/a 
1-2x a week  59  27.8 0.66  0.47, 0.93 0.73 0.51, 1.05 
3-5x a week 282  27.4 0.64  0.52, 0.80 0.72 0.57, 0.91 
>5x a week 540  26.2 0.61  0.50, 0.74 0.68 0.55, 0.84 
1 Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, 
parity, cigarette use, alcohol use, stress, body mass index (BMI), preeclampsia, intrauterine 
infection/inflammation and diabetes mellitus. 
2 Composite measure of supplement intake from 1st to 3rd trimester 




Supplemental Table 4-3: Unadjusted and adjusted odds ratios estimated from logistic 





Spontaneous PTB Medically indicated PTB 
No of 
cases  
(%) aOR 1 95% CI No of 
cases  
(%) aOR 2 95% CI 
Preconception 
 None (ref) 1,270  19.8 1.00  n/a 670  11.5 1.00  n/a 
 Any  83  18.3 0.96  0.75, 1.24 46  11.1 0.84 0.60, 1.17 
First trimester 
 None (ref) 284  23.7 1.00 n/a 118  11.4 1.00  n/a 
 1-2x a week  64  23.9 1.04 0.76, 1.43 33  13.9 1.29 0.85, 1.97 
 3-5x a week 348  19.0 0.82  0.68, 0.99 191  11.4 1.07 0.83, 1.38 
 >5x a week 657  18.4 0.78  0.66, 0.92 374  11.4 1.02 0.81, 1.28 
Second trimester 
 None (ref) 202  23.9 1.00 n/a 88  12.1 1.00  n/a 
 1-2x a week  76  25.7 1.11  0.81, 1.53 32  12.7 1.14 0.73, 1.77 
 3-5x a week 371  19.2 0.83  0.67, 1.01 199  11.3 1.00 0.76, 1.31 
 >5x a week 704  18.6 0.79 0.65, 0.95 397  11.4 0.96 0.74, 1.23 
Third trimester 
 None (ref) 234  26.3 1.00 n/a 111  14.5 1.00  n/a 
 1-2x a week  70  21.5 0.82 0.60, 1.12 29  10.2 0.69 0.45, 1.08 
 3-5x a week 355  18.6 0.71  0.58, 0.86 188  10.8 0.75 0.58, 0.97 
 >5x a week 694  18.6 0.71  0.59, 0.85 388  11.3 0.76 0.60, 0.96 
Pregnancy (1st to 3rd trimester) 
 None (ref) 149  25.5 1.00 n/a 70  13.8 1.00  n/a 
 1-2x a week  288  23.6 0.95  0.75, 1.20 118  11.2 0.83 0.60, 1.15 
 3-5x a week 305  18.2 0.73 0.58, 0.92 171  11.1 0.85 0.62, 1.15 
 >5x a week 611  18.1 0.72  0.58, 0.89 357  11.4 0.83 0.63, 1.11 
1 Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, 
parity, tobacco use, alcohol use, stress, BMI, preeclampsia, intrauterine infection/inflammation 
and diabetes mellitus. 
2 Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, 
parity, tobacco use, alcohol and stress. 
Abbreviation: aOR-adjusted odds ratio; CI- confidence interval; n/a-not applicable; No-number; 
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Chapter Five: Manuscript II 
Inter-relationships of Folate, Preeclampsia, and Medically Indicated Preterm 
Birth: New Insight from the Boston Birth Cohort  






Background: Previous studies suggest that adequate maternal folate status decreased the risk of 
preterm birth (PTB), but its role in preeclampsia and to what degree preeclampsia mediates the 
folate-PTB association are not well studied.   
Objective: We aimed to explore the inter-relationships between maternal folate, preeclampsia, 
and PTB, in particular, the potential role of preeclampsia as a mediator of the folate-PTB 
relationship in a predominantly urban, low-income, minority population in the US. 
Study Design: The analyses included 7,565 mother-infant dyads, enrolled in the Boston Birth 
Cohort study. Folate status was assessed by both maternal self-reported frequency of 
multivitamin supplement intake during preconception and each trimester of pregnancy, as well as 
maternal plasma folate concentrations in a subset (n=2,313) with plasma samples obtained 24-72 
hours after delivery. Simple and multiple logistic regressions were used to explore the 
interrelationships between maternal folate, preeclampsia and PTB, including subtypes 
(spontaneous and medically indicated). 
Results: Intake of multivitamin supplements containing folate, three or more times a week in the 
3rd trimester was associated with reduced risk of preeclampsia (aOR=0.77, 95% CI: 0.65, 0.93). 
Similar results were obtained for multivitamin supplement intake in the 2nd trimester and among 
subgroups of non-Hispanic Black women as well as all nulliparous women.  Each interquartile 
increase in plasma folate reduced the odds of preeclampsia by 20% (aOR=0.80, 95% CI: 0.68, 
0.95). Compared to plasma folate concentrations in the first quartile, the highest quartile was 
associated with 38% reduced odds of preeclampsia (aOR=0.62, 95% CI: 0.43, 0.90). 
Preeclampsia mediated 10% of the multivitamin supplement intake-PTB relationship. Most of 





multivitamin supplement intake-PTB relationship. Preeclampsia did not mediate the relationship 
between folate status and spontaneous PTB. 
Conclusion: In this high-risk urban, low income US population, adequate maternal folate 
appeared to protect against preeclampsia; such association was consistent across strata of parity 
and race/ethnicity. Preeclampsia mediated the beneficial effect of maternal folate against 
medically indicated PTB. Our findings have important clinical and public health implications 
that warrant additional investigation.   








Preeclampsia, a major cause of maternal morbidity and mortality, currently affects 3-6% of 
pregnancies in the US (1) and is more common among non-Hispanic Black women, in parallel 
with a high prevalence of chronic hypertension in this population (2, 3). Preeclampsia and 
associated complications or sequelae have enormous long-term health and societal consequences 
as well as economic implications. For example, the costs associated with preterm birth (PTB) 
from early-onset preeclampsia are approximately 40 to 100 times higher than for a term 
pregnancy (4), and both preeclampsia and PTB have short-and long-term health consequences on 
the child (5, 6).There is a critical need to identify safe and cost-effective ways to prevent 
preeclampsia and mitigate its consequences, including PTB.  
Folate, an essential B vitamin, has received great attention in public health and clinical arena 
over the past two decades. It is the only nutrient that is under mandatory folic acid fortification of 
grain products in the U.S. and many countries in the world, aiming to prevent neural tube 
defects. However, both NHANES (a national representative sample) and our recent data showed 
individual folate status varied greatly from insufficiency to excess, likely due to differences in 
dietary intake, use of folic acid supplementation, and metabolic factors (7). To date, studies on 
maternal folate in relation to preeclampsia are limited and the findings are inconclusive. Some 
studies suggest that folate containing multivitamins or folic acid supplementation (8-11), as well 
as maternal serum and red blood cell folate levels (12), were associated with a lower risk of 
preeclampsia while other studies did not demonstrate any association (13-15). These inconsistent 
results across studies may be attributed to differences in study design, population characteristics, 
assessment of folate status, and adjustment for confounders. This topic is worth of further 





importantly, its biological plausibility and relevance to clinical and public health practice. Folate, 
in addition to its many other important biological functions for maternal and fetal health, 
improves endothelial function and plays an important role in improving cardiovascular health 
(16). Previous studies including our own found that adequate maternal folate status can reduce 
the risk of overall PTB (17-19).  
This study sought to address several important research gaps regarding the inter-relationships 
of maternal folate status, preeclampsia, and PTB. First, the American College of Obstetricians 
and Gynecologists currently recommends that women with prior preeclampsia use folic acid 
supplementation in the preconception period and first trimester (20). Interestingly, despite this, 
there is lack of data on the role of adequate folate status during the 2nd and 3rd trimester, when 
most cases of preeclampsia develop. There is also limited understanding about the role of folate 
in preeclampsia among nulliparous mothers as compared to multiparous mothers.  
Second, given that preeclampsia is a major cause of medically indicated PTB, it could be the 
mediator in the relationship between maternal folate and PTB. If true, it is expected that this 
mediation should occur primarily in medically indicated PTB. A few  international studies 
explored the role of preeclampsia in the relation between folate and overall PTB in Hungary (21) 
and in India (22). In Hungary, there was a lower risk of PTB among pregnant women with early 
onset preeclampsia after folic acid supplementation in early pregnancy, while in India, folate 
levels were comparable among mothers with PTB from other causes and mothers with PTB due 
to preeclampsia. Thus, it is still unclear whether preeclampsia plays a role in mediating the 
association between maternal folate and PTB, especially medically indicated PTB, and how this 





Third, the reasons for the racial/ethnic disparities in preeclampsia and medically indicated 
PTB are not fully understood. Recent NHANES data suggests that 25% of women of 
reproductive age in the US have insufficient folate levels (23) and that non-Hispanic Black 
women are more likely to have lower folate levels than non-Hispanic white women (24). As 
such, it is important to study the inter-relationships of folate status, preeclampsia and PTB 
(including medically indicated PTB) among non-Hispanic Black populations as they remain a 
high-risk group for these health conditions (2, 25, 26) for reasons that we need to understand.  
The objective of this study was to investigate 1) the association between maternal folate 
status and preeclampsia in the Boston Birth Cohort, a large sample of a predominantly urban, 
low-income, non-Hispanic Black US population. We further explored if the association is similar 
in multiparous vs. nulliparous mothers; and to what degree the relationship between maternal 
folate and PTB is mediated by preeclampsia. We also explored whether the mediation is stronger 
in medically indicated compared to spontaneous PTB.   
Materials and Methods 
Study population 
The data are from the ongoing Boston Birth Cohort (BBC) study which commenced in 1998 
(27, 28). To date, over 8500 mother-infant dyads have been enrolled at delivery at the Boston 
Medical Center (BMC), a large urban hospital serving a predominantly low-income, minority, 
inner-city patient population. Eligible cases were defined as mother-infant dyads with singleton, 
live, LBW (<2500 grams) or preterm infants (<37 weeks of gestation) irrespective of 
birthweight; controls were defined as mother-infant dyads with singleton, live, term infants with 





the institutional Review Boards of Boston University Medical Center and Johns Hopkins 
Bloomberg School of Public Health. 
Data Collection 
After obtaining informed consent, epidemiologic data was collected by trained research 
assistants using a face-to-face maternal questionnaire interview administered between 24-72 
hours postpartum. Clinical data were collected from medical records with a standardized 
abstraction form. Maternal blood samples were obtained for plasma folate assay within a few 
days after delivery from a subset of the sample who planned to have their children followed at 
BMC for primary care and consented to enroll their children in a follow up study at BMC (5). 
Complete multivitamin supplement intake information from the preconception period (six 
months before conception) to the third trimester was available from 7576 women while a 
subsample (n=2313) of these women had plasma folate samples assayed. Participants included in 
the full sample and those who had plasma folate data had very similar baseline characteristics, 
except for a higher proportion of non-Hispanic Black women (73% versus 51%) and a slightly 
higher proportion of PTB (31% versus 27%) in the plasma subsample. 
Key Variables 
Preeclampsia disorders were assessed from the medical records of study participants and 
defined as the presence of a diagnosis of gestational hypertension, mild or severe preeclampsia, 
eclampsia, hemolysis, elevated liver enzymes, and/or low platelets (HELLP) syndrome in the 
patient chart. 
PTB was defined as delivery before 37 completed weeks of gestation. Gestational age was 
determined from an algorithm based on the last menstrual period and early ultrasound dating 





Multivitamin supplement intake information was obtained from the following questions in 
the maternal questionnaire: “Did you take prenatal vitamins prescribed by your doctor?” and 
“Did you take any over-the-counter multivitamins?” during pre-pregnancy (6 months prior to 
pregnancy), 1st trimester (day 1 - 90 of pregnancy), 2nd trimester (day 91 -180 of pregnancy), 3rd 
trimester (day 181 of pregnancy to birth)? Response categories included: none, 1 time per week, 
2 times per week, 3-5 times per week, almost daily. Responses to the two questions were 
combined for each trimester. Preconception multivitamin intake was dichotomized into “no 
intake” versus “any intake”. Intake in the 1st to 3rd trimester was dichotomized into consistent 
intake: “less than three” versus “three or more” times per week. In the US, prenatal and over-the-
counter multivitamins usually contain 400 or 800 micrograms of folic acid and are suggested to 
be taken daily (30).  
Plasma folate concentrations were measured using chemiluminescent immunoassay with 
diagnostic kits (Shenzhen New Industries Biomedical Engineering Co., Ltd. China) (31) using a 
Beckman Coulter ACCESS Immunoassay System (Beckman-Coulter Canada, Mississauga, 
Canada) (31).  
Other covariates included sociodemographic factors such as: maternal education 
(≤Elementary, High School or ≥College), race/ethnicity (non-Hispanic Black, Non-Hispanic 
white, Hispanic and Other), marital status (unmarried versus married), parity (nulliparous versus 
multiparous), maternal age at delivery (<20, 20-34 and 35+years), receipt of public assistance 
including: WIC (Women Infants and Children), Food Stamps, AFDC (Aid to Families with 
Dependent Children), Housing assistance or Fuel assistance (yes versus no) and maternal nativity 
(US born versus non-US born). Behavioral risk factors included alcohol use (never versus any), 





pregnancy as being ‘very’ stressful). Biomedical factors included maternal diabetes defined as 
having either gestational or pregestational diabetes, prepregnancy BMI (kg/m2 grouped into 4 
categories: underweight (<18.5kg/m2), normal weight (18.5-24.9kg/m2), overweight (25-
29.9kg/m2), and obesity (>30kg/m2), and chronic hypertension (defined as the presence of pre-
pregnancy hypertension). 
Statistical analysis 
Preliminary data analysis was performed in the full sample and plasma folate subsample to 
compare maternal characteristics by preeclampsia status using chi-squared tests for categorical 
variables and t-tests for continuous variables. Plasma folate concentrations were assessed as a 
categorical variable in quartiles and as a continuous variable in nmol/L in two scales: i) unit 
nmol/L increase and ii) interquartile increase, to assess dose-response relationship. Simple and 
multiple logistic regressions were used to explore the relationship between self-reported 
multivitamin supplement intake and plasma folate concentrations on preeclampsia and PTB. 
Multiple regressions to explore the relationship between folate and preeclampsia controlled for 
the following maternal factors: race, age, nativity, education, marital status, receipt of public 
assistance, parity, tobacco use, alcohol use, stress, BMI, diabetes and chronic hypertension. 
Additional analyses were conducted for subgroups of PTB, spontaneous and medically indicated 
PTB. Mediation analysis was conducted using the Baron and Kenny approach (32, 33), where 
mediation is demonstrated when the following conditions are met: (a) the main independent 
variable is significantly associated with the main dependent variable; (b) the independent 
variable is significantly related to the mediator variable; and [3] the mediator variable is 
significantly associated with the dependent variable when the independent variable is controlled 





variable and indirect effect that occurs via the mediator variable. This can be represented as: 
c = c' + ab where c is the total effect, c’ is the direct effect and ab is the indirect effect which is 
the product of the two path coefficients from the independent to the mediator and from the 
mediator to the dependent variable, as displayed in Supplemental Figure 1.  
The proportion of the total effect that is mediated is ab/c. Our mediation analysis 
demonstrated the total and direct effect of folate status on PTB, the indirect effect and the 
proportion of the folate-PTB relationship mediated through preeclampsia. In Stata, the 
binary_mediation command was used to perform the mediation analysis because the mediating 
variable - preeclampsia disorder - was dichotomous (33). In addition, the bootstrap command 
was used to obtain standard errors and confidence intervals of direct and indirect effects while 
the medeff command was used to provide standard errors and confidence intervals for the 
proportion of the total effect mediated by preeclampsia (34). All analyses were conducted using 
STATA version 14 (College Station, TX: StataCorp LP). All p-values in the analyses were two-






Preeclampsia was present in 13% percent of women in both the total multivitamin 
supplement group and plasma folate subsample. In the full sample, 27% had PTB compared to 
31% in the plasma folate subsample. In the third trimester, 82% of women took multivitamin 
supplements three or more times a week. Plasma folate concentrations at delivery ranged from 
6.63 to 185.5 nmol/L with a median of 30.5nmol/L. The distribution of the sample by key 
characteristics and preeclampsia status in the total multivitamin supplement sample as well as the 
plasma folate subsample is presented in Table 1. In the full sample, women with preeclampsia 
were more likely to be non-Hispanic Black, older, nulliparous, obese, diabetic and have chronic 
hypertension.  
Table 2 displays the independent associations between multivitamin supplement intake and 
preeclampsia. Multivitamin supplement intake in the preconception period as well as first 
trimester was not significantly associated with preeclampsia. Supplement intake of three or more 
times a week in the 2nd and 3rd trimester was associated with reduced odds of preeclampsia 
(aOR=0.82, 95% CI: 0.68, 0.98 and aOR=0.77, 95% CI: 0.65, 0.93 respectively).  
Plasma folate concentrations also demonstrated a similar association with preeclampsia. 
Specifically, each interquartile increase in plasma folate reduced the odds of preeclampsia 
(aOR=0.80, 95% CI: 0.68, 0.95). There were consistent associations between both measures of 
folate (multivitamin supplement intake and plasma folate concentrations) with preeclampsia 
among non-Hispanic Black women only (Supplemental Table 1). In addition, the association of 
multivitamin supplement intake with preeclampsia was stronger among multiparous compared to 
nulliparous women (Table 3). Specifically, among multipara, multivitamin supplement intake 3 





(aOR=0.71, 95% CI: 0.56, 0.90). While the odds of PTB was also lower among nulliparous 
women, this was not statistically significant (aOR= 0.85, 95% CI: 0.64, 1.12). 
Figure 1 shows the direct, indirect and total effects of multivitamin supplement intake on 
PTB as well as the proportion of the total effect mediated by preeclampsia. Multivitamin 
supplement intake of three or more times a week in the third trimester was associated with 
reduced odds of PTB (direct effect=aOR: 0.74, 95% CI: 0.65, 0.84). The indirect effect of 
multivitamin supplement intake leading to reduced odds of preeclampsia and subsequently lower 
odds of PTB accounted for 10% of the total effect (total effect=aOR: 0.72, 95% CI: 0.64, 0.82). 
Furthermore, preeclampsia mediated 62% of the relationship between multivitamin supplement 
intake and medically indicated PTB but none of the multivitamin supplement intake- 
spontaneous PTB relationship. 
Results specific to plasma folate concentrations are presented in Supplemental Figure 2. 
Similarly, preeclampsia accounted for 28% of the plasma folate-PTB relationship, 45% of the 








To our knowledge, this is the first study to investigate the inter-relationship between maternal 
folate status, preeclampsia and PTB outcomes within a low-income urban minority population in 
the US. We used mediation analysis to investigate the indirect effect of folate on PTB and its 
subtypes via preeclampsia. This approach is gaining attention in prevention and treatment 
research, in which interventions are designed to change outcomes of interest by targeting 
mediating variables hypothesized to be causally related to the outcome (35). This is particularly 
relevant, given the need for interventions to address the unacceptably high rate of PTB and 
preeclampsia, especially among African American women (2, 3, 36).   
This study is strengthened by the use of both conventional measures of folate status, maternal 
self-reported multivitamin supplement intake during preconception and in each trimester of 
pregnancy, and an objectively measured folate biomarker in maternal plasma samples obtained 
within a few days of delivery. 
Our study demonstrated that consistent multivitamin supplement intake of three or more 
times a week in the 3rd trimester and higher plasma folate concentrations at delivery were 
associated with reduced odds of preeclampsia.  
This work extends our recent report on the relationship between maternal folate status and 
PTB in our study population (37). Here, we added to current knowledge by investigating the 
mechanistic pathway of preeclampsia in the relationship between maternal folate status and PTB. 
Our study of the interrelations between maternal folate status, preeclampsia and PTB are 
comparable to the Bánhidy et al. population- based study in Hungary (21) where the unadjusted 
odds of PTB was reduced among women with preeclampsia who took folic acid supplements 





with early onset preeclampsia, not late onset preeclampsia. In contrast to our study findings, a 
case-control study conducted in India observed reduced folate levels in women with PTB only, 
not in women with both PTB and preeclampsia (22).  It is noteworthy that these other studies had 
both a different race/ethnicity distribution and folic acid fortification context from our study, 
which was conducted in the US.  
Our study also uniquely explored how maternal folate status and preeclampsia were 
associated with overall PTB and specific PTB subtypes. Preeclampsia mediated a tenth of the 
multivitamin supplement intake and PTB relationship and about a quarter of the plasma folate 
and PTB relationship.  
Furthermore, we demonstrated that most of the mediation effect of preeclampsia was seen 
among those with medically indicated PTB and not spontaneous PTB, a trend that was consistent 
across both measures of maternal folate status. This is presumably because preeclampsia is a 
common reason for induction of labor. 
Nutrition status has long been considered important in pregnancy outcomes for both the 
mother and fetus. While folate has been advocated for use in the periconception period to reduce 
neural tube defects as well as megaloblastic anemia during pregnancy, our findings suggest that 
folate may be beneficial in preventing preeclampsia and mitigating its associated sequelae, 
medically indicated PTB.  
There are plausible mechanisms for the role of maternal folate status in preeclampsia and 
PTB. Suboptimal folate levels during gestation can impair cellular growth and replication in the 
placenta and abnormal placentation has been linked with hypertensive disorders (38). Also, 





oxidized lipids, cytokines and serum soluble vascular endothelial growth factor. These 
substances are responsible for placental and endothelial dysfunction commonly seen in 
preeclampsia (39). In addition, lower levels of folate also interfere with maternal erythropoiesis, 
and growth of the uterus and mammary gland (40).  
Low folate levels as well as preeclampsia may be caused by risk factors as well as biological 
processes that occur before or during pregnancy. Thus, preconception or prenatal interventions 
remain key in ameliorating the effects of these conditions (41-43), as it is hypothesized that the 
most critical time window to improve placental function is in the late first or early second 
trimester (44).  Our data lent support that adequate folate status in 3rd trimester may be also 
important in preventing and mitigating preeclampsia and its consequences.  
This study has some limitations. While folate biomarkers were assessed within 72 hours of 
delivery, although plasma folate concentrations are more objective and not as prone to the recall 
bias observed with dietary history of supplement intake, we recognize that a single plasma folate 
measurement cannot be used to differentiate between a transitory decrease in dietary folate 
intake and chronic deficiency states. However, in populations that have stable sources of folate 
intake, such as in the US where there is mandatory folic acid fortification, plasma folate 
concentrations are unlikely to fluctuate dramatically. We also acknowledge that plasma folate 
concentration at delivery is at best a proxy for third trimester folate status. In addition, our study 
design did not permit for inferences of temporality and causality. Finally, although we have 
adjusted major known confounders in the analyses, unmeasured or unknown confounding may 
have been an issue. Due to these limitations, we would like to stress that our findings serve as 
hypothesis generating rather than as conclusive. There is need for prospective studies to further 





If confirmed, our study findings are of clinical and public health importance as folic acid 
fortification and supplementation remain relatively low cost, safe and feasible clinical and public 
health interventions for all women of childbearing age. Current American College of 
Obstetricians and Gynecologists (ACOG) guidelines recommend delivery after 34 weeks of 
gestation for severe preeclampsia (45) as well as folic acid supplementation in the preconception 
period and first trimester for women with prior preeclampsia (20). Our study found that the 
association between multivitamin supplement intake in the third trimester and preeclampsia was 
stronger among multipara compared to nulliparous women. If our study findings are validated by 
prospective studies, such guidelines might need to consider the administration of folic acid 
among women with preeclampsia beyond the first trimester. 
The benefits of adequate folate against preeclampsia in nulliparous women remain to be 
determined. In fact, in our sample the prevalence of preeclampsia was higher in nulliparous than 
multiparous mothers. Our data suggest that there was a trend of protective effect of adequate 
folate against preeclampsia, but it was not statistically significant. Due to delayed childbearing 
and the rising rates of chronic medical conditions, the prevalence of hypertension and 
preeclampsia is projected to increase over the next decade (46, 47), including among nulliparous 
women. Administering folic acid in combination with anti-hypertensive drugs compared with 
anti-hypertensive drugs alone has been shown to reduce the risk of cardiovascular and stroke 
events in patients with hypertension(48). There is a great need to further investigate the extent to 
which folic acid administration can mitigate preeclampsia complications in pregnancy as well as 
reduce the risk of medically indicated PTB among nulliparous women. 
In summary, in this study, we found that maternal multivitamin supplement intake of three 





protected against preeclampsia, which partially mediated the association between maternal folate 
levels and PTB, particularly medically indicated PTB. An understanding of these relationships in 
low income minority US populations is of great public health importance considering the higher 
prevalence of folate insufficiency, preeclampsia and PTB among such groups. Furthermore, 
improving folate status via folic acid supplementation or fortification remains a simple and cost-
effective intervention, which may prove particularly useful in preventing both preeclampsia and 
its associated PTB. Our findings warrant additional investigation, preferably using a prospective 






Tables and figures 
 
Table 5-1: Characteristics of study population by preeclampsia status 
Maternal 
Characteristics 
Multivitamin supplement sample 
(N=7576) 











Total 6629 (87) 947 (13)  2017 (87) 296 (13)  
Race/ethnicity   <0.001   0.220 
Non-Hispanic Blacka 3308 (50) 539 (57)  1459 (72) 229 (77)  
Non-Hispanic White 825 (12) 95 (10)  84 (4) 8 (3)  
Hispanic 1911 (29) 239 (25)  392 (20) 46 (16)  
Other 552 (8) 62 (7)  84 (4) 13 (4)  
Missing 33 (1) 12 (1)  0 (0) 0 (0)  
Age in years    <0.001   0.001 
<20 716 (11) 87 (9)  203 (10) 23 (8)  
20-34 4861 (73) 638 (67)  1468 (73) 197 (66)  
35+ 1019 (15) 210 (22)  346 (17) 76 (26)  
Missing 33 (1) 12 (1)  0 (0) 0 (0)  
Nativity (US born)   0.218   0.343 
Not born in US  3980 (60) 541 (57)  1184 (59) 163 (55)  
Born in US 2569 (39) 395 (42)  807 (40) 127 (43)  
Missing 80 (1) 11 (1)  26 (1) 6 (2)  
Education   0.034   <0.001 
Less than high 
school 
2047 (31) 256 (27)  580 (29) 58 (20)  
High School/GED 2197 (33) 344 (36)  714 (35) 140 (47)  
Some College and 
above 
2321 (35) 333 (35)  714 (35) 98 (33)  
Missing 64 (1) 14 (2)  9 (1) 3 (0)  
Marital Status   0.770   0.801 
Married 2391 (36) 345 (36)  683 (34) 106 (36)  
Unmarried 4099 (62) 579 (61)  1319 (65) 188 (63)  
Missing 139 (2) 23 (2)  15 (1) 2 (1)  
Receipt of public 
assistance b  
  0.015   0.276 
No 1033 (16) 177 (19)  273 (14) 47(16)  
Yes 5596 (84) 770 (81)  1744 (86) 249 (84)  
Parity   0.001   0.734 
Multiparous 3815 (58) 484 (51)  1198 (59) 160 (54)  
Nulliparous 2799 (42) 460 (49)  816 (41) 135 (46)  





Cigarette smoking   <0.001   0.029 
Never 5202 (79) 781 (82)  1632 (81) 234 (79)  
Ever 477 (7) 74 (8)  151 (7) 36 (12)  
Continued in 
pregnancy 
871 (13) 76 (8)  220 (11) 24 (8)  
Missing 79 (1) 16 (2)  14 (1) 2 (1)  
Alcohol consumption   0.038   0.849 
No 5827 (88) 813 (86)  1812 (90) 263 (89)  
Yes 601 (9) 91 (10)  165 (8) 26 (9)  
Missing 201 (3) 43 (4)  40 (2) 7 (2)  
Stressc   0.022   0.192 
No 5235 (79) 713 (75)  1586 (79) 219 (74)  
Yes 1363 (21) 231 (24)  424 (21) 76 (26)  
Missing 31 (0) 3 (0)  7 (0) 1 (0)  
Body Mass Index 
categories  
  <0.001   <0.001 
Underweight 304 (5) 20 (2)  84 (4) 5 (2)  
Normal 3051 (46) 302 (32)  883 (44) 87 (29)  
Overweight/obese  2791 (42) 549 (58)  944 (47) 187 (63)  
Missing 483 (7) 76 (8)  106 (5) 17 (6)  
Diabetes Mellitus   <0.001   <0.001 
No 6184 (93) 828 (87)  1877 (93) 253 (85)  
Gestational Diabetes 
Mellitus 
274 (4) 70 (7)  78 (4) 24 (8)  
Diabetes Mellitus 112 (2) 42 (4)  48 (2) 17 (6)  
Missing 59 (1) 7 (1)  14 (1) 2 (1)  
Chronic Hypertension   <0.001   <0.001 
No 6366 (97) 764 (81)  1919 (96) 226 (77)  
Yes 224 (3) 176 (19)  88 (4) 69 (23)  
Preterm Birth   <0.001   <0.001 
No 5047 (79) 460 (49)  1483 (74) 110 (37)  
Yes 1582 (24) 487 (51)  534 (26) 186 (63)  
Spontaneous  1280 (19) 73 (8) <0.001 428 (21) 25 (8) <0.001 
Medically 
indicated 
302 (5) 414 (44) <0.001 106 (5) 161 (54) <0.001 
a Non-Hispanic Black includes Black, African American, Haitian, Cape Verdian;  
b Public assistance is defined as receipt of any of the following: WIC (Women Infants and 
Children), food stamps, AFDC (Aid to families with dependent children), housing assistance or 
fuel assistance.  





d Defined as preeclampsia, gestational hypertension and hemolysis, elevated liver enzymes, and 






Table 5-2: Association of multivitamin supplement and plasma folate with preeclampsia 
Multivitamin supplement intake 
Preeclampsia (n=947) 
n (%) cases OR (95% CI) aORa (95% CI) 
Preconception    
None (ref) 868 (12.3) 1.00  1.00  
Anyb 79 (14.7) 1.23 (0.96, 1.57) 1.14 (0.87, 1.49) 
1st trimester    
<3x a week (ref) 207 (12.8) 1.00  1.00  
≥3x a week 740 (12.4) 0.97 (0.82, 1.14) 0.88 (0.74, 1.05) 
2nd trimester    
<3x a week (ref) 175 (13.9) 1.00  1.00  
≥3x a week 772 (12.2) 0.86 (0.72, 1.03) 0.82 (0.68, 0.98) 
3rd trimester    
<3x a week (ref) 198 (14.6) 1.00  1.00  
≥3x a week 749 (12.0) 0.80 (0.67, 0.95) 0.77 (0.65, 0.93) 
 
Plasma Folate (ng/ml) 
 
Preeclampsia (n=296) 
Continuous plasma folate (nmol/L)    
Each unit nmol/l increase  296 0.99 (0.98, 1.00) 0.99 (0.98, 1.00) 
Each interquartile increase  296  0.77 (0.66, 0.90) 0.80 (0.68, 0.95) 
Quartiles of plasma folate (nmol/L)    
Lowest quartile (6.64-20.35; reference) 93 (16.1) 1.00  1.00  
Second quartile (20.36- 30.52) 79 (13.7) 0.83 (0.60, 1.14) 0.77 (0.54, 1.09) 
Third quartile (30.53- 44.02) 65 (11.3) 0.66 (0.47, 0.93) 0.61 (0.43, 0.88) 
Highest quartile Q4 (44.03- 185.51) 59 (10.2) 0.59 (0.42, 0.84) 0.62 (0.43, 0.90) 
Abbreviation: aOR: adjusted odds ratio; CI: confidence interval; n: number of cases; n/a: not 
applicable; OR: odds ratio; ref: reference; SD: standard deviation. 
a Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, 
parity, tobacco use, alcohol use, stress, BMI, diabetes and chronic hypertension.  






Table 5-3: Association of multivitamin supplement with preeclampsia among multiparous 
versus nulliparous women. 
Multivitamin 
supplement intake 
MULTIPAROUS (n=4,299) NULLIPAROUS (n=3,259) 
n (%) cases aORa (95% CI) n (%) cases aORa (95% CI) 
 Preeclampsia (n=484) Preeclampsia (n=460) 
Preconception     
None (ref) 445 (11.2) 1.00  420 (13.8) 1.00  
Anyb 39 (12.6) 1.07 (0.74, 1.56) 40 (17.8) 1.25 (0.84, 1.84) 
1st trimester     
<3x a week (ref) 121 (11.6) 1.00  86 (15.0) 1.00  
≥3x a week 363 (11.2) 0.85 (0.67, 1.07) 374 (13.9) 0.90 (0.69, 1.18) 
2nd trimester     
<3x a week (ref) 104 (12.7) 1.00  71 (16.2) 1.00  
≥3x a week 380 (10.9) 0.79 (0.61, 1.00) 389 (13.8) 0.84 (0.63, 1.13) 
3rd trimester     
<3x a week (ref) 120 (13.8) 1.00  78 (16.2) 1.00  
≥3x a week 364 (10.6) 0.71 (0.56, 0.90) 382 (13.8) 0.85 (0.64, 1.12) 
Abbreviation: aOR: adjusted odds ratio; CI: confidence interval; n: number of cases; OR: odds 
ratio; ref: reference 
a Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, 
parity, tobacco use, alcohol use, stress, BMI, diabetes and chronic hypertension.  







Figure 5-1: Interrelationship between multivitamin supplement intake, preeclampsia and 






SUPPLEMENTAL TABLES AND FIGURES 
Supplemental Table 5-1: Association of multivitamin supplement and plasma folate with 
preeclampsia among non-Hispanic Blacks only 
Multivitamin supplement intake n (%) cases OR (95% CI) aORa (95% CI) 
Preeclampsia (n=539) 
Preconception    
None (ref) 495 (13.8) 1.00 1.00 
Anyb 44 (16.7) 1.25 (0.89, 1.75) 1.28 (0.90, 1.84) 
1st trimester    
<3x a week (ref) 134 (14.6) 1.00 1.00 
≥3x a week 405 (13.8) 0.94 (0.76, 1.16) 0.82 (0.66, 1.03) 
2nd trimester    
<3x a week (ref) 111 (15.8) 1.00 1.00 
≥3x a week 428 (13.6) 0.84 (0.67, 1.05) 0.75 (0.59, 0.96) 
3rd trimester    
<3x a week (ref) 128 (16.9) 1.00 1.00 
≥3x a week 411 (13.3) 0.76 (0.61, 0.94) 0.71 (0.56, 0.89) 
 
Plasma Folate (ng/ml) 
 
Preeclampsia (n=229) 
Continuous plasma folate (nmol/L)    
Each unit nmol/L increase  229 (100) 0.98 (0.98, 0.99) 0.99 (0.98, 0.99) 
Each interquartile increase  229 (100) 0.70 (0.57, 0.84) 0.80 (0.68, 0.95) 
Quartiles of plasma folate (nmol/L)    
Lowest quartile (6.64-20.35; ref) 83 (17.9) 1.00 1.00 
2nd quartile (20.36- 30.52) 59 (14.4) 0.77 (0.54, 1.11) 0.65 (0.44, 0.97) 
3rd quartile (30.53- 44.02) 48 (11.9) 0.62 (0.42, 0.91) 0.57 (0.38, 0.86) 
Highest quartile Q4 (44.03- 185.51) 39 (9.5) 0.48 (0.32, 0.72) 0.49 (0.31, 0.75) 
Abbreviation: aOR: adjusted odds ratio; CI: confidence interval; n: number of cases; n/a: not 
applicable; OR: odds ratio; ref: reference; SD: standard deviation. 
a Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, 
parity, tobacco use, alcohol use, stress, BMI, preeclampsia, diabetes and chronic hypertension.  






Supplemental Figure 5-1: Schematic of mediation analysis showing total, direct and 
indirect effects. 





Supplemental Figure 5-2: Interrelationship between plasma folate and overall PTB (A), 






Supplemental Figure 5-3: Study Participants Flow Chart 
 
  
Women enrolled in  
Boston Birth Cohort 
(n= 8,494) 
Folic acid supplement intake 
data available (total sample) 
(n= 7,576) 
Plasma folate assay conducted 
(subsample) 
(n =2,313) 
Excluded 918 women 
without folic acid 
supplement intake data 
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Chapter Six: Manuscript III 
Inter-relationships of Folate, Intrauterine Infection/Inflammation, and Spontaneous 
Preterm Birth: New Insight from the Boston Birth Cohort  






Objective: To investigate the inter-relationships of maternal folate status, intrauterine 
infection/inflammation (IUI) and preterm birth (PTB) among a high-risk US population 
Design: Birth cohort study 
Setting and sample: The Boston Birth Cohort, a predominantly low-income minority sample of mothers 
and babies recruited at Boston Medical Center. 
Methods: Maternal folate status was assessed using self-reported multivitamin supplement intake in 
pregnancy and plasma folate concentrations at delivery. Multivariate logistic regressions were used to 
explore interrelations between maternal folate status, IUI and PTB. Adjusted logit regressions assessed 
the probability of PTB by maternal plasma folate levels, stratified by IUI status. 
Main outcome measures: IUI (intrapartum fever or placental pathology evidence) and PTB (birth <37 
completed weeks of gestation). 
Results: Both multivitamin supplement intake and plasma folate concentrations were associated with 
reduced odds of IUI (aOR=0.74, 95% CI: 0.63, 0.87; aOR=0.85, 95% CI: 0.73, 0.98, respectively). 
Multivitamin intake ameliorated the relationship between IUI and PTB, particularly spontaneous PTB. 
Adjusted logit regressions showed that regardless of IUI status, the probability of PTB and spontaneous 
PTB decreased as plasma folate concentrations increased. 
Conclusions: Our study findings suggest that folate may be beneficial to mitigate IUI and its associated 
spontaneous PTB.  
 
Keywords:  Maternal folate status, intrauterine infection/inflammation, preterm birth, US population, 






Folate, also known as vitamin B9, is a naturally occurring water-soluble B vitamin involved in many 
cellular pathways and biological reactions needed for growth and normal immune function (1). Reduced 
folate levels have been linked with a dysfunction of cell-mediated immunity by reducing the capacity of 
CD8(+) cells to proliferate in response to activation (2), and dysfunctional humoral immunity by 
reducing antibody responses to several antigens (1). The phagocytic and bactericidal properties of 
polymorph nuclear white blood cells are reduced in people with folate deficiency, increasing their 
susceptibility to overt and subclinical infections (3).  
Folate sufficiency is particularly important in pregnancy during which deficient levels have been 
linked to adverse pregnancy outcomes such as anemia, preeclampsia and birth defects (4).  Of interest is 
the association between maternal folate levels and preterm birth (PTB) – delivery before 37 completed 
weeks of gestation. Studies including our own have demonstrated a link between reduced maternal 
blood folate concentration or folic acid supplementation and PTB (5-8). One postulated mechanism in 
which a reduced folate level may be associated with PTB is via inflammation, since folate has anti-
inflammatory properties (9). PTB, which is associated with abnormal inflammatory responses, may be 
triggered by a lower genital tract infection or intrauterine infection (3, 10). The term intrauterine 
infection/inflammation (IUI), proposed by the National Institute of Child Health and Human 
Development as a replacement for chorioamnionitis, refers to a heterogeneous setting of conditions 
characterized by intrauterine infection and/or inflammation or both that occur in pregnancy (11). The 
diagnosis of IUI is based on the presence of clinical and histopathologic features in addition to maternal 
fever (12). The literature suggests that IUI is a primary cause of over a quarter of PTB cases (13). One 





While studies have demonstrated the link between lower plasma folate concentrations in early 
pregnancy and at delivery and lower genital tract infections such as bacterial vaginosis (15), the 
association between folate and IUI is not well investigated.  A US based study found that the link 
between maternal folate and lower genital tract infection represents a possible pathway for the 
relationship between maternal folate status and PTB (5, 16). The study analyzed plasma folate and 
cervical fluid cytokine assays in a low income, predominantly Black population. Each of the standard 
deviation (SD) increases in serum total folate and serum 5-methyltetrahydrofolate (5MeTHF) 
concentrations was associated with significant reductions in the risk of spontaneous PTB (P < 0.05), 
while serum 5MeTHF concentrations were also associated with cervical cytokine concentrations, 
suggesting a possible mechanistic link between folate and PTB risk.  
Other studies in South Korea and Nepal have explored the relationship between maternal folate 
status and C-reactive protein (CRP) levels in pregnancy and resulting PTB. In the South Korea study, 
serum folate concentration, dietary recall and serum CRP were collected at 12 and 28 weeks of 
gestation. Serum folate was inversely correlated with serum CRP levels while CRP was positively 
associated with PTB (17). This is in contrast with the study in Nepal which demonstrated that though 
CRP was associated with PTB, multiple micronutrient supplementation was not related to CRP (18). 
Given the scant literature specific to the US, this paper aims to systematically investigate the 
interrelationship of maternal folate, IUI and PTB among a high-risk US population. We hypothesize that 
higher maternal folate status, assessed using complementary measures of reported multivitamin 
supplement intake and plasma folate concentrations, i) is negatively associated with IUI and ii) 







Materials and Methods 
The study sample consisted of a subgroup of mother–infant dyads recruited from 1998 to date as part 
of the Boston Birth Cohort (BBC), an ongoing prospective cohort enrolled at the Boston Medical Center 
(BMC). BMC serves a predominantly low-income urban minority population. The BBC has been 
enriched for PTBs and other adverse pregnancy complications by recruiting at a ratio of approximately 
one PTB for every two term births. Multiple births as well as newborns with major birth defects were 
excluded from the BBC study. Patient recruitment and data collection methods are detailed elsewhere 
(19). Briefly, enrollment took place within 72 hours after birth, and informed written consent was 
obtained from all study participants. Epidemiologic data was collected via a face to face maternal 
questionnaire interview while clinical data was collected from maternal and newborn medical records 
using a standardized abstraction form. Of the 8,570 eligible women enrolled in the BBC (approximately 
85% response rate of those approached), we excluded 918 women without multivitamin supplement 
intake information and 526 women without IUI information.   
The final sample for analyses included 7050 women with information on multivitamin supplement 
intake, IUI, as well as birth outcomes.  Of those, a subsample of women (n=2241) had plasma folate 
levels measured in blood samples collected within a few days after delivery (Supplemental Figure 1 
displays the study flow chart). This subsample included women who consented to enroll their children in 
a follow up study at BMC (20). Women in the full multivitamin supplement intake sample and plasma 
folate subsample had very similar baseline characteristics, except for higher proportion of African 







Multivitamin supplement intake was assessed from responses to two questions from the maternal 
questionnaire: “Did you take prenatal vitamins prescribed by your doctor?” and “Did you take any over-
the-counter multivitamins?” as published elsewhere (21). Follow up questions assessed the frequency of 
multivitamin supplement use during specific time periods: prepregnancy (6 months prepregnancy), 1st 
trimester (day one – day 90 of pregnancy), 2nd trimester (day 91 to 180), 3rd trimester (day 181 to birth). 
Response options for each time period included: none, 1 time per week, 2 times per week, 3-5 times per 
week, almost daily. Preconception multivitamin intake was categorized into: “no intake” versus “any 
intake”. Intake in the 1st to 3rd trimester was categorized as: “less than three” versus “three or more 
times” per week. Typically, prenatal prescribed and over-the-counter multivitamins usually contain 400 
or 800 micrograms of folic acid and are suggested to be taken daily in the US (22).  
Plasma folate concentrations were assessed from maternal plasma samples using chemiluminescent 
immunoassay with diagnostic kits using a Beckman Coulter ACCESS Immunoassay System (Beckman-
Coulter Canada, Mississauga, Canada) (23).  
Measurement and definition of IUI has been published elsewhere (24). Briefly, placental samples 
were obtained at the time of delivery for pathology review. Using algorithms consistent with the 
guidelines of the College of American Pathologists (25, 26), pathologists reported the presence of 
inflammation in the umbilical cord, amnion, chorionic plate, decidua and chorion. IUI was defined as 
the presence of any of the following criteria: intrapartum maternal fever >38oC or placental 
histopathology consistent with IUI including villitis, deciduitis, chorioamnionitis, chorionitis, 
subchorionitis, funisitis and free membranitis.  
PTB was defined as delivery at <37 weeks of gestation, based on an algorithm of the last menstrual 





Other covariates included in the analysis include maternal age (<20, 20-34 and 35+ years), 
race/ethnicity (African American, Non-Hispanic white, Hispanic and Other), marital status (unmarried 
versus married), education (≤Elementary, High School or ≥College), nativity (US born versus foreign 
born), parity (nulliparous versus multiparous), receipt of public assistance (yes or no), perceived stress 
(mother’s report of life or pregnancy as being ‘very’ stressful), smoking status (never used, ever used, 
used in pregnancy), alcohol use in pregnancy (never versus any). 
Statistical analysis 
Exploratory data analysis was performed on the full sample as well as the plasma folate subsample. 
Chi-square- and t- tests were used to compare maternal characteristics by the presence or absence of 
IUI. Histogram plots were used to display the distribution of plasma folate concentrations by IUI status. 
Multivariate logistic regressions were used to explore associations between both measures of maternal 
folate status and IUI adjusting for potential confounding covariates: maternal race, age, nativity, 
education, marital status, receipt of public assistance, parity, smoking status, alcohol use and stress. 
Sensitivity analysis was also conducted using multivariate logistic regressions among non-Hispanic 
Black women only. To further explore the combined effect of folate and IUI on PTB, multivitamin 
supplement intake and IUI status were cross-classified into a single variable with four categories: i) IUI 
with low multivitamin supplement intake, ii) IUI with high multivitamin supplement intake, iii) No IUI 
with low supplement intake and iv) No IUI with high supplement intake. The odds of PTB and PTB 
subtypes was assessed across these four categories with the highest risk group, IUI and low multivitamin 
supplement intake, as the reference group. In the subsample with plasma folate levels, adjusted logit 
regressions were used to graph the probability of PTB by plasma folate level, stratified by women with 






In the final sample, most women were unmarried, high-school educated, and on public assistance. 
Non-Hispanic Black women made up 52% of the full sample while 16% had IUI and 28% had a PTB. 
Table 1 shows the difference in maternal characteristics by IUI status among the full sample as well as 
plasma folate subsample while Supplemental Table 1 compares maternal characteristics of women with 
and without IUI data. As seen in Table 1, for both the full sample as well as plasma subsample, 
demographic characteristics associated with IUI included nativity and marital status. Specifically, 
women with IUI were more likely to be born in the US and be unmarried. In addition, women with IUI 
were more likely to have experienced overall PTB as well as spontaneous PTB.  
Table 2 displays crude and adjusted associations between maternal folate status (multivitamin 
supplement intake and plasma folate concentration) and IUI. Multivitamin supplement intake in the 
preconception period was not significantly associated with IUI. Intake of three or more times a week in 
the 1st trimester (aOR=0.78, 95% CI: 0.67, 0.91), 2nd trimester (aOR=0.79, 95% CI: 0.67, 0.93) and 3rd 
trimester (aOR=0.74, 95% CI: 0.63, 0.87) was associated with reduced odds of IUI. Plasma folate 
concentration also demonstrated an inverse association with IUI. Specifically, each interquartile increase 
in plasma folate reduced the odds of IUI by about 15% (aOR=0.85, 95% CI: 0.73, 0.98). Compared with 
plasma folate concentration in the lowest quartile, the highest quartile was associated with a 38% 
reduction in the odds of IUI (aOR= 0.62, 95% CI: 0.44, 0.88). The sensitivity analysis presented in 
Supplemental Table 2 shows that the associations between multivitamin supplement intake or plasma 
folate concentrations with IUI persisted among all non-Hispanic Black women specifically. 
Supplemental Tables 3-5 show a similar pattern for multivitamin supplement intake during the first and 





As presented in Table 3, there was a significant relationship between both multivitamin supplement 
intake and IUI with PTB and spontaneous PTB but not with medically indicated PTB. Women with IUI 
had increased odds of PTB (aOR=1.75, 95% CI: 1.53, 2.01). This was primarily due to higher odds of 
spontaneous PTB (aOR=2.33, 95% CI: 2.00, 2.70). In addition, multivitamin supplement intake of three 
time or more a week in the third trimester was associated with reduced PTB odds (aOR=0.76, 95% CI: 
(0.66, 0.86) as well as reduced odds of spontaneous PTB (aOR= 0.71, 95% CI: 0.61, 0.83). Joint 
analysis of IUI and multivitamin supplement intake showed that multivitamin intake attenuated the 
relationship between IUI and PTB. Compared to the reference group with IUI and low multivitamin 
supplement intake, women with IUI but higher levels of multivitamin intake had lower odds of PTB 
than the reference group (aOR=0.70; 95% CI: 0.53, 0.94). Moreover, the odds of PTB were lowest 
among women without IUI but with high multivitamin supplement intake (aOR=0.42; 95% CI: 0.32, 
0.54). A stronger association was seen with spontaneous PTB but not with medically indicated PTB; 
compared to the reference group, women without IUI and high multivitamin supplement intake had the 
lowest odds of spontaneous PTB (aOR: 0.29, 95% CI: 0.22, 0.38).  
The interrelationships between plasma folate concentrations, IUI and PTB (as well as spontaneous 
PTB) are presented graphically in Figure 1. The probability of PTB and spontaneous PTB across plasma 
folate concentrations are stratified by IUI status. Regardless of IUI status, the probability of PTB and 
spontaneous PTB decrease as plasma folate concentrations increase. Also, regardless of folate status, the 
probability of PTB and spontaneous PTB was higher among women with IUI compared to those without 
IUI. In other words, low folate levels and IUI additively increase the risk of overall PTB and 







To the best of our knowledge, this is the first study to investigate the interrelationships of maternal 
folate status, IUI, and PTB in a predominantly urban, low-income, minority US population. In our study 
population, IUI was positively associated with PTB as well as spontaneous PTB, corroborating existing 
literature that IUI can lead to  PTB via activation of pathological inflammatory processes resulting in 
preterm labor, preterm premature rupture of membranes (ROM) and dilation of the cervix (27, 28). 
Normal term labor also involves multiple physiological mechanisms that initiate inflammatory 
mechanisms, which lead to membrane rupture, cervical ripening and onset of coordinated uterine 
contractions timed with fetal maturation. While preterm labor frequently involves early activation of the 
same inflammatory mechanisms seen in normal labor due to pathological causes, the scale and nature of 
the inflammatory response may be abnormal (29). Pathological inflammatory insults occurring during 
pregnancy, such as oxidative stress or infection can precipitate PTB, often involve common pathways 
(29). IUI remains not only an important cause of early PTB, it is associated with the delivery of infants 
at greatest risk of death and disability (30). 
Importantly, we found a protective role of higher maternal folate status against IUI across the 
two complementary measures of folate status. In addition, this association was also seen among a 
subgroup of non-Hispanic Black women.  This is biologically plausible given the anti-inflammatory 
properties of folate through its inverse relationship with homocysteine (31). Moreover, the presence of 
inflammation promotes nitric oxide synthesis, which in turn produces hyperhomocysteinemia and 
oxidative stress and in turn more inflammation (32). Hyperhomocysteinemia has been demonstrated as a 
risk factor for many inflammatory conditions such as cardiovascular disease, stroke, renal failure and 






Even more important, our study demonstrated that higher folate status can mitigate the positive 
association between IUI and PTB (particularly spontaneous PTB). The lowest odds of spontaneous PTB 
was observed in mothers with high folate status and no IUI; their odds of spontaneous PTB was more 
than 70% lower than that of mothers with both risk factors, low folate status and IUI. This finding was 
also consistent across two measures of maternal folate status:   reported multivitamin supplement intake 
and measured plasma folate concentrations.  While the mechanistic pathway by which folate could 
mitigate the IUI- PTB relationship is still unclear, our findings are supported by animal models where 
pretreatment of mice with folic acid prevented maternal lipopolysaccharide-induced preterm delivery 
(35). Additional research is needed using prospective studies to corroborate and elucidate our findings.   
This study had some limitations. Plasma folate levels were assessed within 72 hours of delivery 
and although they are more objective and less prone to the recall bias observed with dietary 
history/supplement intake, we recognize that a single plasma folate measurement cannot be used to 
differentiate between a transitory decrease in dietary folate intake and a chronic deficiency state. We 
used plasma folate concentration at delivery as a proxy for third trimester folate level as it reflects short 
term folate status (36, 37). In addition, multivitamin supplement intake was based on self-report, which 
is subject to recall bias. Due to the high correlations between multivitamin supplement intake across all 
trimesters (rho: 0.58- 0.85, p<0.001), further adjustments for intake in other trimesters were not 
conducted when exploring the associations in each trimester. This was an observational study, and by its 
nature cannot enable causal inference (38). While no randomized controlled trial has been conducted in 
the US and is unlikely given the advantageous effect of folate on pregnancy outcomes, our study 
findings need to be confirmed in prospective longitudinal studies. Our study population included a 





other countries with low folate intake, caution is needed in extrapolating these findings to populations 
with different demographic and clinical characteristics and contexts. 
If further confirmed, our findings have important clinical and public health implications as folic 
acid supplementation and fortification are proven interventions to improve maternal folate status. This is 
particularly relevant for members of low income and minority populations in the US who typically are 





Tables and figures 
Table 6-1: Characteristics of the study sample by IUI status in the full multivitamin supplement 
intake sample and plasma folate subsample 
Maternal 
Characteristics 
Multivitamin supplement intake 
(N=7050) 










N (%) N (%)  N (%) N (%)  
Race/ethnicity   0.029   0.298 
Non-Hispanic Black a 3028 (51) 625 (56)  1390 (72) 247 (77)  
Non-Hispanic White 721 (12) 134 (12)  77 (4) 12 (4)  
Hispanic 1704 (29) 282 (25)  374 (20) 52 (16)  
Other 475 (8) 81 (7)  80 (4) 9 (3)  
Age in years    0.001   0.076 
<20 600 (10) 147 (13)  184 (10) 37 (12)  
20-34 4321 (73) 820 (73)  1371 (71) 238 (74)  
35+ 1007 (17) 155 (14)  366 (19) 45 (14)  
Nativity (US born)   0.002   0.034 
Not born in US  3576 (60) 627 (56)  1142 (59) 169 (53)  
Born in US 2279 (38) 488 (44)  754 (39) 149 (47)  
Missing 73 (1) 7 (1)  25 (1) 2 (1)  
Education   0.488   0.928 
Less than high school 1813 (31) 352 (31)  533 (28) 86 (27)  
High School/GED 1985 (34) 382 (34)  703 (37) 123 (38)  
Some College and 
above 
2108 (36) 381 (34)  677 (35) 110 34)  
Missing 22 (0) 7 (1)  8 (0) 1 (0)  
Marital Status   0.003   0.032 
Married 2186 (37) 357 (32)  672 (35) 90 (28)  
Unmarried 3660 (62) 743 (66)  1234 (64) 229 (72)  
Missing 82 (1) 22 (2)  15 (1) 1 (0)  
Receipt of public 
assistance b  
  0.890   0.156 
No 936 (16) 179 (16)  261 (14) 53 (17)  
Yes 4992 (84) 943 (84)  1660 (86) 267 (83)  
Parity   <0.001   <0.001 
Multiparous 3482 (59) 498 (44)  1157 (60) 153 (48)  
Nulliparous 2432 (71) 622 (55)  760 (40) 167 (52)  
Missing 14 (0) 2 (0)  4 (0) 0 (0)  
Cigarette smoking   0.186   0.430 
Never 4711 (80) 861 (77)  1555 (81) 250 (78)  
Ever 434 (7) 90 (8)  153 (8) 29 (9)  
Continuous in 
pregnancy 
742 (13) 164 (15)  198 (10) 40 (13)  
Missing 41 (1) 7 (1)  15 (1) 1 (0)  
Alcohol consumption   0.009   0.120 





Yes 546 (9) 116 (10)  151 (8) 36 (11)  
Missing 134 (2) 41 (4)  32 (2) 6 (2)  
Stressc   0.445   0.514 
No 4644 (78) 871 (78)  1494 (78) 253 (79)  
Yes 1262 (21) 244 (22)  420 (22) 67 (21)  
Missing 22 (0) 7 (1)  7 (0) 0 (0)  
BMI categories  
  
0.907   0.609 
Underweight 249 (4) 50 (5)  75 (4) 13 (4)  
Normal 2638 (45) 509 (45)  803 (42) 138 (43)  
Overweight/Obese 2646 (45) 491 (44)  946 (49) 148 (46)  
Missing 395 (7) 72 (6)  97 (5) 21 (7)  
Diabetes Mellitus   0.456   0.667 
No 5483 (93) 1039 (93)  1767 (92) 296 (93)  
GDM 281 (5) 45 (4)  89 (5) 11 (3)  
DM 119 (2) 29 (3)  54 (3) 10 (3)  
Missing 45 (1) 9 (1)  11 (1) 3 (1)  
Preterm birth 
  
<0.001   <0.001 
No 4371 (74) 690 (62)  1361 (71) 169 (53)  
Yes 1557 (26) 432 (39)  560 (29) 151 (47)  
Spontaneous PTB 944 (16) 348 (31) <0.001 319 (17) 129 (40) 0.001 
Medically induced 
PTB 
613 (10) 84 (8) 0.003 241 (13) 22 (7) 0.004 
a Non- Hispanic Black includes Black, African American, Haitian, Cape Verdian.  
b Public assistance is defined as receipt of any of the following: WIC (Women Infants and Children), 
food stamps, AFDC (Aid to families with dependent children), housing assistance or fuel assistance.  








Table 6-2: Relationship between maternal folate status and intrauterine infection/inflammation (N=7050)  
Maternal Folate Status n (%) IUI 
cases 
OR (95% CI) aORa (95% CI) 
Multivitamin supplement intake (n=7050) IUI (n=1122) 
Preconception    
None (reference) 1039 (15.8) 1.00  1.00  
Any 83 (17.9) 1.16 (0.91, 1.49) 1.21 (0.94, 1.56) 
1st trimester    
<3x a week (reference) 277 (18.5) 1.00  1.00  
≥3x a week 845 (15.2) 0.79 (0.68, 0.92) 0.78 (0.67, 0.91) 
2nd trimester    
<3x a week (reference) 217 (18.4) 1.00  1.00  
≥3x a week 905 (15.4) 0.81 (0.68, 0.95) 0.79 (0.67, 0.93) 
3rd trimester    
<3x a week (reference) 243 (19.1) 1.00  1.00  
≥3x a week 879 (15.2) 0.76 (0.65, 0.89) 0.74 (0.63, 0.87) 
 
Plasma Folate in nmol/L (n=2241) 
 
IUI (n=320) 
Continuous     
Each unit nmol/L increase 320 (100) 0.99 (0.99, 1.00) 0.99 (0.99, 1.00) 
Each interquartile increase  320 (100) 0.85 (0.74, 0.98) 0.85 (0.73, 0.98) 
Categorical: quartiles (nmol/L)    
Lowest quartile: 6.6 to 19.4 (reference) 95 (16.7) 1.00  1.00  
Second quartile: 19.4- 30.0 86 (15.3) 0.90 (0.66, 1.24) 0.89 (0.64, 1.23) 
Third quartile:30.0-43.8 76 (13.8) 0.80 (0.58, 1.11) 0.78 (0.56, 1.09) 
Highest quartile: 43.8-185.5 63 (11.3) 0.64 (0.45, 0.90) 0.62 (0.44, 0.88) 
Abbreviation: aOR: adjusted odds ratio; CI: confidence interval; IUI: intrauterine 
infection/inflammation; n: number of cases; n/a: not applicable. 
a Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, parity, 






Table 6-3: Individual and joint association of intrauterine infection/inflammation (IUI) with 
multivitamin supplement intake in the third trimester on preterm birth (overall and subtypes) 
(N=7050) 
Characteristic PTB (n=1989) sPTB (n=1292) mPTB (n=697) 












Intrauterine infection/inflammation (IUI) 
No (ref) 1557 (26) 1.00 944 (18) 1.00 613 (12) 1.00 
Yes 432 (39) 1.75 
(1.53, 2.01) 
348 (34) 2.33 
(2.00, 2.70) 
84 (11) 0.85 
(0.66, 1.09) 
Multivitamin supplement intake (MVI) in third trimester  
< 3x a week (ref) 431 (34) 1.00 296 (26) 1.00 135 (14) 1.00 
≥3x a week  1558 (27) 0.76 
(0.66, 0.86) 
996 (19) 0.71 
(0.61, 0.83) 
562 (12) 0.86 
(0.70, 1.06) 
Joint Analysis of IUI with multivitamin supplement intake in third trimester 
IUI MVI       




1.00 100  
(44) 
1.00 14 (10) 1.00 








70 (11) 1.25 
(0.68, 2.31) 








121 (15) 1.67 
(0.92, 3.02) 








492 (12) 1.36 
(0.77, 2.40) 
Abbreviation: aOR: adjusted odds ratio; CI: confidence interval; IUI: intrauterine 
infection/inflammation; n: number of cases; n/a: not applicable. 
a Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, parity, 






Figure 6-1: Adjusted probability of preterm (top panel) and spontaneous preterm birth (bottom 
panel) by plasma folate concentrations stratified by intrauterine infection/inflammation status 
 
Notes: IUII-intrauterine infection/inflammation; Probability adjusted for potential confounding 
variables- maternal race, age, nativity, education, marital status, receipt of public assistance, parity, 
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Supplemental Table 6-1: Comparison of characteristics of women in the study sample with women 
with missing IUI data 
Characteristics 
 
IUI data present 
(N=7050) 




No. % No. % No. % 
Race/ethnicity       
Non-Hispanic Black a 3653 51.8 194 36.9 3847 50.8 
Non-Hispanic White 855 12.1 65 12.4 920 12.1 
Hispanic 1986 28.2 164 31.2 2150 28.4 
Other 556 7.9 58 11 614 8.1 
Missing 0 0 45 8.6 45 0.6 
Age in years        
<20 747 10.6 56 10.6 803 10.6 
20-34 5141 72.9 358 68.1 5499 72.6 
35+ 1162 16.5 67 12.7 1229 16.2 
Missing 0 0 45 8.6 45 0.6 
Nativity (US born)       
Not born in US  4203 59.6 318 60.5 4521 59.7 
Born in US 2767 39.2 197 37.5 2964 39.1 
Missing 80 1.1 11 2.1 91 1.2 
Education       
Less than high school 2165 30.7 138 26.2 2303 30.4 
High School/GED 2367 33.6 174 33.1 2541 33.5 
Some College and above 2489 35.3 165 31.4 2654 35 
Missing 29 0.4 49 9.3 78 1 
Marital Status       
Married 2543 36.1 193 36.7 2736 36.1 
Unmarried 4403 62.5 275 52.3 4678 61.7 
Missing 104 1.5 58 11 162 2.1 
Receipt of public assistance b        
No 1115 15.8 95 18.1 1210 16 
Yes 5935 84.2 431 81.9 6366 84 
Parity       
Multiparous 3980 56.5 154 29.3 2064 27.2 
Nulliparous 3054 43.3 370 70.3 5494 72.5 
Missing 16 0.2 2 0.4 18 0.2 
Cigarette smoking       
Never 5572 79 411 78.1 5983 79 
Ever 524 7.4 27 5.1 551 7.3 
Continuous in pregnancy 906 12.9 41 7.8 947 12.5 
Missing 48 0.7 47 8.9 95 1.3 
Alcohol consumption       
No 6213 88.1 427 81.2 6640 87.6 
Yes 662 9.4 30 5.7 692 9.1 
Missing       
Stressc       
No 5515 78.2 433 82.3 5948 78.5 





Missing 29 0.4 5 1 34 0.4 
BMI categories  
      
Underweight 299 4.2 25 4.8 324 4.3 
Normal 3147 44.6 206 39.2 3353 44.3 
Overweight/Obese 3137 44.5 203 38.6 3340 44.1 
Missing 467 6.6 92 17.5 559 7.4 
Diabetes Mellitus       
No 6522 92.5 490 93.2 7012 92.6 
Gestational DM 326 4.6 18 3.4 344 4.5 
DM 148 2.1 6 1.1 154 2 
Missing 54 0.8 12 2.3 66 0.9 
Preterm birth 
      
No 5061 71.8 446 84.8 5507 72.7 
Yes 1989 28.2 80 15.2 2069 27.3 
Spontaneous PTB 1292 20.3 61 11.6 1353 17.9 
Medically induced PTB 697 12.1 19 3.6 716 9.5 
Abbreviation: IUI: DM: Diabetes Mellitus; GED: General Education Diploma; Intrauterine 
Infection/Inflammation; PTB: Preterm Birth; US: United States 
a Non- Hispanic Black includes Black, African American, Haitian, Cape Verdian;  
b public assistance is defined as receipt of any of the following: including: WIC (Women Infants and 
Children), food stamps, AFDC (Aid to families with dependent children), housing assistance or fuel 
assistance.  






Supplemental Table 6-2: Relationship between IUI and multivitamin supplement intake in the 
third trimester (N=3653) and plasma folate concentration at delivery (n=1630) among non-
Hispanic Blacks only. 
Maternal Folate Status n (%) cases OR (95% CI) aORa (95% CI) 
Multivitamin supplement intake (N=3653) IUI (n=625) 
Preconception    
None (ref) 581 (17.0) 1.00 (reference) 1.00 (reference) 
Any 44 (18.3) 1.09 (0.78, 1.53) 1.17 (0.83, 1.66) 
1st trimester    
<3x a week (ref) 171 (19.8) 1.00 (reference) 1.00 (reference) 
≥3x a week 454 (16.3) 0.79 (0.65, 0.96) 0.72 (0.59, 0.89) 
2nd trimester    
<3x a week (ref) 135 (20.1) 1.00 (reference) 1.00 (reference) 
≥3x a week 490 (16.4) 0.78 (0.63, 0.97) 0.72 (0.58, 0.90) 
3rd trimester    
<3x a week (ref) 155 (21.4) 1.00 (reference) 1.00 (reference) 
≥3x a week 470 (16.1) 0.70 (0.58, 0.86) 0.65 (0.53, 0.81) 
 
Plasma Folate in nmol/L (n=1630) 
 
IUI (n=247) 
Continuous     
Each unit nmol/L increase 247 (100) 0.99 (0.99, 1.00) 0.99 (0.99, 1.00) 
Each interquartile increase  247 (100) 0.82 (0.70, 0.97) 0.82 (0.69, 0.97) 
Categorical: quartiles (nmol/L)    
Lowest quartile: 6.6 to 19.4 (reference) 78 (17.1) 1.00 (reference) 1.00 (reference) 
Second quartile: 19.4- 30.0 70 (17.5) 1.03 (0.73, 1.47) 1.01 (0.70, 1.45) 
Third quartile:30.0-43.8 55 (14.3) 0.81 (0.56, 1.18) 0.75 (0.51, 1.10) 
Highest quartile: 43.8-185.5 44 (11.1) 0.61 (0.41, 0.90) 0.58 (0.39, 0.87) 
Abbreviation: aOR: adjusted odds ratio; CI: confidence interval; IUI: intrauterine 
infection/inflammation; n: number of cases. 
a Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, 






Supplemental Table 6-3: Individual and joint association of IUI with multivitamin supplement 
intake in the 1st trimester on preterm birth (N=7050) 
Characteristic PTB (n=1989) sPTB (n=1292) mPTB (n=697) 












Intrauterine infection/inflammation (IUI) 
No (ref) 1557 (26) 1.00 944 
(18) 
1.00 613 (12) 1.00 






84 (11) 0.85 
(0.66, 1.09) 
Multivitamin supplement intake (MVI) in first trimester  
≥3x a week (ref) 1509 (27) 1.00 959 
(19) 
1.00 550 (12) 1.00 






147 (13) 1.01 
(0.82, 1.23) 
Joint Analysis of IUI with multivitamin supplement intake in third trimester 
IUI MVI       






1.00 16 (9) 1.00 








68 (11) 1.42 
(0.79, 2.53) 








131 (14) 1.62 
(0.93, 2.82) 








482 (12) 1.52 
(0.90, 2.59) 
Abbreviation: aOR-adjusted odds ratio; CI: confidence interval; IUI: intrauterine 
infection/inflammation mPTB: medically indicated PTB; MVI: multivitamin supplement intake; n-
number of cases; ref- reference; PTB: preterm birth; sPTB: spontaneous PTB. 
a Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, 






Supplemental Table 6-4: Individual and joint association of IUI with multivitamin supplement 
intake in 2nd trimester on Preterm Birth (N=7050) 
Characteristic PTB (n=1989) sPTB (n=1292) mPTB (n=697) 












Intrauterine infection/inflammation (IUI) 













84 (11) 0.85 
(0.66, 1.09) 
Multivitamin intake (MVI) in second trimester  




1.00 581 (12) 1.00 








116 (12) 1.06  
(0.85, 1.31) 
Joint Analysis of IUI with multivitamin supplement intake in third trimester 
IUI MVI       




1.00 82 (40) 1.00 11 (8) 1.00 








73 (11) 1.57 
(0.80, 3.07) 








105 (14) 1.85 
(0.96, 3.56) 
No ≥ 3x/week 1265 
(25) 
0.48 





508 (12) 1.63 
(0.87, 3.05) 
Abbreviation: aOR-adjusted odds ratio; CI: confidence interval; IUI: intrauterine 
infection/inflammation mPTB: medically indicated PTB; MVI: multivitamin supplement intake; n-
number of cases; ref- reference; PTB: preterm birth; sPTB: spontaneous PTB. 
a Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, 








Supplemental Table 6-5: Individual and joint association of IUI with multivitamin supplement 
intake in overall pregnancy on Preterm Birth (N=7050) 
Characteristic PTB (n=1989) sPTB (n=1292) mPTB (n=697) 












Intrauterine infection/inflammation (IUI) 













84 (11) 0.85 
(0.66, 1.09) 
Multivitamin intake (MVI) in second trimester  




1.00 514 (12) 1.00 








183 (13) 1.04 
(0.86, 1.25) 
Joint Analysis of IUI with multivitamin supplement intake in third trimester 
IUI MVI       






1.00 18 (8) 1.00 








66 (12) 1.55 
(0.89, 2.70) 








165 (13) 1.77 
(1.05, 2.96) 








448 (12) 1.59 
(0.96, 2.61) 
Abbreviation: aOR-adjusted odds ratio; CI: confidence interval; IUI: intrauterine infection/inflammation 
mPTB: medically indicated PTB; MVI: multivitamin supplement intake; n-number of cases; ref- 
reference; PTB: preterm birth; sPTB: spontaneous PTB. 
a Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, parity, 
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This chapter summarizes this dissertation which aimed to: i) Evaluate the relationship between 
maternal folate status (using multiple measures and assessed from preconception to delivery) and 
risk of PTB (overall and subtype of PTB) and ii) Investigate the biologic plausibility of the 
folate-PTB association by evaluating the role of folate on major pathogenic pathways- 
preeclampsia and IUI- leading to PTB. The chapter begins with a brief discussion of the main 
findings, followed by a discussion of strengths and limitations, public health implications and 
conclusions of the research. 
Key Findings 
Relationship between maternal folate status and PTB 
Unadjusted and adjusted logistic regressions revealed an inverse relationship between the 
frequency of multivitamin supplement intake and PTB. Compared to less frequent use, 
multivitamin supplement intake 3-5 times/week (adjusted odds ratio (aOR)= 0.78, 95% 
confidence interval (CI): 0.64, 0.96) or >5 times/week (aOR= 0.77, 95% CI: 0.64, 0.93) 
throughout pregnancy was associated with reduced risk of PTB. Consistently, higher plasma 
folate levels (highest versus lowest quartile) were associated with lower risk of PTB (aOR= 0.74, 
95% CI: 0.56, 0.97). The above associations were similar among spontaneous and medically 
indicated PTBs.  
Interrelationships between maternal folate status, preeclampsia and medically indicated PTB 
Intake of multivitamin supplements containing folate, three or more times a week in the 3rd 
trimester was associated with reduced odds of preeclampsia (aOR=0.77, 95% CI: 0.65, 0.93). 
Each interquartile increase in plasma folate reduced the odds of preeclampsia by 20% 





the highest quartile was associated with reduced risk of preeclampsia (aOR=0.62, 95% CI: 0.43, 
0.90). Preeclampsia mediated 62% of the multivitamin supplement intake-medically indicated 
PTB relationship. Preeclampsia did not mediate the relationship between either measure of folate 
status and spontaneous PTB. 
Interrelationships between maternal folate status, IUI and spontaneous PTB 
Both multivitamin supplement intake and plasma folate concentrations were associated with 
reduced odds of IUI (aOR=0.74, 95% CI: 0.63, 0.87; aOR=0.85, 95% CI: 0.73, 0.98, 
respectively). Joint analysis of IUI and multivitamin supplement intake showed that multivitamin 
intake attenuated the relationship between IUI and spontaneous PTB. Compared to the reference 
group with IUI and low multivitamin supplement intake, women without IUI and high 
multivitamin supplement intake had the lowest odds of spontaneous PTB (aOR: 0.29, 95% CI: 
0.22, 0.38). Adjusted logit regressions showed that regardless of IUI status, the probability of 
PTB and spontaneous PTB decreased as plasma folate concentrations increased. 
 
Strengths and Limitations 
This section presents the strengths and limitations of the study. 
Strengths: The strengths of this dissertation include the following: 
Study sample: The study consisted of a high risk, predominantly low income urban minority US 
population. Study findings are generalizable to similar low income urban women populations in 
the US who are more likely to have lower folate intake and bear greater risk of preeclampsia, 
IUI, and PTB. Thus, findings from this study are directly relevant to the design of relevant 





Multiple measures of folate status: This study employed two complementary measures of 
folate status- self reported multivitamin supplement intake from preconception to third trimester 
as well as plasma folate samples taken at delivery. In general, study findings were consistent 
across measures of folate status, strengthening the validity of study findings. 
Large sample size: This study sample size is among the latest ever conducted in the US 
population, and it is further strengthened by the availability of data on PTB subtypes, 
preeclampsia and IUI. The plasma folate subsample was one of the largest US sample sizes to 
date. There were also large samples of pregnancy complications such as preeclampsia and IUI to 
enable mediation/moderation analysis.  
Extensive covariables: Data from this study included epidemiologic data from a face to face 
maternal questionnaire interview, clinical data from abstracted medical records, and biomarkers 
from maternal and placental samples, which provided opportunities to address the study 
hypotheses while controlling for potential confounding factors.  
Novel statistical methods: This dissertation employed novel statistical methods including 
mediation analysis and additive as well as multiplicative interaction analysis. This enabled the 
exploration of intersection of nutritional, biomedical and psychosocial risk factors influencing 
PTB. 
 
Study Limitations: This study however acknowledges the following limitations.  
Maternal folate status: Plasma folate levels were assessed within 72 hours of delivery and 
though they are objective and not prone to the recall bias observed with dietary 





to differentiate between a transitory decrease in dietary folate intake and chronic deficiency 
states. Plasma folate at delivery can only be used as a proxy for third trimester folate levels as it 
reflects short term folate status (1, 2). In addition, multivitamin supplement intake was based on 
self-report, which is subject to recall bias. Also, the determination of folate status from the 
frequency of supplement intake may be incomplete as folate status may also be influenced by 
dietary intake of folate rich/fortified foods and other factors affecting folate metabolism. Due to 
the high correlations multivitamin supplement intake across all trimesters (rho: 0.58- 0.85, 
p<0.001), further adjustments for intake in other trimesters were not conducted when exploring 
the associations in each trimester.  
Causality: This is an observational study, and by its nature cannot enable causal inference (3) as 
unobserved confounding remains a threat to validity. Randomized Control Trials (RCT) have 
been lauded as the gold standard of clinical research (4). However, no RCT on the relationships 
between folate status and PTB, preeclampsia or intrauterine infection has been conducted in the 
US and is unlikely given the advantageous role of folate on pregnancy outcomes, study findings 
need to be confirmed in prospective longitudinal studies.  
Generalizability: Not all participants of the BBC study are included in this dissertation based on 
the eligibility criteria. It is possible that those who are not included might differ in some way 
from the study sample. Furthermore, results of this dissertation are only generalizable to similar 
urban low-income minority populations in the US such as Detroit, Baltimore, New York (5). 
Study findings may also have implications for populations in the developing countries with low 
folate intake, but caution is needed in extrapolating our findings to populations with different 
demographic and clinical characteristics and contexts. This dissertation is also limited by its 





minority populations such as Asians and Alaska Native/ American Indians are not explored in 
this study. 
Selection Bias: There were some differences in the full and plasma subsample of study 
participants. Women who consented to be in the subsample were women who intended to receive 
follow up pediatric care at BMC. The proportion of non-Hispanic Blacks as well as PTB was 
higher in the plasma subsample compared to full sample of study participants. Other 
characteristics remained comparable across samples. 
Missing Data:  A total of 526 women in the full sample did not have data on IUI and thus had to 
be excluded from the analysis when the outcomes of interest were IUI (hypothesis 2c-d). The 
sample characteristics of these women were similar to women included in the study.  
 
Study Implications 
This study demonstrates the importance of maternal folate nutrition during pregnancy and 
adverse pregnancy outcomes. The link between maternal folate and PTB is corroborated in this 
study. In addition, plausible pathways in the folate-PTB relationship are identified. The study 
findings, if further confirmed, are very important given the need to identify modifiable risk 
factors for PTB to inform relevant research, policy and programmatic and clinical interventions 
to mitigate PTB risk.  
Research Implications 
Causality: In 1965 Hill and others proposed certain aspects of evidence that should be 
considered when trying to draw conclusions about causality. These include strength of 





evidence, and analogy (6). In this dissertation, the strength of association and biological gradient 
was partially addressed with the dose-response effects of maternal folate status on key outcomes. 
Consistency was ensured with the similar results from both multivitamin supplement intake and 
plasma folate levels. This dissertation also provided biologically plausible mechanistic pathways 
for relationships that were identified such as folate-PTB, folate-preeclampsia and folate-IUI. 
However, this research was unable to address specificity, given the multiple etiologies of PTB. 
Also, temporality remains an issue given that all the measures of maternal folate were collected 
after delivery. Finally, as the research was unable to manipulate participants into a treatment or 
control group, experimental evidence and analogy remain an issue. Future longitudinal studies 
should attempt to address causal criteria that this dissertation was unable to. 
Folate status measurement: Additional efforts needed in future longitudinal studies include the 
use of standardized folic acid supplementation across the study sample. Also, adequate sample 
sizes of preconceptional folic acid supplement intake is needed to explore the role of 
preconceptional folate status on key pregnancy outcomes. Folic acid supplementation should also 
be measured as soon as possible after intake preferably through a longitudinal design in order to 
avoid recall bias. The use of intake diaries can also help ensure the accuracy of supplementation 
intake data. Ideally, plasma folate samples should also be collected from all study participants in 
each trimester and not just at delivery. Alternatively, red cell folate can be collected at fewer 
intervals compared to plasma folate as red cell folate is a better measure of long term folate 
status. 
Study populations: In addition to research among vulnerable populations, additional studies are 
needed among low-risk populations such as non-Hispanic Whites and middle/high income 





such populations. Research among nationally representative samples may help inform the 
generalizability of the associations between maternal folate status and key pregnancy outcomes. 
Analytical methods: In future longitudinal studies, additional analysis that may prove useful in 
further elucidating the role of folate in mitigating adverse pregnancy outcomes include 
population attributable risk- for example this method can demonstrate the proportion of PTB 
cases that are due to lower maternal folate status. Propensity score matching is another analytical 
method that can also be used to estimate the effect of maternal folate status on key outcomes, 
accounting for confounding covariates. Structural equation modelling and path analysis can also 
be used to explore the interrelationships between folate, other maternal characteristics and 
pregnancy outcomes. For example, the effect of maternal race/ethnicity, parity and age on 
maternal folate status as well as PTB. This may help clarify to what extent folate status may 
explain racial disparities in PTB.  
Animal studies: Experimental studies involving appropriate animal models can prove useful in 
describing the temporal events from low folate status to PTB, particularly in the setting of 
intrauterine infection or preeclampsia. The use of animal models to investigate specific 
hypotheses related to PTB and to demonstrate the pathophysiological events associated with PTB 
will aid the development of rational and efficacious treatment and prevention strategies for PTB 
(7). 
Data collection: given the lack of natality data on PTB subtypes- spontaneous versus medically 
indicated on a national level, there is need for systematic data collection on this. Information on 
presentation at labor should be included with information at gestational age to ascertain whether 





trends of each PTB subtype. Likewise, information on maternal folate status should be collected 
routinely. This includes dietary habits and supplement intake from preconception to delivery. 
National level perinatal research such as Pregnancy Risk Assessment Monitoring System 
(PRAMS) such include information on sub-types of PTB. Data should also be collected on 
multivitamin supplement intake in pregnancy. 
Behavior change research: behavior change research is intricately tied in with folate status as 
dietary habits as well as supplementation intake are individual behaviors. There is need for 
additional efforts to understand the drivers and deterrents of these behaviors. This includes 
knowledge, attitudes and perceptions towards folate rich foods or folic acid supplementation. For 
example, women may simply not know how important folic acid supplementation is for birth 
outcomes. In addition, behavior change theories may be used to explore how to design 
interventions to improve maternal folate status. For example, the Extended Parallel Processing 
Model describes how rational considerations (efficacy beliefs) and emotional reactions (fear of a 
health threat) combine to determine behavioral decisions. Potential questions under the 
constructs of EPPM include: i) Perceived severity–How serious are the consequences of poor 
birth outcomes? ii) Perceived susceptibility–How likely is it that you might have a poor birth 
outcome as a result? iii) Response efficacy–How effective is folic acid supplementation to 
prevent these outcomes? iv) Self-efficacy–How confident are you that you can successfully take 
folic acid supplements throughout pregnancy? 
EPPM can be used to segment audiences and come up with relevant strategies. For example, 
among women with high efficacy and high perceived threat, the strategy would be to provide 
calls to action. Whereas, among women with low efficacy and low perceived threat, the strategy 





groups among women can be used to elucidate the issues regarding folic acid supplementation at 
an individual level. 
Similar to the need for research among women, behavior change research may be beneficial 
among clinicians. Research may explore clinician’s knowledge and perceptions regard folate 
supplementation while qualitative interviews with clinicians can help understand barriers to 
effective counselling and patient communication. Findings from such research can inform the 
design of relevant clinical interventions such as the use of job aids, training on interpersonal 
communication. 
In summary, key research recommendations include the following: 
 Conduct longitudinal studies in which women are enrolled from periconception to 
delivery 
 Use standardized measurement of folic acid supplement intake e.g., mg/day 
 Monitor folic acid supplement intake closely preferably weekly 
 Conduct behavior change studies among women and clinicians 
 Collect data on PTB subtypes and multivitamin supplement intake in national research 
such as PRAMS. 
Policy Implications 
This research highlighted several relevant policies as described below. 
Folic acid supplementation:  In 1991, the Centers for Disease Control and Prevention (CDC) 
recommended that women with a prior NTD-affected pregnancy should consume 4000 µg of 
folic acid daily starting at the time they begin planning a pregnancy(8). Shortly after, in 1992, the 





folic acid daily through fortification, supplementation, and diet to prevent NTDs (9).  In 1998, 
the Institute of Medicine (IOM) recommended that women capable of becoming pregnant should 
consume 400 µg of folic acid daily from fortified foods or supplements, or both, in addition to 
their diet. Also, the Institute of Medicine recommends higher doses of folate are for pregnant 
(600 mcg DFE) and lactating (500 mcg DFE) mothers to prevent neural tube defects (10). In 
2009 and 2017, the U.S. Preventive Services Task Force published updated guidelines that 
reinforced these recommendations- that all women who are planning or capable of pregnancy 
take a daily supplement containing 0.4 to 0.8 mg (400 to 800 µg) of folic acid (11). 
This dissertation showed that maternal folate status in later pregnancy and not just early 
pregnancy was associated with PTB. Interestingly the policies do not explicitly tell women to 
continue taking folic acid supplements throughout pregnancy. Thus, if this dissertation findings 
are confirmed, policies may need to be updated and encourage that pregnant women take folic 
acid supplements throughout pregnancy. Furthermore, minority populations are less likely to 
know about or consume folic acid supplements. This suggests additional efforts are needed to 
ensure that the policy is dispersed across all populations.  
Mandatory folic acid fortification: In the US, mandatory fortification of enriched cereal grain 
products with folic acid was authorized in 1996 and fully implemented in 1998 (12). The U.S. 
program adds 140 µg of folic acid per 100 g of enriched cereal grain product and has been 
estimated to provide 100–200 µg of folic acid per day to women of childbearing age (13). 
Although mandatory flour fortification programs increase folic acid intake, research has shown 
that they do not reach all women of reproductive age adequately with Hispanic and non-Hispanic 
women less likely to consume foods fortified with folic acid (14). In Hispanics, this is 





In 2016, the FDA approved the addition of folic acid to corn masa flour, an ingredient in foods 
including tortillas, tacos, tortilla chips and tamales. Foods made from this flour are staple foods 
of Mexican and some Central and South American diets (15). Additional efforts are needed to 
ensure that foods typically consumed by non-Hispanic Blacks are also fortified with folic acid.  
American College of Obstetricians and Gynecologists recommendations: In addition to 
recommending the use of 0.4mg of folic acid for at least one month before pregnancy and during 
pregnancy to prevent neural tube defects, ACOG recommends a nutritious diet and folic acid and 
iron supplementation for treatment of pregnancy-induced folic acid deficiency (16). This is 
relevant given the fact that this dissertation highlighted the prevalence of folate insufficiency in 
pregnancy among a high-risk population. Also, ACOG guidelines recommend delivery after 34 
weeks of gestation for severe preeclampsia (17) as well as folic acid supplementation in the 
preconception period and first trimester for women with prior preeclampsia (18). In this study, 
multivitamin supplement intake and plasma folate levels were generally adequate or high, as 
expected in this era of mandatory folic acid fortification of the food supply. However, about a 
quarter of women had relatively low plasma folate levels (<19.4nmol/L), which was associated 
with an increased risk of PTB, preeclampsia and IUI. This study also found comparable 
relationships between folate and preeclampsia among nulliparous and multiparous women. If 
study findings of the relationship between maternal folate status and preeclampsia, as well as the 
role of preeclampsia as a mediator in the folate-PTB relationship are validated by prospective 
studies, such guidelines might need to consider the administration of folic acid among women 
with preeclampsia beyond the first trimester and among nulliparous women. 





 Encourage women to continue folic acid supplements throughout pregnancy. 
 Explore folic acid fortification policies that consider cultural differences in diet among 
minority populations 
 Investigate the need to update ACOG recommendations for folic acid supplementation 
beyond women with prior preeclampsia 
 
Programmatic Implications 
Preterm Birth Prevention: This study has implications for PTB prevention among 
individuals, governmental, non-governmental organizations 
Individual: Interventions to prevent PTB should explore opportunities to sensitize the 
public on the adverse effects of PTB as well as modifiable risk factors for PTB. In addition, 
women should be able to assess their risk for PTB and be informed of necessary actions to 
take such as meet with their health care provider. Interventions should also focus on the 
improving women’s knowledge and perceptions regarding improving their folate status 
through diet and folic acid supplementation Example of health communication interventions 
include the use of mass-media such as social media, radio, television, flyers, websites and 
brochures.  
Governmental nutritional programs: Efforts should be made to explore opportunities 
to leverage already existing nutrition programs such as Women Infants and Children (WIC) 
to incorporate relevant nutritional interventions to improve folate status. For example, 
recipients of WIC should be informed about the need for an optimal folate status and this 
may involve the use of posters, flyers and brochures at WIC offices that remind women to 





low-income minority women and prenatal WIC participation has been found to be associated 
with significant improvements pregnancy outcomes among such women (19). 
Health departments: PTB must be considered a priority health issue in many areas in 
the US and this should be operationalized with the formation of coalitions involving 
multidisciplinary experts in relevant areas such as clinicians, nutritionists, psychologists, etc. 
The PTB coalition can advocate for funding of interventions to address PTB in their 
community, explore opportunities to work synergistically with other similar coalitions and 
champion outreaches among clinics and communities where relevant information is 
disseminated among audiences.  
Non-governmental institutions: There are several opportunities in which non-
governmental organizations can be engaged in mitigating PTB. The March of Dimes is a 
non-governmental organization committed to addressing the unacceptably high PTB rates in 
the US and globally. In 2017, the March of Dimes convened the Prematurity Campaign 
Collaborative of 200 leading maternal and child health organizations and experts nationwide. 
The March of Dimes Prematurity Campaign activities include research and discovery, 
community engagement, advocacy and education. Opportunities should be made available to 
organizations such as March of Dimes to continue to gain strides in the fight against PTB in 
the US and across the world. 
 In summary, key programmatic recommendations include the following: Health 
communication interventions are needed to improve knowledge and perceptions related 
to PTB, eating healthy and taking folic acid supplements 
 Explore opportunities to within existing nutritional programs such as WIC to incorporate 





 PTB coalitions should continue to be supported financially and other necessary resources 
to address PTB rates and risk in vulnerable populations 
 
Clinical Implications 
Optimizing maternal folate status: Improving folate status before and during pregnancy would 
be a low-cost intervention to prevent PTB. With over a third of all US pregnancies being 
unintended (20), improving pre-pregnancy health is important for all women of reproductive age 
in order to optimize maternal and child health outcomes on a national level. (21). In keeping with 
ACOG recommendations, folic acid supplementation should be given to women with low levels 
in pregnancy.  
Screening for folate status in pregnancy: This means that clinicians need to directly ask their 
patients of childbearing age about their dietary habits as well as folic acid consumption. Also, 
obstetricians need to monitor their patients’ nutritional status and folic acid consumption closely. 
The indications or guidelines for the collection of biomarkers of folate status versus reliance on 
self-reported supplement intake needs to be developed or updated. Prenatal assessment 
commonly conducted by clinicians during the first prenatal visit is a good opportunity to collect 
information on and assess maternal folate status as well as address indicators of lower maternal 
folate status such as poor diet or low supplement intake. This would involve an additional set of 
checklists on the form for supplement intake and dietary habits. 
Patient care coordination: There is a great need to not just diagnose patients with low folate 
status or other risks for PTB but to connect patients to where they can get the help that they need 
to address identified health issues.  Hospitals, service organizations and health departments 





by clinicians to be at risk for PTB or have low folate status with available services to address 
their needs such as home visiting, nutrition/weight programs, social services. An example is 
HealthCare Access Maryland, a nonprofit agency that connects residents to public health care 
coverage and helps them navigate services effectively. Each year, HealthCare Access Maryland 
employees connect more than 125,000 uninsured and underinsured clients to health insurance, 
health care, and vital community resources. The programs and services offered by HealthCare 
Access Maryland are designed to bridge gaps in services to pregnant and postpartum women, 
and other vulnerable groups. Such programs are especially useful among low income urban 
minority populations. 
Counseling on consistent folic acid supplementation: This study reaffirmed the importance of 
consistent folate intake throughout pregnancy and not just in the periconception period to 
mitigate PTB risk (22-24). The study demonstrated minimal difference in PTB mitigation by 
multivitamin supplement intake of 3-5 times versus >5 times/week, suggesting a possible 
threshold dosing schedule of 3 times/week. If corroborated by other studies, this finding may 
impact the recommendations for frequency of multivitamin supplement intake before and during 
pregnancy. Specifically, it suggests that the same protective benefit can be derived from a thrice 
weekly compared to a daily dosing. However, it is crucial that women continue to take their 
supplements throughout pregnancy and not discontinue use prior to delivery. Clinicians should 
be trained and given resources to counsel women adequately on optimizing their folate status. 
Mitigating effects of preeclampsia or IUI: as a result of delayed childbearing ,the prevalence 
of hypertension and preeclampsia is projected to increase over the next decade (25, 26). 
Administering folic acid in combination with anti-hypertensive drugs compared with only anti-





patients with hypertension (27). There is a great need to further investigate the extent to which 
folic acid administration can mitigate preeclampsia complications in pregnancy as well as reduce 
the need for medically indicated PTB. 
In summary, key clinical recommendations include: 
 Include dietary habits and use of multivitamin supplements in prenatal assessments 
 Clinicians should be trained on how to counsel women on how to optimize folate status 
 Efficient patient care coordination is needed to link women with low folate status and 
other modifiable PTB risk factors to the services that they need 
 
Conclusion 
PTB is considered one of the leading health indicators of a nation and is a public health 
priority in the US because of its associated infant and childhood morbidity and mortality as 
well its substantial economic burden for the U.S (28, 29). Thus, additional novel and early 
prevention or intervention approach is needed to further lower PTB rates in the US and in 
the world. An article by Jain and Gyamfi-Bannerman (30) stated “with evidence that 95% of 
cases of spontaneous preterm birth are intractable to current interventions, our best hope in 
resolving this problem may lie in new, innovative ideas”.  
This dissertation presented a new and innovative approach to understanding and 
mitigating PTB risk. The research addressed a key gap in maternal health research and added 
to the literature on the relationship between maternal folate status and PTB as well as the 
little known mechanistic pathway underlying the association between maternal folate status 





multivitamin supplement intake from preconception to third trimester; as well as maternal 
plasma folate status at delivery. In addition, the study investigated to what degree the 
observed association between maternal folate and PTB was mediated by preeclampsia or 
(IUI)- two major pathways for PTB.  
The analyses included 7565 mother-newborn dyads and a subsample (n=2313) with 
plasma folate assay at delivery in Boston Birth Cohort, a predominantly urban, low income 
minority population. Unadjusted and adjusted logistic regressions revealed an inverse 
relationship between both multivitamin supplement intake and plasma folate levels with 
PTB. Throughout pregnancy, consistent intake of 3-5 times or more than 5 times a week was 
associated with reduced PTB risk. Such beneficial effect was observed in the third trimester.  
Consistently, compared to the lowest quartile, the highest quartile of plasma folate level was 
associated with a reduction in PTB risk; and the association was consistent for spontaneous 
and medically indicated PTB.  
Consistent multivitamin supplement intake of three or more times a week in the 3rd 
trimester as well as higher levels of plasma folate was associated with reduced odds of 
preeclampsia as well as IUI. Preeclampsia mediated 62% of the multivitamin supplement 
intake- medically indicated PTB relationship. Both multivitamin supplement intake and 
plasma folate concentrations were associated with reduced odds of IUI. Multivitamin intake 
ameliorated the relationship between IUI and PTB, particularly spontaneous PTB. Adjusted 
logit regressions showed that regardless of IUI status, the probability of PTB and 
spontaneous PTB decreased as plasma folate concentrations increased. 
Thus, this dissertation demonstrated that optimizing maternal folate levels across 





folate against preeclampsia and IUI.  
Additional prospective research is needed to corroborate study findings as this research 
is directly relevant to policy on the recommendation of folate intake and interventions, 
specifically among vulnerable US- urban low-income minority populations. The results of 
this dissertation have a potential impact on ongoing research, clinical and programmatic 
efforts to improve prepregnancy and prenatal nutrition and birth outcomes and may help 
inform the design and implementation of nutrition-based screening and interventions to 
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I am an internationally trained physician and certified public health 
expert with over ten years’ experience. I am highly proficient in 
survey design, training of data collectors, survey implementation, 
data analysis and results dissemination. I have analyzed DHS/MIS 
data from various countries and very familiar with the malaria 
modules, the mobile DHS app and StatCompiler. As a researcher, I 
am abreast of all aspects of vector control, chemoprevention, testing, 
diagnosis and treatment of malaria. My background in Sub- Saharan 
Africa affords me a unique understanding of the challenges and 
opportunities of survey implementation low resource settings. I am a 
dynamic leader with excellent verbal and written communication 
skills. I am also well versed in innovative electronic/mobile data 
collection technology for survey implementation. I am certified in 
DHIS2, proficient in GIS and advanced statistical methods. My 
passion is researching and implementing interventions to improve 
health outcomes among vulnerable and minority populations. 
PROFESSIONAL EXPERIENCE- PUBLIC HEALTH 
RESEARCH 
SENIOR RESEARCH DATA ANALYST 
Center for Communication Programs: 02/2016- Date 
The Center for Communications programs (CCP) is a renowned 
heath communication organization with over 60 projects in more 
than 30 countries and with a yearly expenditure of over $100 million 
Provide high level technical oversight to all levels of public health 
research, monitoring and evaluation activities such as 
 Designing the malaria behavior assessment questionnaire 
 Analysis of DHS/MIS data 
 Conceptualizing research protocols and study tools  
 Developing mHealth data collection tools 
 Training in-country data collectors  
 Report writing and dissemination 
Select Projects include: VectorWorks- Global, Health 
Communication Capacity Collaborative- Global, Urban 
Reproductive Health Initiative- Nigeria 
FOCAL AREAS 
Malaria  
Intermittent Presumptive Treatment in 
pregnancy; Insecticide Treated Net 
Use, Seasonal Chemoprophylaxis, 
Rapid Diagnosis and Testing, Social 
Behavior Change Communication,  
 
 
Survey Implementation:  
-Study Protocols development 
-Institutional board review 
 Training agendas/manuals 
-Interactive learner friendly training 
-Teleform data entry 
-Mobile data collection 
-Performance Monitoring  
-Meta data analysis 
 
Biostatistics:  
Longitudinal-, Multilevel-, Factor- 
Analysis; Propensity Score Matching; 
Structural Equations, Path-, 









Statistics: STATA, R, SPSS, MPLUS, 
UCINET/ NetDraw 
 
Geographic Information System: 
ArcGIS, CartoDB, Google Earth 
 
Qualitative data: Atlat.ti, Nvivo 
 
Business Intelligence: REDCAP, 
PowerBI 
 
Mobile Data Collection: Magpi, 
Open Data Kit, SurveyCTO, 
Commcare 
 
Literature Review: Endnote, 
Mendeley, Refworks 






JHPIEGO- September - December 2015 
Worked with the Immediate Postpartum Implants (IPPI) project- a 
Gates funded research initiative to increase the understanding, 
acceptability and feasibility of immediate postpartum implants in 
Indonesia and Kenya. Duties included:  
 Conceptualization of study research design. 
 Analysis of Demographic Health Survey (DHS) data 
 Development of study research protocol and tools 
 
Johns Hopkins School of Public Health: 2014–2015 
Worked as the data entry team leader and research assistant with the 
Department of Population, Family and Reproductive Health. 
Specific duties include:  
 Conducting literature reviews. 
 Advanced quantitative data analysis.  
 Developed protocols for data entry.  
 Monitored all stages of data entry.  
 Manuscript writing 
 
Johns Hopkins Center for Communication Programs: 2012 - 
2014 
Provided technical support to formative and evaluation research 
activities in several countries and conducted qualitative and 
quantitative analysis on national databases. Select projects include:  
Urban Reproductive Health Initiative (Nigeria and Kenya) 
Provided technical support to the following studies: longitudinal 
study on contraceptive discontinuation, simulated client study to 
assess capacity of family planning providers, and baseline and 
midterm evaluation of the flagship project. 
EDUCATION 
 
Johns Hopkins Bloomberg School of 
Public Health 
PhD Candidate, ‘18 
 
Johns Hopkins Bloomberg School of 
Public Health 
MSPH Public Health, ‘12 
 







Chenoweth-Pate Award; 2016 




Metamorforces Nigeria Award 





Certified in Public Health 
(CPH)  
USAID Global Health 
Certificate in Maternal Health 
JHSPH Certificate in Maternal 
and Child Health 
Strategic Leadership 
CITI certification in human 
subjects’ research 
 





 Activities included literature reviews, development of study tools 
and training manuals for research, development of technical reports 
and dissemination tools, co-authoring of peer-reviewed papers for 
publication.  
 
Behavior Change Support Project (Ghana) 
Provided key technical support on this integrated multi-focus health 
and behavior change program. Key focus areas included family 
planning, maternal and child health, nutrition, water and sanitation 
and malaria.  
 Activities included: revisions to study protocol and data collection 
tools, submission to institutional review boards; development of 
training agenda for field staff, database cleaning and management, 
analysis of quantitative endline survey data and development of a 
final report.  
Research to Prevention (R2P) (Botswana) 
Present in-country as the Senior Research Coordinator for this 
HIV/AIDS risk/prevention study.  
 Represented CCP on collaborations and meetings with project 
stakeholders including in-country MOH and PEPFAR staff;  
 Assisted with training the local team on time-location sampling 
procedures, use of mHealth technology, database development and 
field supervision 
 Coordinated field activities for this translational research study on 
alcohol use, behavior risk and HIV, coaching team leaders in quality 
control checks and problem solving. 
 Used Magpi software to develop all phases of an electronic survey 
for mobile data collection. 
 Conducted capacity strengthening for in-country staff on 
qualitative and quantitative analysis using Atlas.ti and SPSS 
respectively. 
 Assisted with the generation of codebooks, coding of transcriptions 
and qualitative data analysis using Atlas.ti 
  
SELECTED PAPERS 
Olapeju, B et al. Maternal Folate 
Status and Preterm Birth in the Boston 
Birth Cohort (submitted 2017) 
 
Makinde, O, Olapeju, B, Ogbuoji, 
O, Babalola, S.(2017). Trends in the 
Completeness of Birth Registration 
in Nigeria: 2002 – 2010. 
Demographic Research 
 
Babalola, S., Kusemiju, B., Calhoun, L., 
Corroon, M., & Olapeju, B. (2015). 
Factors associated with contraceptive 
ideation among urban men in Nigeria. 
IJOG. 
 
Babalola, S., John, N., Ajao, B., & 
Speizer, I. S. (2015). Ideation and 
intention to use contraceptives in 





Who Buys Nets? Factors 
Associated with Mosquito Net 
Purchase in Sub-Saharan Africa. 
2017 
 
Influence of a Mass Media Health 
Communication Campaign on 
Family Planning Behaviors and 
Intentions in Ghana. 2015.  
 
Modern Contraceptive Use 
among Married Women in 
Indonesia who are Undecided on 
Their Next Pregnancy. 2015 






PROFESSIONAL EXPERIENCE- PUBLIC HEALTH 
PROGRAMS 
PHYSICIAN: 2008 – 2011 
Lagos University Teaching Hospital 
Worked at the Hematology Center which received funding and 
support from the International Center for AIDS Care and Treatment 
Programs (ICAP) and President’s Emergency Plan for AIDS Relief 
(PEPFAR). Duties included:  
 Provided clinical care, support and treatment to PLWHA 
 Managed the day-to-day operations of HIV clinics 
 Implemented community-based capacity-strengthening programs 
to increase and knowledge of HIV in rural communities.  
 
COMMUNITY HEALTH MOBILIZER/ PROGRAM 
COORDINATOR 
(2002-2007) 
Nigerian Conference of Medical and Dental Students 
 Developed entertainment-education campaigns focusing on global 
health issues such as malaria, HIV/AIDS, maternal and child health. 
 Organized the provision of basic food and clothing for women and 
children in the poorest communities 
 Provided mental health counselling. 
 Supported community health awareness programs on maternal, 
child and geriatric health.  
 
SELECTED REPORTS 
ITN Use Access Ratio Report.2017 
 
Ghana ITN Use Memo.2017 
 
Post-Campaign Survey for Social 
Marketing of Long Lasting 
Insecticide-treated Nets in Dakar, 
Senegal, 2017. 
 
National Knowledge, Attitude and 
Practices Survey on Ebola Virus 
Disease in Liberia. 2017 
 
 
Nigerian Urban Reproductive 
Health Institute- Simulated Client 
Study. Baseline Report 2014 
 
 
Ghana Behavior Change Support 
Project. Evaluation Report. 2014 
 
 
Integrated HIV Serological and 
Behavioral Surveillance among 
Persons Attending Alcohol 
Consumption Venues in 
Gaborone, Botswana. 2013 
 
 
Nigeria Northern Education 
Initiative. Baseline Study on 
Gender Inequalities in Education 
and Living Conditions of Orphans 
and Vulnerable Children in Bauchi 
and Sokoto States. 2012 
 
